

Independent Auditors' Reports as Required by Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance) and *Government Auditing Standards* and Related Information

Year ended June 30, 2021

(With Independent Auditors' Report Thereon)

# **Table of Contents**

	Page
Independent Auditors' Report	1
Basic Consolidated Financial Statements – Year ended June 30, 2021	3
Schedule of Expenditures of Federal Awards – Year ended June 30, 2021	53
Schedule of Expenditures of State Awards – Year ended June 30, 2021	63
Notes to Schedule of Expenditures of Federal Awards and Schedule of Expenditures of State Awards	64
Independent Auditors' Report on Internal Control over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with Government Auditing Standards	67
Independent Auditors' Report on Compliance for Each Major Federal Program; Report on Internal Control over Compliance; and Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance and the Schedule of Expenditures of State Award	69
Schedule of Findings and Questioned Costs	72



KPMG LLP Suite 800 500 W 5th St Winston-Salem, NC 27101

## **Independent Auditors' Report**

The Board of Trustees Wake Forest University:

# **Report on the Financial Statements**

We have audited the accompanying consolidated financial statements of Wake Forest University (the University), which comprise the consolidated balance sheet as of June 30, 2021, and the related statements of activities, and cash flows for the year then ended, and the related notes to the consolidated financial statements.

# Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

# Auditors' Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

#### Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Wake Forest University as of June 30, 2021, and the changes in its net assets and its cash flows for the year then ended in accordance with U.S. generally accepted accounting principles.



## Report on Summarized Comparative Information

We have previously audited Wake Forest University's 2020 consolidated financial statements, and we expressed an unmodified audit opinion on those audited consolidated financial statements in our report dated October 21, 2020. In our opinion, the summarized comparative information presented herein as of and for the year ended June 30, 2020 is consistent, in all material respects, with the audited consolidated financial statements from which it has been derived.

# Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated October 25, 2021 on our consideration of the University's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the University's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the University's internal control over financial reporting and compliance.

KPMG LLP

Greensboro, North Carolina October 25, 2021

Consolidated Balance Sheet

June 30, 2021

(with summarized comparative financial information as of June 30, 2020)

(Dollars in thousands)

		Supplementary	y information		
		Reynolda			
		Campus	WFUHS	2021	2020
Assets:					
Cash and cash equivalents	\$	37,133	177,688	214,821	166,839
Accounts receivable, net		19,857	77,160	97,017	123,886
Patient receivables		_	77,899	77,899	63,317
Contributions receivable, net		126,714	12,597	139,311	126,853
Notes receivable, net		12,720	302	13,022	16,763
Investments		1,692,466	1,206,516	2,898,982	1,992,587
Direct investments in real estate		12,397	_	12,397	12,863
Other assets		10,588	25,969	36,557	33,006
Deposit with bond trustee		8,611	_	8,611	8,609
Right-of-use assets-operating		27,564	155,141	182,705	208,223
Land, buildings, and equipment, net		683,420	340,036	1,023,456	1,051,097
Total assets	\$_	2,631,470	2,073,308	4,704,778	3,804,043
Liabilities:					
Accounts payable and accruals	\$	65,599	332,353	397,952	255,836
Other liabilities and deferrals		86,421	153,935	240,356	239,799
Annuities payable		20,219	3,014	23,233	18,945
Operating lease obligations		26,946	159,998	186,944	211,997
Notes payable and finance leases		71,511	49,622	121,133	174,742
Bonds payable		527,493	134,273	661,766	546,423
Postretirement benefits		14,542	24,108	38,650	39,786
Government grants refundable		2,049		2,049	4,533
Total liabilities	_	814,780	857,303	1,672,083	1,492,061
Net assets:					
Without donor restrictions		801,732	922,549	1,724,281	1,262,859
Noncontrolling interest in affiliate		279	813	1,092	719
With donor restrictions	_	1,014,679	292,643	1,307,322	1,048,404
Total net assets	_	1,816,690	1,216,005	3,032,695	2,311,982
Total liabilities and net assets	\$	2,631,470	2,073,308	4,704,778	3,804,043

#### Consolidated Statement of Activities

 $\label{eq:Year} Year\ \text{ended June 30, 2021}$  (with summarized comparative financial information for the year ended June 30, 2020)

(Dollars in thousands)

		ithout donor	With donor restrictions	2021	2020
Operating revenues:					
Student tuition and fees	\$	324,929	_	324,929	301,648
Government grants and contracts		234,536	_	234,536	201,194
Private grants and contracts		6,220	20,341	26,561	45,666
Contributions		25,966	25,409	51,375	48,199
Investment return designated for current operations		51,973	76,886	128,859	75,800
Patient revenue		691,518	_	691,518	621,338
Other		274,866	_	274,866	277,991
Sales and services of auxiliary enterprises		83,726	_	83,726	91,344
Net assets released from restrictions		74,020	(74,020)		
Total operating revenues		1,767,754	48,616	1,816,370	1,663,180
Operating expenses:					
Salaries and wages		961,552	_	961,552	894,835
Employee benefits		207,261	_	207,261	189,808
Student aid		11,998	_	11,998	11,840
Services		225,292	_	225,292	226,968
Clinical and laboratory supplies		96,436	_	96,436	86,674
Other operating expenses		131,560	_	131,560	141,323
Depreciation and amortization		87,143	_	87,143	88,465
Interest on debt	_	23,535		23,535	23,535
Total operating expenses	_	1,744,777		1,744,777	1,663,448
Operating excess		22,977	48,616	71,593	(268)
Nonoperating activities:					
Restricted contributions		_	214,484	214,484	46,865
Net assets released from restriction		161,429	(161,429)	_	_
Investment return in excess of amounts					
designated for current operations		170,333	164,888	335,221	(59,970)
Actuarial losses on annuity obligations		_	(6,896)	(6,896)	(243)
Unrealized gains (losses) on interest rate swaps Postretirement related changes other than service		8,475	_	8,475	(10,181)
costs		2,874	_	2,874	2,127
Gains from affiliates, equity method		88,317	_	88,317	22,239
Other, net		7,017	(745)	6,272	732
Change from nonoperating activities		438,445	210,302	648,747	1,569
Change in net assets		461,422	258,918	720,340	1,301
Change in net assets attributable to noncontrolling					
interest		373	_	373	422
Net assets attributable to noncontrolling interest at					
beginning of year		719	_	719	_
Adjusted net assets at beginning of year		1,262,859	1,048,404	2,311,263	2,310,259
Net assets at end of year	\$	1,725,373	1,307,322	3,032,695	2,311,982

# Consolidated Statement of Activities

College of Arts and Sciences, Schools of Law, Business, and Divinity, and Reynolda House, Inc. (Supplementary Information)

Year ended June 30, 2021

(Dollars in thousands)

	Without donor restrictions	With donor restrictions	Total
Operating revenues:			
Student tuition and fees	\$ 284,929	_	284,929
Government grants and contracts	18,259	_	18,259
Private grants and contracts	5,147	_	5,147
Contributions	22,821	20,728	43,549
Investment return designated for current operations	26,279	26,046	52,325
Other	7,282	_	7,282
Sales and services of auxiliary enterprises	83,726	_	83,726
Net assets released from restrictions	35,787	(35,787)	
Total operating revenues	484,230	10,987	495,217
Operating expenses:			
Salaries and wages	224,894	_	224,894
Employee benefits	61,660	_	61,660
Student aid	3,331	_	3,331
Services	59,010	_	59,010
Other operating expenses	54,534	_	54,534
Depreciation and amortization	50,746	_	50,746
Interest on debt	15,751		15,751
Total operating expenses	469,926		469,926
Operating excess	14,304	10,987	25,291
Nonoperating activities:			
Restricted contributions	_	55,181	55,181
Net assets released from restriction	11,429	(11,429)	_
Investment return in excess of amounts			
designated for current operations	82,025	161,156	243,181
Actuarial losses on annuity obligations	_	(6,367)	(6,367)
Unrealized gains on interest rate swaps	7,077	_	7,077
Postretirement related changes other than service costs	50	. <del>-</del>	50
Other, net	305	(745)	(440)
Change from nonoperating activities	100,886	197,796	298,682
Change in net assets	115,190	208,783	323,973
Change in net assets attributable to noncontrolling interest Net assets attributable to noncontrolling interest at	110	_	110
beginning of year	169	_	169
Adjusted net assets at beginning of year	686,542	805,896	1,492,438
Net assets at end of year	\$ 802,011	1,014,679	1,816,690

Consolidated Statement of Activities

Wake Forest University Health Sciences (Supplementary Information)

Year ended June 30, 2021

(Dollars in thousands)

		Without donor restrictions	With donor restrictions	Total
Operating revenues:				
Student tuition and fees	\$	40,000	_	40,000
Government grants and contracts		216,277	_	216,277
Private grants and contracts		1,073	20,341	21,414
Contributions		3,145	4,681	7,826
Investment return designated for current operations		25,694	50,840	76,534
Patient service revenue		691,518	· —	691,518
Other		267,584	_	267,584
Net assets released from restrictions	i	38,233	(38,233)	
Total operating revenues	·	1,283,524	37,629	1,321,153
Operating expenses:				
Salaries and wages		736,658	_	736,658
Employee benefits		145,601	_	145,601
Student aid		8,667	_	8,667
Services		166,282	_	166,282
Clinical and laboratory supplies		96,436	_	96,436
Other operating expenses		77,026	_	77,026
Depreciation and amortization		36,397	_	36,397
Interest on debt	i	7,784		7,784
Total operating expenses	,	1,274,851		1,274,851
Operating excess	·	8,673	37,629	46,302
Nonoperating activities:				
Restricted contributions		_	159,303	159,303
Net assets released from restriction		150,000	(150,000)	_
Investment return in excess of amounts designated for				
current operations		88,308	3,732	92,040
Actuarial losses on annuity obligations		_	(529)	(529)
Unrealized gains on interest rate swaps		1,398	· —	1,398
Postretirement related changes other than service costs		2,824	_	2,824
Gain from affiliates, equity method		88,317	_	88,317
Other, net	,	6,712		6,712
Change from nonoperating activities	i	337,559	12,506	350,065
Change in net assets		346,232	50,135	396,367
Change in net assets attributable to noncontrolling interest Net assets attributable to noncontrolling interest at		263	_	263
beginning of year Adjusted net assets at beginning of year		550 576,317	<u> </u>	550 818,825
Net assets at end of year	\$	923,362	292,643	1,216,005

#### Consolidated Statement of Cash Flows

Year ended June 30, 2021 (with summarized comparative financial information for the year ended June 30, 2020)

(Dollars in thousands)

	Supplementary information				
		Reynolda Campus	WFUHS	2021	2020
Cash flows from operating activities:					
Change in net assets	\$	324,083	396,630	720,713	1,723
Adjustments to reconcile change in net assets to net cash provided by (used in) operating activities:					
Depreciation and amortization		50,608	36,397	87,005	88,465
Amortization of debt related costs		(969)	(1,137)	(2,106)	(2,106)
Amortization of right-of-use operating assets  Net depreciation (gains) on investments		3,315 (279,988)	20,654 (168,574)	23,969	(27,430) 828
Noncash gifts		(279,988)	(100,574)	(448,562)	(15)
Private gifts restricted for capital and long-term investment		(55,181)	(9,414)	(64,595)	(47,017)
Losses (gains) on disposals of property and equipment		(60)	(0,414)	(60)	6,086
Losses on impairment of property held for sale		293	(88,317)	(88,024)	_
Gains from equity method affiliates		_	(1,398)	(1,398)	(22,239)
Unrealized (gains) losses on interest rate swaps		(7,077)	59	(7,018)	10,181
Bad debt expense and change in allowance for contributions receivable		(366)	_	(366)	416
Changes in operating assets and liabilities:					
Accounts and patient receivables		122	1,449	1,571	26,713
Contributions receivable		(9,425)		(9,425)	(4,546)
Notes receivable		(540)	643	643	(3)
Operating lease right-of-use assets, net		(546)	1,099	553	(180,794)
Other assets and other liabilities and deferrals  Accounts payable and accruals		10,199 32.980	(5,464) 112.806	4,735 145.786	3,069 59.871
Operating lease liabilities		(2,994)	(21,063)	(24,057)	211,997
Postretirement benefits		918	(2,054)	(1,136)	(1,323)
Annuities payable	_	3,759	529	4,288	(1,521)
Net cash provided by operating activities	_	69,671	272,845	342,516	122,355
Cash flows from investing activities:					
Purchases of land, buildings, and equipment		(30,907)	(31,383)	(62,290)	(115,115)
Proceeds from sale of land, buildings, and equipment		1,797	3	1,800	21
Disbursements of loans to students and other		(464)	_	(464)	(215)
Repayments of loans to students and other		3,552		3,552	3,096
Purchases of investments		(444,753)	(197,960)	(642,713)	(656,174)
Net proceeds from sales and maturities of investments Increase in deposits with bond trustees		244,715 (2)	34,422	279,137 (2)	675,832 —
Net cash used in investing activities		(226,062)	(194,918)	(420,980)	(92,555)
Cash flows from financing activities:					
Change in government grants refundable		(2,484)	_	(2,484)	(3,605)
Proceeds from notes payable		348	_	348	50,961
Principal payments on notes payable		(41,826)	(10,120)	(51,946)	(4,433)
Proceeds from issuance of bonds payable		125,000	_	125,000	· —
Payments to retire or defease bonds payable		(1,250)	(5,560)	(6,810)	(11,805)
Bond issuance costs		(740)	_	(740)	114
Proceeds from finance lease obligations		2,584	(0.000)	2,584	7,098
Payments on finance lease obligations		(2,833)	(2,283)	(5,116)	(12,887)
Proceeds from private gifts restricted for long-term investment  Other revenue restricted for long-term investment		55,181 (8,423)	9,414	64,595 (8,423)	40,208 7,742
Net cash provided by (used in) financing activities	-	125,557	(8,549)	117,008	73,393
Net (decrease) increase cash equivalents and restricted cash	_	(30,834)	69,378	38,544	103,193
Cash, cash equivalents and restricted cash at beginning of year		76,578	112,200	188,778	85,585
Cash, cash equivalents and restricted cash at end of year	\$	45,744	181,578	227,322	188,778
Cash and cash equivalents Restricted cash	\$	37,133 8,611	177,688 3,890	214,821 12,501	166,839 21,939
Total cash, cash equivalents, and restricted cash	\$	45,744	181,578	227,322	188,778
Supplemental disclosures of cash flow information:	_				
Cash paid for interest, net of amounts capitalized	\$	16,584	8.461	25,045	25.221
Capital expenditures included in account payable	φ	3,546	615	4.161	32.158
Operating cash flows from finance leases		2,630	_	2,630	1,913
Operating cash flows from operating leases		4,455	_	4,455	33,289
Financing cash flows from finance leases		2,584	_	2,584	(3,619)
Income taxes paid		. —	244	244	
•					

Notes to Consolidated Financial Statements

June 30, 2021

# (1) Organization and Summary of Significant Accounting Policies

## (a) Description of Wake Forest University

Wake Forest University (the University) is a private, coeducational, not-for-profit institution of higher education and research located in Winston-Salem, North Carolina. The consolidated financial statements of the University include the Reynolda Campus and Wake Forest University Health Sciences (WFUHS), and all entities over which the University has control, including all of the subsidiaries of Reynolda Campus and WFUHS.

**Reynolda Campus** – includes the College of Arts and Sciences, Schools of Law, Business, and Divinity, and consolidated subsidiaries including: Verger Capital Management, LLC (VCM), and Reynolda House, Inc. (collectively, Reynolda Campus).

**WFUHS** – a wholly owned subsidiary of the University, WFUHS is a North Carolina nonprofit corporation with the University as its sole member, that operates the Wake Forest University School of Medicine, educating medical students and others, providing patient care in a variety of clinical, hospital, and other healthcare settings, and conducting biomedical research. Its wholly owned affiliates are the Dialysis Centers of Wake Forest University, Wake Forest Innovation Quarter Development Co., Wake Forest Innovation Quarter CDC, Wake Forest Innovation Quarter Management Co., WFIQ Holdings, LLC, WFIQ Holdings II, LLC, WFIQ Holdings III, LLC, Seed Stage Associates, LLC, Park IMP 1, LLC, BRF – A1, LLC, BRF Deck 1, LLC, BRF – A1a, LLC, Childress Institute for Pediatric Trauma, Wake Forest Emergency Providers, North District Owners Association, and RegenMed Development Organization.

Effective July 1, 2010, the governing boards of the University, WFUHS, North Carolina Baptist Hospital (NCBH), and Wake Forest University Baptist Medical Center (WFUBMC) approved a Medical Center Integration Agreement (the Integration Agreement, or MCIA) whereby an integrated academic medical center was created that combined clinical care, medical education and research under the delegated operational management and oversight of WFUBMC.

Pursuant to a health system integration agreement among the University, WFUBMC, WFUHS, North Carolina Baptist Hospital (NCBH), and the Charlotte-Mecklenburg Hospital Authority ("CMHA"), a North Carolina hospital authority that operates a multi-state integrated healthcare system in the southeastern United States, effective on October 9, 2020, WFUBMC and CMHA became participants in a single, integrated healthcare delivery and academic system (the "Enterprise") managed and overseen by Atrium Health, Inc., a new joint operating company without members ("Atrium") whose 16-person board of directors (the "Atrium Board") initially consists of 13 CMHA designees and three WFUBMC designees; the Medical Center Integration Agreement (MCIA) was amended to include Atrium as a third member of WFUBMC and to reconstitute the WFUBMC Board to include seventeen voting directors of whom the University designates six, NCBH designates six, Atrium designates three, and the WFUBMC board elects two; and the Medical Center (including WFUHS and the School of Medicine) was established as the academic core of the Enterprise responsible for its academic and research activities.

Under this arrangement, each Enterprise participant and its affiliates will maintain its separate legal existence and continue to own its assets and retain all power, authorities, rights and remedies necessary or appropriate to allow it to comply with its pre-existing debt instruments and any new

Notes to Consolidated Financial Statements

June 30, 2021

debt instruments; all debt and other liabilities of each Enterprise participant will remain the debt and liabilities of such Enterprise participant regardless of when incurred (unless otherwise agreed); and no Enterprise participant assumes or guarantees the debt or other liabilities of any other Enterprise participant.

WFUBMC and CMHA delegated authority to Atrium to manage and oversee their activities and operations, subject to the authority of the University, WFUHS, and WFUBMC over academic and research matters, the exercise of certain reserved powers, and the carrying out of certain responsibilities by the WFUBMC Board and the CMHA Board of Commissioners.

The reserved powers of each Enterprise participant include the power to approve a change in its fundamental business or mission and, subject to the Atrium Board's approval, to develop its strategic plans (which will be generally consistent with those of the entire Enterprise) and its capital and operating budgets.

The School of Medicine continues as an academic unit owned and operated by the University through WFUHS. The Chief Academic Officer (CAO) reports exclusively to the President of the University on School of Medicine related academic matters and the President must consent to the appointment of the Dean of the School of Medicine by the CAO. The University, generally through the School of Medicine, continues to be responsible for, and have the authority regarding, all academic functions of the School of Medicine, including: setting the tuition rates, managing research activities and support, compliance with regulatory and accreditation standards, medical curriculum and academic programs and classes, standards and process for appointing, compensation, evaluating, promoting, granting tenure and dismissing faculty, requirements, standards, and processes relating to student admission, matriculation, conduct, evaluation/grading, promotion, and graduation (including awarding degrees in the School of Medicine);student clinical rotations, including assignments; processing and administering financial aid, student support services; administration and support of research, grant-processing, and research performed by faculty, staff, and students of the School of Medicine; and other customary academic functions associated with the operation of medical schools and health science related programs. As such, the University shall continue to hold and exercise, at minimum, the degree of academic and academically related administrative authority over WFUBMC, the School of Medicine, and WFUHS that the University exercised prior to the creation of the Enterprise.

In addition to forming a unified health system, a second medical school campus of the School of Medicine will be established in Charlotte, which will operate under the authority of the University as stated above and which will be affiliated with Atrium and is scheduled to open to first-year M.D. students in 2024. The addition of the second campus is expected to approximately double the enrollment of the School of Medicine. The integration transaction's objectives include fostering the mission of the School of Medicine through its new relationship with Atrium and the continued flourishing of the Medical Center.

The University is not obligated for repayment of indebtedness issued by or for the performance of obligations of NCBH, WFUHS, the Medical Center, the School of Medicine, CMHA, Atrium or any other affiliate. The University has not been pledged to secure obligations of NCBH, WFUHS, the Medical Center, the School of Medicine, CMHA, Atrium or any other affiliate. Similarly, neither NCBH, WFUHS, the Medical Center, the School of Medicine, CMHA, Atrium nor any other affiliate

Notes to Consolidated Financial Statements
June 30, 2021

is obligated for the payment of the 2021 bonds or other obligations of the University and none of the property or other assets of NCBH, WFUHS, the Medical Center, the School of Medicine, CMHA, Atrium or any other affiliate has been pledged to secure payment of the 2021 bonds or other obligations of the University.

All significant intercompany balances and transactions have been eliminated in consolidation.

# (b) Basis of Presentation

The consolidated financial statements have been prepared on the accrual basis in conformity with GAAP.

Net assets are reported based on the existence or absence of donor-imposed restrictions and serve as the foundation of the accompanying consolidated financial statements.

Accordingly, net assets of the University and changes therein are classified and reported as follows:

- Net Assets without donor restrictions Net assets that are not subject to donor-imposed restrictions and may be expended for any purpose in performing the primary objectives of the organization.
- Net Assets with donor restrictions Net assets subject to donor-imposed stipulations. Some donor
  restrictions are temporary in nature; those restrictions will be met by actions of the University
  and/or by the passage of time. Other donor restrictions are perpetual in nature, whereby the donor
  has stipulated the funds be maintained in perpetuity; generally, the donors of these assets permit
  the University to use all or part of the income earned on related investments for general or specific
  purposes.

Revenues are reported as increases in net assets without donor restrictions unless their use is limited by donor-imposed restrictions. Donor-restricted contributions are reported as increases in net assets with donor restrictions. Contributions which impose restrictions that are met in the same fiscal year they are received are reported as increases in net assets without donor restrictions. Expenses are reported as decreases in net assets without donor restrictions. Gains and losses on investments and other assets or liabilities are reported as increases or decreases, respectively, in net assets without donor restrictions unless their use is restricted by explicit donor stipulations or by law. Expirations of restrictions on net assets (i.e., the donor-stipulated purpose has been fulfilled and/or the stipulated time period has elapsed) are reported as reclassifications from net assets with donor restrictions to net assets without donor restrictions in the consolidated statement of activities. For gifts of long-lived assets, these releases of restrictions are treated as nonoperating.

# (c) Effects of COVID-19 Pandemic on Operations

In March 2020, the World Health Organization declared the novel coronavirus (COVID-19) a pandemic. The outbreak of the disease has affected travel, commerce and financial markets globally, including in the United States. The continued spread of COVID-19 and its impact on social interaction, travel, economies and financial markets may adversely affect operations and financial condition, including, among other things, (i) the cost of operations, (ii) governmental and non-governmental funding, and (iii) financial markets impacting investments valuation and interest rates.

Notes to Consolidated Financial Statements

June 30, 2021

## Reynolda Campus

Reynolda Campus cancelled classes the week of March 16, 2020 and resumed remote instruction on March 23, 2020 and most students vacated the campus. The University granted refunds in fiscal year 2020 for certain fees, housing and dining services not provided after March 16, 2020. Students continued to meet their academic requirements for the remainder of the 2019 – 20 academic year. While some faculty and staff were working on-campus to ensure continuity of essential operations, most faculty and staff transitioned to remote work.

Reynolda Campus successfully reopened the 2020-2021 academic year in socially distanced blended learning modality. The University altered the academic calendar to limit potential student travel and offered housing and dining refunds at the end of the fall semester to account for the decrease in the days on campus. Reynolda Campus continued allowing faculty and staff to work remotely to help with dedensification. The University experienced increased operating expenses due to COVID testing costs, quarantine and additional campus housing costs, and costs associated with preparing the academic and student life spaces for socially distanced requirements.

The Coronavirus Aid, Relief, and Economic Security Act (CARES Act) provided funding from the Department of Education which provided funds for disbursement to universities for students impacted by COVID-19 and to the University to replace lost revenues or reimburse for COVID-19 related costs. Reynolda Campus received and disbursed approximately \$8.1 million of federal revenue, including approximately \$0.8 million for WFUHS, recorded in Government grants and contracts, with \$3.5 million directly disbursed to impacted students, recorded in Student tuition and fees as financial aid, and \$4.6 million was reimbursed to the University to offset lost revenue, recorded in Sales and services of auxiliary enterprises, for year ended June 30, 2021. During 2021, the University also received CARES Act funding through the State of North Carolina totaling \$0.8 million, including \$0.4 million allocated for student aid, and \$0.4 million allocated for reimbursement of personal protective equipment and costs associated with the conversion to online learning.

### **WFUHS**

WFUHS ceased elective surgeries during the period from mid-March 2020 to May 2020, resulting in significant unexpected revenue declines during that period.

The Coronavirus Aid, Relief, and Economic Security Act (CARES Act) provided funding to the Department of Health and Human Services (DHHS) Public Health and Social Services Emergency Fund (Relief Fund), which provided funds to qualifying healthcare providers treating COVID-19 patients to replace lost revenues or reimburse for COVID-19 related costs. WFUHS received approximately \$16 million of revenues from the Relief Fund to replace lost revenues attributable to COVID-19 for the year ended June 30, 2020. WFUHS recorded approximately \$1 million and \$15 million to government grants and contracts revenue for the years ended June 30, 2021 and 2020, respectively. The unrecognized funds received at June 30, 2020 were recorded as other liabilities and deferrals in the consolidated balance sheets. These Relief Fund payments are not subject to repayment, provided WFUHS is able to attest to and comply with the terms and conditions of the funding, including demonstrating that the distributions received have been used to replace lost revenue attributable to COVID-19 or to reimburse for COVID-19 related costs.

Notes to Consolidated Financial Statements

June 30, 2021

Additionally, DHHS Centers for Medicare and Medicaid Services (CMS) provided approximately \$17.8 million of Medicare advance payments to WFUHS in fiscal year 2020, which were recorded as other liabilities and deferrals at June 30, 2020 in the consolidated balance sheets. In fiscal year 2021, following CMS guidance, WFUHS determined the recoupment schedule for paying back these advances through September 2022. Accordingly, at June 30, 2021, WFUHS recorded approximately \$11.9 million of Medicare advance payments within other liabilities and deferrals that represents the current portion and approximately \$3.7 million of Medicare advance payments within other liabilities and deferrals which represents the long-term portion in the consolidated balance sheets.

The COVID-19 pandemic has negatively affected national, state, and local economies and global financial markets, and the higher education and healthcare landscape in general. While the financial impact on the University cannot be quantified at this time, the pandemic may have a material adverse effect on the current and future financial profile and operating performance of the University. The University continues to monitor the course of the pandemic and is prepared to take additional measures to protect the health of the University community and promote the continuity of its academic, healthcare, and biomedical research missions.

# (d) Operating Excess (Deficiency)

Revenues earned, expenses incurred, and returns made available for the University's operating purposes of teaching, research, patient care, and other programs and services are components of the operating excess or deficiency presented in the consolidated statement of activities. The University considers the following items to be nonoperating activities: restricted contributions for capital and long-term investment and the related net assets released from restriction, investment return in excess of amounts designated for current operations, actuarial gain or loss on annuity obligations, unrealized gain or loss on interest rate swaps, postretirement related changes other than service cost, gain or loss from affiliates (equity method), donor designation changes and other, net, including costs incurred related to a cloud computing arrangement.

#### (e) Fair Value Measurements

The fair value hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The hierarchy requires the use of observable market data when available. The three levels of the fair value hierarchy are as follows:

- Level 1 Valuations for assets and liabilities traded in active exchange markets as of the reporting date. Valuations are obtained from readily available pricing sources for market transactions involving identical assets or liabilities.
- Level 2 Valuations for assets and liabilities are determined through direct or indirect observations other than quoted market prices.
- Level 3 Valuations for assets and liabilities that are derived from other valuation methodologies including discounted cash flow models and similar techniques, and not based on market exchange, dealer or broker traded transactions.

Notes to Consolidated Financial Statements

June 30, 2021

Net asset value (NAV) – Certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been categorized in the fair value hierarchy.

In the event that changes in the inputs used in the fair value measurement of an asset or liability result in a transfer of the fair value measurement to a different categorization (e.g., from Level 3 to Level 2), such transfers between fair value categories are recognized at the end of the reporting period.

The carrying amounts of cash and cash equivalents (Level 1), patient receivables (Level 2), and accounts receivable (Level 2) approximate fair value because of the terms and relatively short maturity of these financial instruments. The carrying amounts of contributions receivable represent the present value of estimated future cash flows, which approximates fair value (Level 3). Investments (Levels 1-3, see note 10) and deposits with bond trustee (Level 1) are reported at fair value. The fair value of notes receivable from students under government loan programs cannot be made because such loans are not sellable and can only be assigned to the U.S. government or its designees. The fair value of receivables from students under University loan programs (Level 2) approximates carrying value.

The carrying amounts of accounts payable and other accruals (Level 2) approximate fair value because of the relatively short maturity of these financial instruments. Annuities payable (Level 2) are recorded at fair value using a single discount rate equivalent to the University's tax-exempt borrowing rate. The carrying amounts of notes and bonds payable (Level 2) with variable interest rates approximate their fair value because substantially all of these financial instruments bear interest at rates that approximate current market rates for borrowings with similar maturities and credit quality.

#### (f) Cash and Cash Equivalents

Cash equivalents include highly liquid investments with original maturities at date of purchase of three months or less. Such assets, reported at fair value, primarily consist of depository account balances, and money market funds. The University maintains bank accounts at various financial institutions covered by the Federal Depository Insurance Corporation (FDIC). At various times throughout the year, the University may maintain bank accounts in excess of the FDIC-insured limit. Management believes that the risk associated with these bank accounts is minimal.

Cash and cash equivalents that are managed as part of the University's investments are reported within investments on the consolidated balance sheet and excluded from cash in the consolidated statement of cash flows as these funds are not used for operating needs.

# (g) Contributions Receivable

Pledges that represent unconditional promises to give are recognized at fair value as contributions with donor restrictions in the period such promises are made by donors. Pledges are recorded after discounting, using rates ranging from 0.61%–1.43% in order to derive the present value of the future cash flows. An allowance for uncollectible contributions receivable is provided based upon management's judgment, considering such factors as prior collection history, type of contribution, relationship with donor, and nature of fund-raising activity.

Notes to Consolidated Financial Statements

June 30, 2021

#### (h) Notes Receivable

Notes receivable, which are recorded at face value, principally represent amounts due from students under Perkins. A general allowance is made for uncollectible student loans after considering long-term collection experience and current trends. Other notes receivable are evaluated individually for impairment, with allowances based on management's expectations given facts and circumstances related to each note.

The University assigns loans receivable from students under governmental loan programs, also carried at cost, to the federal government. The University classifies refundable advances from the federal government as liabilities in the consolidated statement of financial position. Outstanding loans cancelled under a governmental program result in a reduction of the funds available for loan and a decrease in the liability to the government.

#### (i) Investments

The University's Board of Trustees created an asset management company, VCM, that provides research, advice, counsel and management with respect to the University's primary investment portfolio. VCM manages the investment funds of Verger Capital Fund, LLC (Master Fund), Verger Fund I, LLC (Verger Fund I), and Verger Fund II, LLC (Verger Fund II). The Master Fund is controlled by the University and provides investment services for Verger Fund I and Verger Fund II. Verger Fund I was created to hold the Reynolda Campus long-term endowment and working capital pool and Verger Fund II was created to hold the WFUHS and Reynolda House long-term endowment and working capital pools.

Certain investments, however, are held in specific instruments outside of VCM to comply with donor restrictions or other considerations.

Valuation – Investments are recorded at fair value in the consolidated balance sheet. Investments in readily marketable debt and equity securities are stated at their fair values, which are determined based on quoted market prices. For shares in mutual funds, the University considers fair value based on share prices reported by the funds as of the last business day of the fiscal year. Investments in private equity and absolute return funds are generally reported at the net asset value (NAV) reported by fund managers and these values are reviewed and evaluated by the University's investment management company. Unless it is probable that all or a portion of the investment will be sold for an amount other than NAV, the University has concluded, as a practical expedient, that the NAV approximates fair value. Additionally, the University's interest in both Verger Fund I and Verger Fund II are included at NAV in investments on the consolidated balance sheet. Investments in joint ventures are accounted for using the equity method.

**Risks** – Investments are exposed to several risks, including interest rate, currency, market and credit risks. Due to the level of risk associated with certain investments, it is at least possible that changes in the values of the investments will occur in the near term and that such changes could materially affect the amounts reported in the University's consolidated financial statements.

**Reporting** – Investment transactions are accounted for on a trade date basis. Short and Intermediate term investment income is reported as investment return included in operating revenues and realized and unrealized gains (losses) are reported as nonoperating revenues.

Notes to Consolidated Financial Statements

June 30, 2021

Long-term investment spending rate distribution (see Note 9) is reported as operating revenues and any excess (deficiency) of income and realized and unrealized gains (losses) earned on investments above (below) spending rate, including split-interest agreements are reported as nonoperating revenues. Investment management fees are netted against investment return.

# (j) Investments in Real Estate

Investments in real estate are primarily comprised of rental properties of the University and are valued at the lower of net book value or market. The University records depreciation on rental properties over 40 years. Depreciation is calculated using the straight-line method. Real estate gifts held for sale are recorded at fair value, based on periodic external appraisals.

# (k) Interests in Perpetual Trusts Held by Others and Split-Interest Agreements

The University's split-interest agreements with donors consist primarily of irrevocable charitable remainder trusts for which the University serves as trustee and charitable gift annuities. Assets held in these trusts are stated at fair value and are included in investments. Contribution revenue is recognized at the dates the trusts are established. The University recognizes the change in value of split-interest agreements according to the fair value of assets that are associated with each trust and recalculates the liability for the present value of annuity obligations. Any change in fair value is recognized in the consolidated statement of activities.

The University is also the beneficiary of certain trusts and other assets held and administered by others. The University's share of these assets is recognized in investments at fair value.

#### (I) Other Assets

Other assets are primarily comprised of prepaid expenses, intangible assets, deferred expenses, and inventories. Inventories are valued at the lower of average cost or net realizable value.

#### (m) Land, Buildings, and Equipment

Land, buildings, and equipment are recorded at cost at date of acquisition or estimated fair value on the date received for donated items. Depreciation is calculated using the straight-line method over the estimated useful life of each class or component of depreciable asset. Estimated lives range from 3 to 60 years. Depreciation is not calculated on land and construction in progress. Gains or losses on the disposal of land, buildings, and equipment are included in the consolidated statement of activities. Interest cost incurred on borrowed funds during the period of construction of capital assets is capitalized as a component of the cost of constructing these assets.

## (n) Impairment of Long-Lived Assets

The University periodically assesses the realizability of its long-lived assets and evaluates such assets for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. For assets to be held, impairment is determined to exist if estimated future cash flows, undiscounted and without interest charges, are less than the carrying amount. The University recognizes an impairment charge when the fair value of the asset or group of assets is less than the carrying value.

Notes to Consolidated Financial Statements

June 30, 2021

## (o) Asset Retirement Obligations

The University has asset retirement obligations (AROs) arising from regulatory requirements to perform certain asset retirement activities at the time that certain buildings and equipment are disposed of or renovated. The liability was initially measured at fair value and subsequently is adjusted for accretion expense and changes in the amount or timing of the estimated cash flows. The corresponding asset retirement costs are capitalized as part of the carrying amount of the related long-lived asset and depreciated over the asset's useful life. The University revalues asset retirement obligations as remediation costs are incurred or as additional cost information becomes available.

# (p) Leases

The University has operating and finance leases for real estate and equipment. The University determines if an arrangement is a lease at inception. The University has both leases under which it is obligated as a lessee and leases for which it is a lessor. Operating leases as a lessee are included in right-of-use assets-operating and operating lease obligations in the consolidated balance sheet. Finance leases as a lessee are included in land, building, and equipment, net, and notes payable and finance leases in the consolidated balance sheet.

Right-of-use assets represent the University's right to use an underlying asset for the lease term. Lease obligations represent the University's liability to make lease payments arising from the lease. Operating and finance lease right-of-use assets and related obligations are recognized at commencement date based on the net present value of lease payments over the lease term discounted using an appropriate incremental borrowing rate. As most of the University's leases do not provide an implicit rate, the University uses its incremental borrowing rate which is based on the information available at commencement date in determining the present value of lease payments. The University considers recent debt issuances, as well as publicly available data for instruments with similar characteristics when calculating its incremental borrowing rates. The value of an option to extend or terminate a lease is reflected to the extent it is reasonably certain management will exercise the option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Interest expense is recognized as a component of the lease payment for finance leases.

Rental income arising from operating leases as a lessor is included in operating revenue in sales and services of auxiliary enterprises in the consolidated statement of activities.

#### (q) Derivative Instruments

The University holds certain interest rate swap agreements to manage the fixed/variable mix of its debt portfolio. The notional amounts of the agreements dictate the payments between the counterparties based on agreed-upon rates as determined in the agreements. The University records all derivative instruments on the consolidated balance sheet at their respective fair values. All changes in fair value are reflected in the consolidated statement of activities. Cash payments and receipts are included in interest on debt.

# (r) Postretirement Plans

The University records annual amounts relating to its postretirement plans based on calculations that incorporate various actuarial and other assumptions including discount rates, mortality, retirement rates, and healthcare cost trend rates. The University reviews its assumptions on an annual basis and

Notes to Consolidated Financial Statements

June 30, 2021

makes modifications to the assumptions based on current rates and trends when it is appropriate to do so. The effect of modifications to those assumptions is recorded as a change in unrestricted net assets and amortized to net periodic benefit cost over future periods using the corridor method. The University believes that the assumptions utilized in recording its obligations under its plans are reasonable based on its experience and market conditions. The net periodic benefit costs are recognized as employees render the services necessary to earn the postretirement benefits. The University records the service cost component of net benefit cost in the employee benefits expense line item and all other costs associated with net benefit costs are reflected in nonoperating activities.

# (s) Revenue Recognition

The University recognizes revenue based on either ASU 2014-09 (*Topic 606*) or ASU 2018-08 (*Topic 958*) as appropriate based on the underlying transactions within each revenue category.

The University's significant revenue recognition policies are as follows:

**Student tuition and fees** – Student tuition and fees for instruction and other educational services, net of scholarships and fellowships, are substantially billed and collected prior to the end of each semester. Revenues are earned and recognized over the course of each semester as education services are delivered. Student tuition and fees received in advance of services to be rendered are recorded as deferred revenue. Student aid provided by the University is reflected as a reduction in student tuition and fee revenue up to the cost of attendance. Student financial aid in excess of the cost of attendance is reflected as a reduction in auxiliary revenue. Student aid does not include payments made to students for services rendered to the University.

Grants and contracts – Grants for basic research and other sponsored programs are generally subject to restrictions and conditions that must be met before the University is entitled to funding. Accordingly, advances from granting agencies are generally considered refundable in the unlikely event specified services are not performed. The University recognizes revenues on grants for basic research and other sponsored programs as the awards for such programs are expended, since expenditures in accordance with award terms typically results in the simultaneous release of restrictions and conditions imposed by the grantor. Revenue from exchange contracts for applied research is recognized as the University's contractual performance obligations are substantially met. Indirect cost recovery by the University on U.S. government grants and contracts is based upon a predetermined negotiated rate and is recorded as private grants and contracts revenue and government grants and contracts revenue.

**Contributions** – Contributions, including unconditional promises to give, are recognized in the period the contributions or promise is made. Contributions of assets other than cash are recorded at their estimated fair value. Unconditional promises expected to be collected in future years are recorded at the present value of expected future cash flows discounted at an appropriate discount rate commensurate with the risks involved. Amortization of discounts is recorded as additional contribution revenue in accordance with donor-imposed restrictions, if any, on the contributions. Conditional promises to give are not recognized until they become unconditional, that is, when the conditions on which they depend are substantially met.

**Patient revenue** – Patient revenue is reported at the amount that reflects the consideration to which WFUHS expects to be entitled for providing patient care. These amounts are due from

Notes to Consolidated Financial Statements

June 30, 2021

patients, third party payers, and others, and includes variable consideration for retroactive revenue adjustments due to settlement of reviews and audits. Revenue is recognized as performance obligations are satisfied.

Performance obligations are determined based on the nature of the services provided by WFUHS. Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected or actual charges. WFUHS believes that this method provides a reasonable depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation. Generally, performance obligations satisfied over time relate to patients receiving inpatient acute care services. WFUHS measures the performance obligation from admission into the hospital to the point when it is no longer required to provide services to that patient, which is generally at the time of discharge. These services are considered to be a single performance obligation. Revenue for performance obligations satisfied at a point in time is recognized when services are provided and WFUHS does not believe it is required to provide additional services to the patient. Generally, performance obligations satisfied at a point in time relate to outpatient services and pharmacy revenue.

Because all of its performance obligations relate to contracts with a duration of less than one year, WFUHS has elected to apply the optional exemption provided in FASB ASC 606-10-50-14(a) and, therefore, is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.

WFUHS is utilizing the portfolio approach practical expedient in ASC 606 for contracts related to net patient service revenue. WFUHS accounts for the contracts within each portfolio as a collective group, rather than individual contracts, based on the payment pattern expected in each portfolio category and the similar nature and characteristics of the patients within each portfolio. The portfolios consist of major payer classes for inpatient revenue and outpatient revenue. Based on historical collection trends and other analyses, WFUHS has concluded that revenue for a given portfolio would not be materially different than if accounting for revenue on a contract-by-contract basis.

WFUHS has agreements with third party payers that provide for payments to WFUHS at amounts different from its established rates. Payment arrangements include prospectively determined rates per discharge, reimbursed costs, discounted charges, and per diem payments. For uninsured patients who do not qualify for charity care, WFUHS recognizes revenue based on established rates, subject to certain discounts and implicit price concessions as determined by WFUHS. WFUHS determines the transaction price based on standard charges for services provided, reduced by explicit price concessions provided to third party payers, discounts provided to uninsured patients in accordance with WFUHS's policy, and implicit price concessions provided to uninsured patients. Explicit price concessions are based on contractual agreements, discount policies, and historical experience. Implicit price concessions represent differences between amounts billed and the estimated consideration WFUHS expects to receive from patients, which

Notes to Consolidated Financial Statements

June 30, 2021

are determined based on historical collection experience, current market conditions, and other factors.

Generally, patients who are covered by third party payers are responsible for patient responsibility balances, including deductibles and coinsurance, which vary in amount. WFUHS estimates the transaction price for patients with deductibles and coinsurance based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by any explicit price concessions, discounts, and implicit price concessions. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to patient service revenue in the period of the change. Adjustments arising from a change in the transaction price were not significant in fiscal year 2021 or 2020. Subsequent changes that are determined to be the result of an adverse change in the patient's ability to pay are recorded as bad debt expense. Bad debt expense for the years ended June 30, 2021 and 2020 was not material to the consolidated statement of activities.

Under the Medicare and Medicaid programs, WFUHS is entitled to reimbursement for billed current procedural terminology codes at fee schedule rates determined by federal and state governments. Differences between established billing rates and reimbursements from these programs are recorded as contractual adjustments to arrive at net patient service revenue.

**Charity care** – WFUHS cares for patients who meet certain criteria under its charity care policy without charge or at amounts less than its established rates. WFUHS does not pursue collection of amounts determined to qualify as charity care, and accordingly, such amounts are not recognized as revenue.

Sales and services of auxiliary enterprises – Sales and services of auxiliary enterprises primarily consist of revenues from athletics, residence halls, dining services, parking, real estate, and retail stores, which furnish goods and services to students, faculty, staff, and in some cases, the general public. Fee charges are directly related to the cost of goods provided or services rendered and are recognized accordingly. Student aid provided by the University in excess of tuition is reflected as a reduction of sales and services of auxiliary enterprises.

Certain auxiliary revenues arise from contracts. Revenues from intercollegiate athletics ticket sales, media rights, licensing and royalties and other contracts are received and recognized concurrent with event-based obligations or the passage of contract terms, but typically within the fiscal year. However, season ticket proceeds received prior to the report date for events scheduled in the upcoming fiscal year are recorded as deferred revenue and recognized as the associated events are completed. Charges to students for campus residence, and dining are substantially billed and collected prior to the end of each semester. Associated revenues are earned and recognized over the course of each semester as these services are delivered. Accounts receivable from students are typically insignificant at the end of each fiscal year.

#### (t) Use of Estimates

The University prepares its consolidated financial statements in accordance with GAAP that requires management to make estimates and assumptions relating to the reporting of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items

Notes to Consolidated Financial Statements

June 30, 2021

subject to such estimates and assumptions include the carrying amount of right of use assets-operating, land, buildings, and equipment, the valuation of nonreadily marketable investments, investments in real estate, allowances for receivables, third-party payer settlements, and any other implicit price concessions, AROs, professional liabilities, operating lease obligations, interest rate swap obligations and obligations related to employee benefits. Actual results could differ from those estimates.

# (u) Income Taxes

The University is a tax-exempt organization as described in Section 501(c)(3) of the Internal Revenue Code (the Code) and is generally exempt from federal income taxes on related income pursuant to Section 501(a) of the Code. If applicable, unrelated business income is reported by all member and subsidiary organizations on IRS Form 990-T. Fiscal years ending on or after June 30, 2018 remain subject to examination by federal and state tax authorities. The University has evaluated uncertain tax positions for the year ended June 30, 2021, including a quantification of tax risks in areas such as unrelated business income and taxation of its for-profit subsidiaries. This evaluation did not identify any material items that effect the consolidated financial statements for the year ended June 30, 2021.

# (v) Comparative Financial Information

The consolidated financial statements include certain prior year information for comparative purposes, which does not include sufficient detail to constitute a presentation in conformity with GAAP. Accordingly, such information should be read in conjunction with the University's consolidated financial statements for the year ended June 30, 2020 from which this information was derived.

# (2) Liquidity and Availability

Financial assets available for general expenditure within one year of June 30 are as follows:

			2021		
	_	Reynolda Campus	WFUHS	Total	2020
Cash and cash equivalents	\$	37,133	177,688	214,821	166,839
Accounts receivable, net		19,857	77,160	97,017	114,386
Patient receivables Investments available to be		_	77,899	77,899	63,317
liquidated	_	380,998	499,141	880,139	605,198
Total financial assets available					
within one year	\$_	437,988	831,888	1,269,876	949,740

In addition to amounts included above, as part of the University's liquidity management, it invests cash in excess of daily requirements in short-term investments. To help manage unanticipated liquidity needs, Reynolda Campus and WFUHS have committed lines of credit with a total borrowing capacity of \$150,000 and \$300,000, respectively, at June 30, 2021 and \$100,000 and \$300,000 at June 30, 2020, respectively, which could be drawn upon. Additionally, Reynolda Campus and WFUHS have board-designated

Notes to Consolidated Financial Statements

June 30, 2021

endowment funds of \$270,018 and \$522,371, respectively at June 30, 2021 and \$221,229 and \$289,446 at June 30, 2020, respectively. Although the University does not intend to spend from the board-designated endowment funds other than amounts appropriated for general expenditures as part of its annual budget approval and appropriation, amounts from the board-designated endowment funds could be made available, subject to certain lock-up provisions that reduce the total investments that could be made available if necessary.

## (3) Accounts Receivable

The following is an analysis of accounts receivable at June 30, 2021 and 2020:

			2021		
	_	Reynolda Campus	WFUHS	Total	2020 Total
Accounts receivable Grants receivable	\$_	15,995 4,294	28,260 51,280	44,255 55,574	83,649 43,779
Total accounts receivable		20,289	79,540	99,829	127,428
Less allowance for bad debts	_	(432)	(2,380)	(2,812)	(3,542)
Accounts receivable, net	\$	19,857	77,160	97,017	123,886

## (4) Student Services Revenue

Student services revenue consists of revenue for tuition and fees, housing, and dining. The revenue is determined based on published rates for such services less any institutional financial aid awarded by the University to qualifying students. The University's policy attributes aid first to tuition and fees and any excess to auxiliary services, for financial reporting purposes.

	2021					2020						
	Re	ynolda Camp	us		WFUHS		Re	ynolda Camp	us		WFUHS	
	Published	Financial	Net	Published	Financial	Net	Published	Financial	Net	Published	Financial	Net
	rates	aid	revenue	rates	aid	revenue	rates	aid	revenue	rates	aid	revenue
Student tuition and												
fees \$	395,351	(110,422)	284,929	58,541	(18,541)	40,000	368,471	(105,539)	262,932	55,909	(17,193)	38,716
Housing and dining	37,185	(15,813)	21,372				36,275	(14,441)	21,834			
Total \$	432,536	(126,235)	306,301	58,541	(18,541)	40,000	404,746	(119,980)	284,766	55,909	(17,193)	38,716

Notes to Consolidated Financial Statements

June 30, 2021

## (5) Patient Revenue and Patient Receivables

Patient revenue by major payer source, net of price concessions, is as follows for the years ended June 30:

	 20	21	2020		
Medicare	\$ 235,348	34 %	208,308	34 %	
Medicaid	80,682	12	70,914	11	
Managed care and					
commercial insurance	340,561	49	301,457	48	
Self-pay, after insurance	7,320	1	5,557	1	
Self-pay, uninsured	5,639	1	6,788	1	
Other	 21,968	3	28,314	5	
Patient service					
revenue	\$ 691,518	100 %	621,338	100 %	

#### Concentration of Credit Risk

WFUHS grants credit without collateral to its patients, most of whom are insured under third-party payer agreements. The mix of receivables from patients and third-party payers was as follows as of June 30:

	2021	2020
Medicare	25 %	24 %
Medicaid	14	11
Managed care and commercial insurance	24	22
Self-pay, after insurance	14	16
Self-pay, uninsured	11	13
Other	12	14
	100 %	100 %

As a result of certain changes required by ASU 2014-09, the majority of WFUHS' provision for bad debts is recorded as a direct reduction to patient revenue instead of being presented as a separate line on the consolidated statement of activities.

WFUHS maintains records to identify and monitor the level of charity care it provides. These records include the amount of charges foregone and estimated costs incurred for services and supplies furnished under its charity care policy and equivalent service statistics. Costs incurred are estimated based on the ratio of total operating expenses to gross charges applied to charity care charges foregone. The amounts of direct and indirect costs incurred for services and supplies furnished under WFUHS' charity care policy totaled \$4,698 and \$13,257 in 2021 and 2020, respectively.

Notes to Consolidated Financial Statements

June 30, 2021

#### (6) Contributions Receivable

The following is an analysis of the maturities of the University's contributions receivable at June 30, 2021 and 2020:

	_				
	_	Reynolda Campus	WFUHS	Total	2020 Total
One year or less	\$	28,793	5,851	34,644	36,357
Between one and five years		67,703	7,872	75,575	57,957
More than five years	_	94,410	900	95,310	99,483
Contributions receivable, gross		190,906	14,623	205,529	193,797
Estimated uncollectible amounts		(6,869)	(1,532)	(8,401) (57,817)	(8,656)
Discount to present value	_	(57,323)	(494)	(57,817)	(58,288)
Contributions receivable,					
net	\$_	126,714	12,597	139,311	126,853

Contributions receivable are discounted at a rate commensurate with the scheduled timing of receipt. Such amounts outstanding as of June 30, 2021, and 2020, were discounted at rates ranging from 0.61% to 0.62% for Reynolda Campus, respectively, and 1.43% to 1.71% for WFUHS, respectively.

Contributions receivable, net for Reynolda Campus included significant pledges from a few donors and perpetual commitments from a foundation with a long-standing history of support to the University. These long-term unconditional promises to give represented 61% and 64% of Reynolda Campus' net contributions receivable as of June 30, 2021 and 2020, respectively.

Notes to Consolidated Financial Statements

June 30, 2021

#### (7) Notes Receivable

The following is an analysis of notes receivable at June 30, 2021 and 2020:

		Reynolda Campus	WFUHS	Total	2020 Total
Student loans receivable Other notes receivable	\$ _	9,815 3,605	336 	10,151 3,605	12,690 4,797
Total notes receivable		13,420	336	13,756	17,487
Less estimated uncollectible amounts		(700)	(34)	(734)	(724)
Notes receivable, net	\$	12,720	302	13,022	16,763

The University makes uncollateralized loans to students based on financial need. Student loans are funded through Federal government loan programs or institutional resources. At June 30, 2021 and 2020, student loans receivable consisted of Federal loan programs of \$9,271 and \$11,735, respectively, and institutional loan programs of \$880 and \$955, respectively. The University participates in the Perkins federal revolving loan program. Cumulative funds advanced by the Federal government of \$2,049 and \$4,533 at June 30, 2021 and 2020, respectively, are ultimately refundable to the federal government and are reported as government grants refundable on the consolidated balance sheet. Outstanding loans canceled under the program result in a decrease in the liability to the federal government. The Federal Perkins Loan Program expired on September 30, 2017, and the University has implemented procedures to wind-down the program. The University plans to continue servicing the Perkins loan portfolio during the wind-down period until it is no longer administratively feasible. Based on review of the prior collection history the University has recorded an allowance for uncollectible Perkins loan amounts of \$458 and \$458 as of June 30, 2021 and 2020, respectively. Allowances for uncollectible institutional student loans are based on prior collection experience and current economic factors, which, in management's judgment, could influence the ability of loan recipients to repay the amounts per the loan terms. Institutional student loan balances are written off only when they are deemed to be permanently uncollectible. At June 30, 2021 and 2020, the allowance for uncollectible institutional student loan amounts was \$276 and \$266, respectively.

Notes to Consolidated Financial Statements

June 30, 2021

#### (8) Investments

Investments at June 30, 2021 and 2020 consist of the following:

	_	2021	2020
Short-term investments <sup>(a)</sup>	\$	25,046	36,466
Absolute return <sup>(b)</sup>		1,877,649	1,336,945
Commodities <sup>(c)</sup>		14,060	10,428
Fixed income: (d)			
Domestic		475,221	259,508
International		9,970	1,727
Private equity <sup>(e)</sup>		1,046	1,135
Public equity: <sup>(f)</sup>			
Domestic		50,105	70,095
International		44,428	3,436
Real estate <sup>(g)</sup>		12,953	8,393
Beneficial interest in perpetual trusts and assets held by others (h	1)	33,733	28,423
Other <sup>(i)</sup>	_	354,771	236,031
Total investments	\$_	2,898,982	1,992,587

- (a) Includes short duration U.S. Treasury debt securities and other short-term, higher quality debt securities, cash and money market mutual funds.
- (b) Includes investments in hedge funds and hedge fund-of-funds that invest both long and short on a global basis primarily in: equity securities (common stocks), credit securities (both investment grade and noninvestment grade), commodities, and currencies. In aggregate, the expectation is that the returns of this segment should not be highly correlated to the broad equity market. Includes \$1,867,495 and \$1,323,525 of funds managed by Verger valued under the NAV practical expedient in fiscal years 2021 and 2020, respectively, whose underlying investments were comprised of 56.1% and 50.0% of equities, 12.8% and 11.9% of real assets, 15.8% and 20.5% of absolute return, and 15.3% and 17.6% fixed income in fiscal years 2021 and 2020, respectively.
- (c) Includes primarily illiquid investments in timberland, oil and gas properties, and water rights and entitlements held through limited partnership interests. While many of the investments are U.S. focused, some are more global. The category also includes more liquid allocations made to commodity (precious metals, industrial materials, and energy) mutual funds.
- (d) Includes long only, hedge strategies, and illiquid investments in various fixed income strategies (both U.S. and non-U.S.) including: investment grade securities, noninvestment grade securities, mortgage backed securities, asset backed securities, Treasury Inflation Protected Securities (TIPS), distressed debt, senior loans, and bank loans. The long only position also includes mutual funds that have daily liquidity in U.S. and non-U.S. fixed income markets.

Notes to Consolidated Financial Statements

June 30, 2021

- (e) Includes illiquid investments primarily in buyout, growth equity, and venture capital (both U.S. and non-U.S.) held through limited partnership interests.
- (f) Includes investments primarily in U.S. and non-U.S. common stocks (including emerging markets) as well as funds that invest in U.S. and non-U.S. common stocks (including emerging markets), mutual funds, and exchange traded funds. While most of the assets are invested long only, some assets are invested on a hedged basis (both long and short).
- (9) Includes illiquid investments in commercial real estate, residential real estate, and farmland held through limited partnership interests. While many of the investments are U.S. focused, some are more global. The category also includes real estate mutual funds and exchange traded funds and real estate held for sale.
- (h) Includes trusts and certain other assets held and administered by others which the University has an unconditional right to receive all or a portion of the specified cash flows.
- (i) Includes primarily funds held under retirement and benefit plans and other miscellaneous investments.

In addition to the long-term pool, the University also manages other investment portfolios. Generally, these portfolios are invested in mutual funds, U.S. Treasury debt securities, and fixed income securities with daily liquidity. Each portfolio's asset allocation is customized based upon the return and risk objectives and distribution requirements of the portfolio.

### (9) Endowment

The University's pooled endowment was established for a variety of purposes including both donor-restricted endowment funds and funds designated by the Board of Trustees to function as endowments. Net assets associated with endowment funds are classified and reported based on the existence or absence of donor-imposed restrictions. Gift annuities, beneficial interest in perpetual trusts and assets held by others, and contributions receivable are not considered components of the endowment.

The Board of Trustees has interpreted the Uniform Prudent Management of Institutional Funds Act (UPMIFA) as allowing the University to appropriate for expenditure or accumulate so much of an endowment fund as the University determines is prudent for the uses, benefits, purposes, and duration for which the endowment fund is established, subject to the intent of the donor as expressed in the gift instrument. As a result of this interpretation, the University's policy is to report as donor restricted net assets (a) the original value of gifts donated to the donor restricted endowment, (b) the original value of subsequent gifts to the donor restricted endowment, and (c) accumulations to the donor restricted endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund.

In accordance with UPMIFA, the board of trustees considers the following factors in making a determination to appropriate or accumulate donor-restricted endowment funds:

- 1. The duration and preservation of the fund
- 2. The purposes of the University and the donor-restricted endowment fund

Notes to Consolidated Financial Statements

June 30, 2021

- 3. General economic conditions
- 4. The possible effect of inflation and deflation
- 5. The expected total return from income and the appreciation of investments
- 6. Other resources of the University
- 7. The investment policies of the University

The University has adopted investment and spending policies for endowment assets that support the objectives of optimizing long-term returns and providing a sustainable level of endowment income distribution to support the University's activities through the annual operating budget while preserving the real (inflation adjusted) purchasing power of the endowment. The University's primary investment objective is to maximize total return within reasonable and prudent levels of risk while maintaining sufficient liquidity to meet disbursement needs. The endowment spending rate is calculated as a percentage of the average of the previous three-year semiannual moving market value per unit and subject to a 10% maximum annual growth or decline in per-unit spending. The endowment spending rate for the years ended June 30, 2021 and 2020, respectively were 4.70% and 4.85%, respectively, for Reynolda Campus, and 5.30% for WFUHS.

The portfolio is constructed on a foundation of modern portfolio theory and strategic asset allocation. Under the direction of VCM the University diversifies its investments among various asset classes incorporating multiple strategies and investment advisors to help manage risk. Management and investment decisions are not made in isolation, but in the context of the portfolio of investments as a whole and as part of the overall investment strategy.

The University invests the majority of these assets in Verger Capital Fund. The University has established three individual unitized endowment pools for Reynolda Campus, Reynolda House, and WFUHS. The internal long-term pools are reported on a fair value basis, with each individual fund subscribing to or disposing of units based on the fair value per unit at the beginning of each quarter after which the transaction took place.

# Notes to Consolidated Financial Statements June 30, 2021

Endowment net assets consist of the following at June 30, 2021 and 2020:

Without donor	With donor		2020
restriction	restriction	Total	Total
_	A72 515	A72 515	448,103
_	•	335,618	190,284
_	808,133	808,133	638,387
270,018	_	270,018	221,229
	(1,451)	(1,451)	(10,583)
270,018	806,682	1,076,700	849,033
S —	173,842	173,842	164,193
	66,788	66,788	25,655
_	240,630	240,630	189,848
522,371	_	522,371	289,446
_	(623)	(623)	(2,806)
1,860	21,972	23,832	24,666
524,231	261,979	786,210	501,154
	restriction	restriction	Without donor restriction         With donor restriction         Total           5         —         472,515         472,515           —         335,618         335,618           —         808,133         808,133           270,018         —         270,018           —         (1,451)         (1,451)           5         270,018         806,682         1,076,700           6         —         173,842         66,788           —         66,788         66,788           —         240,630         240,630           522,371         —         522,371           —         (623)         (623)           1,860         21,972         23,832

Notes to Consolidated Financial Statements
June 30, 2021

Changes in endowment net assets for the years ended June 30, 2021 and 2020 are as follows:

	Without donor	With donor	_	2020
	restriction	restriction	Total	Total
Reynolda Campus:				
Endowment, beginning of year \$	221,229	627,804	849,033	868,436
Investment returns, net	57,748	181,148	238,896	(3,351)
Contributions	100	24,184	24,284	21,437
Transfers	609	(137)	472	_
Appropriation for expenditure	(9,668)	(26,317)	(35,985)	(37,489)
Endowment, end of year \$	270,018	806,682	1,076,700	849,033
WFUHS:				
Endowment, beginning of year \$	291,776	209,378	501,154	506,962
Investment returns, net	93,473	53,891	147,364	5,123
Contributions	_	9,736	9,736	7,721
Transfers	153,870	_	153,870	4,660
Appropriation for expenditure	(14,888)	(11,026)	(25,914)	(23,312)
Endowment, end of year \$	524,231	261,979	786,210	501,154

A donor-restricted endowment fund is considered to be underwater if the fair value of the fund is less than either the original gift amount or the amount required by law. At times, the University may have individual donor-restricted endowment funds that are underwater. The University has a policy that permits spending from underwater funds depending on the degree to which the fund is underwater, unless specifically prohibited by the donor or relevant laws and regulations. At June 30, 2021, and 2020 the amount by which funds were underwater was calculated as follows:

	Reynolda				2020
	_	Campus	WFUHS	Total	Total
Aggregate original gift amount	\$	12,262	5,956	18,218	286,120
Aggregate fair value	_	10,811	5,333	16,144	272,731
Aggregate					
deficiency	\$_	(1,451)	(623)	(2,074)	(13,389)

Notes to Consolidated Financial Statements
June 30, 2021

The purpose of endowed net assets as of June 30, 2021 and 2020 are as follows:

			2021		
	•	Without donor	With donor		2020
		restriction	restriction	Total	Total
Reynolda Campus:					
Instruction and research	\$	8,537	202,399	210,936	163,198
Student aid		18,774	550,700	569,474	446,856
Program support		242,707	53,583	296,290	238,979
Total endowment					
net assets	\$	270,018	806,682	1,076,700	849,033
WFUHS:					
Instruction and research	\$	196,064	79,952	276,016	96,738
Student aid		5,681	59,809	65,490	49,583
Healthcare services		13,057	596	13,653	11,422
Program support		309,429	121,622	431,051	343,411
Total endowment					
net assets	\$	524,231	261,979	786,210	501,154

# (10) Fair Values of Financial Instruments

The following table summarizes the valuation of the University's financial assets and liabilities within the fair value hierarchy levels as of June 30:

0004

2021					
	Level 1	Level 2	Level 3	NAV	Total
\$	214,821	_	_	_	214,821
	25,046	_	_	_	25,046
	10,154	_	_	1,867,495	1,877,649
	14,060	_	_	_	14,060
	475,221	_	_	_	475,221
	9,970	_	_	_	9,970
	_	_	948	98	1,046
	50,105	_	_	_	50,105
	44,428	_	_	_	44,428
	12,860	_		93	12,953
	_	_	33,733	_	33,733
_		124,417		230,354	354,771
\$	856,665	124,417	34,681	2,098,040	3,113,803
	_	\$ 214,821 25,046 10,154 14,060 475,221 9,970 — 50,105 44,428 12,860	\$ 214,821 —  25,046 — 10,154 — 14,060 —  475,221 — 9,970 —  50,105 — 44,428 — 12,860 —  ——————————————————————————————————	Level 1         Level 2         Level 3           \$ 214,821         —         —           25,046         —         —           10,154         —         —           14,060         —         —           475,221         —         —           9,970         —         —           —         948           50,105         —         —           44,428         —         —           12,860         —         —           —         33,733         —           —         124,417         —	Level 1         Level 2         Level 3         NAV           \$ 214,821         —         —         —           \$ 25,046         —         —         —           \$ 10,154         —         —         1,867,495           \$ 14,060         —         —         —           \$ 475,221         —         —         —           \$ 9,970         —         —         —           \$ -         948         98           \$ 50,105         —         —         —           \$ 44,428         —         —         —           \$ 12,860         —         93

# Notes to Consolidated Financial Statements June 30, 2021

				2021		
		Level 1	Level 2	Level 3	NAV	Total
Financial liabilities: Other liabilities and deferrals: Employee benefits – nonrecurring	\$	_	124,417	_	_	124,417
Interest rate swap agreements Annuities payable	_		23,911 23,233			23,911 23,233
Total liabilities	\$_		171,561			171,561
	_			2020	NAV	<del>-</del>
	_	Level 1	Level 2	Level 3	NAV	Total
Financial assets: Cash and cash equivalents	\$	166,839	_	_	_	166,839
Investments: Short-term investments Absolute return		36,466 13,420	_	_	— 1,323,525	36,466 1,336,945
Commodities Fixed income:		10,428	_	_	—	10,428
Domestic		259,508	_	_	_	259,508
International Private equity Public equity:		1,727 —	_	1,037	98	1,727 1,135
Domestic International		70,095 3,436	_		_	70,095 3,436
Real estate  Beneficial interest in perpetual trusts and assets held by		7,727	_	_	666	8,393
others Other		 3,599	90,197	28,423 —	 142,235	28,423 236,031
Total assets	\$_	573,245	90,197	29,460	1,466,524	2,159,426
Financial liabilities: Other liabilities and deferrals: Employee benefits –						
nonrecurring	\$	_	90,197	_	_	90,197
Interest rate swap agreements Annuities payable	_		32,385 18,945			32,385 18,945
Total liabilities	\$_	<u> </u>	141,527			141,527

The classification of investments in the fair value hierarchy is not necessarily an indication of the risks or liquidity of each investment's underlying assets and liabilities. In general, for Level 2 and Level 3 investments, the University utilizes the investment manager to provide a valuation estimate based on disclosed techniques and processes, which have been reviewed for propriety and consistency with consideration given to type and investment strategy.

Notes to Consolidated Financial Statements

June 30, 2021

The University's policy is to recognize transfers into and out of Levels 1, 2, and 3 as of the end of the year or when a change in level becomes known. There were no transfers between Level 1 and Level 2 securities during the years ended June 30, 2021 or 2020. Transfers into and out of Level 3 are typically the result of a change in observation of significant valuation inputs required by various models.

Fair value for LIBOR-based interest rate swaps is determined using a relative price approach, by discounting the future expected cash flows at the market discount rate. For the variable leg of a swap, the expected cash flows are based on implied market forward rates for the appropriate underlying index. A credit value adjustment is applied to the total market value of the swap and quantifies the default risk of a counterparty using a default probability assumption based on the counterparty's credit default swap pricing at year-end.

Obligations under split-interest agreements reported in annuities payable, which approximates fair value, were discounted at a rate that is equivalent to the University's tax-exempt borrowing rate of 1.21% and 1.15% at June 30, 2021 and 2020, respectively.

The following tables present the reconciliation of Level 3 assets measured at fair value for the years ended June 30, 2021 and June 30, 2020, respectively. Both observable and unobservable inputs may be used to determine the fair value of positions that the University has classified as Level 3.

	_	Balances as of June 30, 2020	Total realized and unrealized (losses) gains	Purchases	Sales	Net transfers out of Level 3	June 30, 2021
Investments: Private equity Beneficial interest in perpetual trusts and	\$	1,037	2	_	(91)	_	948
assets held by others	_	28,423	5,618	1,317	(1,625)		33,733
Total Level 3 investments	\$_	29,460	5,620	1,317	(1,716)		34,681
		Balances as of June 30, 2019	Total realized and unrealized (losses) gains	Purchases	Sales	Net transfers out of Level 3	June 30, 2020
Investments: Private equity Beneficial interest in	\$	as of June 30,	realized and unrealized (losses)	Purchases —	<b>Sales</b> (32)	transfers out of	,
Private equity	\$	as of June 30, 2019	realized and unrealized (losses)	Purchases  — 164		transfers out of	2020

Notes to Consolidated Financial Statements

June 30, 2021

Private investments are generally made through limited partnership agreements where the University is normally one of many limited partners. Under the terms of such agreements, the University is required to provide funding, up to the total amount committed by the University, when fund managers make capital calls. These partnerships have a stated maturity date, but can provide for annual extensions for the purpose of disposing remaining portfolio positions and returning capital to investors. Alternatively, the fund may dispose of all portfolio investments and return all capital to investors before the stated maturity date. While the timing and amount of future capital calls and distributions in any particular year are inherently uncertain, the University considers these factors when allocating funds to private investments and believes that it has adequate liquidity to meet its obligations.

As of June 30, 2021, redemption frequency and the corresponding notice period for all investments are as follows:

	Redemption frequency (in days) (if currently	Redemption notice period
Category	eligible)	(in days)
Short-term investments	1 to 7 days	1 day
Absolute return	Daily to >365	1 to 90 days
Commodities	1 to N/A	1 to N/A
Fixed income:		
Domestic	1 to 180 days	Daily to monthly
International	N/A	N/A
Private equity	N/A	N/A
Public equity:		
Domestic	1 to 65 days	Daily to quarterly
International	90 days	Quarterly
Real estate	N/A	N/A
Beneficial interest in perpetual trusts and assets held by others	N/A	N/A
Other	N/A	N/A

Notes to Consolidated Financial Statements

June 30, 2021

## (11) Land, Buildings, and Equipment

Land, buildings, and equipment are summarized as follows at June 30, 2021 and 2020:

		Reynolda	2020		
	_	Campus	WFUHS	Total	Total
Land	\$	44,281	111,013	155,294	152,466
Buildings and other					
improvements		978,819	472,014	1,450,833	1,412,991
Equipment and furnishings		135,463	285,474	420,937	436,174
Construction in progress	_	30,480	25,088	55,568	69,090
		1,189,043	893,589	2,082,632	2,070,721
Less accumulated					
depreciation	_	(505,623)	(553,553)	(1,059,176)	(1,019,624)
	\$_	683,420	340,036	1,023,456	1,051,097

Total depreciation expense on buildings, improvements, equipment, and furnishings was \$87,143 and \$88,465 for the years ended June 30, 2021 and 2020, respectively.

As of June 30, 2021, gross land, buildings, and equipment includes \$54,390 associated with land, building and equipment finance leases.

The University's policy is to capitalize interest cost incurred on debt during the construction of major projects exceeding one year. Interest cost of \$1,669 and \$2,412 was capitalized in the years ended June 30, 2021 and 2020, respectively.

The liabilities associated with AROs for the years ended June 30, 2021 and 2020 were \$5,795 and \$6,330, respectively, for Reynolda Campus, and \$2,659 and \$2,686, respectively, for WFUHS. These liabilities are reported in other liabilities and deferrals on the accompanying consolidated balance sheet.

# (12) Leases

The University has operating and finance leases for real estate and equipment. The University determines if an arrangement is a lease at the inception of the contract. The University elected to apply the short-term lease exception under ASU 2016-02; therefore, leases with an initial term of twelve months or less are not recorded on the consolidated balance sheet.

The University has lease agreements which require payments for lease and non-lease components and has elected to account for these as a single lease component. For leases that commenced before the effective date of ASU 2016-02, July 1, 2019, the University elected the permitted practical expedients to not reassess the following: (1) whether any expired or existing contracts contain leases; (2) the lease classification for any expired or existing leases; and (3) initial direct costs for any existing leases.

Notes to Consolidated Financial Statements

June 30, 2021

The following table presents the components of the lease right-of-use assets and lease liabilities and their classification in the consolidated balance sheet at June 30, 2021.

Components of lease balances	Classification in consolidated balance sheet		WFU	WFUHS	Total	2020 Total
Assets:						
Operating lease assets	Right-of-use assets-operating	\$	27,564	155,141	182,705	208,223
Finance lease assets	Land, buildings, and equipment, ne	et _	5,591	36,626	42,217	45,046
Total leased assets		=	33,155	191,767	224,922	253,269
Liabilities:						
Operating lease liabilities	Operating lease obligations		26,946	159,998	186,944	211,997
Finance lease liabilities	Notes payable and finance leases	_	5,575	39,237	44,812	45,801
Total lease liabilities		\$_	32,521	199,235	231,756	257,798
	Classification in consolidated					2020
Components of lease expense	statement of activities	_	WFU	WFUHS	Total	Total
Operating lease expense	Other operating expenses	\$	3,910	29,022	32,932	33,629
Finance lease expense:						
Amortization of leased assets	Depreciation and amortization		2,369	1,823	4,192	3,521
Interest on lease liabilities	Interest on debt	_	70	1,821	1,891	1,913
Total finance lease						
expense			2,439	3,644	6,083	5,434
Variable and short-term lease						
expense	Other operating expenses	_		1,783	1,783	2,209
Total lease expense		\$_	6,349	34,449	40,798	41,272

The University is committed to minimal annual rent payments under several long-term noncancellable operating and finance leases for equipment and space through fiscal year 2032.

## Other information:

	Reynolda	
	Campus	WFUHS
Weighted-average remaining lease term – finance leases	2.76 years	20.01 years
Weighted-average remaining lease term – operating leases	9.90 years	6.58 years
Weighted-average discount rate – finance leases	0.79 %	4.55 %
Weighted-average discount rate – operating leases	2.04 %	2.91 %

Notes to Consolidated Financial Statements
June 30, 2021

Payments due include options to extend finance leases through fiscal year 2032, are summarized below as of June 30, 2021:

	_	Reynolda Campus	WFUHS	Total
2022	\$	2,137	3,119	5,256
2023		2,140	3,112	5,252
2024		857	3,054	3,911
2025		441	3,024	3,465
2026		_	2,959	2,959
In total hereafter	_		44,378	44,378
	\$_	5,575	59,646	65,221

Payments due include options to extend operating leases through fiscal year 2032, are summarized below as of June 30, 2021:

	 Reynolda Campus	WFUHS	Total
2022	\$ 3,490	28,291	31,781
2023	3,150	27,024	30,174
2024	2,412	26,284	28,696
2025	2,066	25,247	27,313
2026	2,159	24,610	26,769
In total hereafter	 13,669	46,035	59,704
	\$ 26,946	177,491	204,437

The University maintains rental properties and has entered into long-term operating lease agreements for this real estate providing for future rental income as follows:

		Reynolda		
	_	Campus	WFUHS	Total
Year ending June 30:				
2022	\$	8,556	948	9,504
2023		7,169	942	8,111
2024		7,312	903	8,215
2025		7,459	645	8,104
2026	_	7,607	455	8,062
	\$	38,103	3,893	41,996

Notes to Consolidated Financial Statements

June 30, 2021

Total income from real estate was \$8,608 and \$8,360 for Reynolda Campus and \$1,461 and \$2,065 for WFUHS for the years ended June 30, 2021 and 2020, respectively.

## (13) Notes, Finance Leases, and Bonds Payable

Notes, finance leases, and bonds payable at June 30, 2021 and 2020 consist of the following:

Reynolda Campus	Years to nominal maturity	Interest rate at June 30, 2021			2021	2020
Notes payable and finance leases:						
Line of credit	>1	LIBOR plus 0.50%	Variable	\$	49,562	89,261
Promissory note	>1	LIBOR plus 0.75%	Variable		14,625	16,125
Finance leases	<1 to 4	0.48% to 2.55%	Fixed		5,575	5,837
Other installment loans	1 to 3	0.53% to 1.46%	Fixed	_	1,749	2,028
Total notes payable						
and finance leases				_	71,511	113,251
Bonds payable:						
2012 Series serial taxable	21	2.60% to 3.10%	Fixed		20,425	20,425
2012 Series term taxable	21	3.45% to 3.70%	Fixed		104,575	104,575
2016 Series serial tax-exempt	25	4.00% to 5.00%	Fixed		135,480	136,730
2016 Series term tax-exempt	25	2.75% to 3.00%	Fixed		22,370	22,370
2018 Series serial tax-exempt	27	4.47 %	Fixed		12,100	12,100
2018 Series term tax-exempt	27	3.38% to 5.00%	Fixed		15,920	15,920
2018 Series term tax-exempt	27	3.50% to 5.00%	Fixed		69,950	69,950
2021 Series term taxable	30	2.91 %	Fixed		25,000	
2021 Series bullet taxable	30	3.01 %	Fixed		100,000	
Unamortized bond premium Unamortized bond issuance					25,003	25,972
costs				_	(3,330)	(2,590)
Total bonds payable				_	527,493	405,452
Total notes payable,						
finance leases, and bonds payable				\$	599,004	518,703

Reynolda Campus entered into a capital projects financing agreement with Truist Bank (formerly Branch banking and Trust("BB&T") that permits the University to borrow up to \$100,000. The line of credit is due on July 1, 2022 and bears interest at the one-month LIBOR plus 0.50%, 0.59% at June 30, 2021. Additionally, the University has a supplemental line of credit with Truist Bank that permits the University to borrow up to \$50,000. The line of credit is due on December 31, 2021 and bears interest at the one-month LIBOR plus 1.00%, no less than 2.00%. The balance on this line was \$0 at June 30, 2021.

Reynolda Campus entered into a financing agreement with Truist Bank to finance the purchase and implementation of an enterprise resource-planning program that permits the University to borrow up to \$12,000. The term loan is due on July 1, 2026 and bears interest at the one-month LIBOR plus 0.75%, 0.84% at June 30, 2021.

Notes to Consolidated Financial Statements

June 30, 2021

Reynolda Campus entered into a promissory note with Winston-Salem First to finance the purchase of real property for which the University borrowed \$7,000. The note is due on January 5, 2023 and bears interest at the rate of 0.00%.

The Series 2012 taxable bonds are evidenced by a loan agreement dated August 2, 2012, by and between the University and Truist Bank, as trustee. The Series 2012 taxable bonds have final maturities of January 15, 2027 for the serial bonds and January 15, 2042 for the term bonds. The 2012 bonds maturing on January 15, 2032 and 2042 are subject to mandatory sinking fund redemptions through 2032 and 2042 in increasing annual amounts of \$5,445 to \$6,205 and \$6,405 to \$8,830, respectively. Interest is payable each January 15 and July 15. The University's obligation under the loan agreement is an unsecured, unconditional obligation. There are no related covenants underlying the bonds and the University has complied with all continuing disclosure requirements.

Reynolda Campus issued \$159,100 of tax-exempt North Carolina Capital Facilities Finance Agency Educational Facilities Revenue and Revenue Refunding Bonds, Series 2016. The 2016 Series bonds were issued for the purpose of the current refunding and defeasance of the Series 2009 tax-exempt bonds (\$110,000) and financing the costs of acquisition, construction, renovation and installation of capital assets of the Reynolda Campus. The Series 2016 tax-exempt bonds are evidenced by a loan agreement dated July 1, 2016, by and between the University and Truist Bank, as trustee. The Series 2016 tax-exempt bonds have final maturities of January 1, 2039 for the series bonds and January 1, 2041 and 2046 for the term bonds. The 2016 bonds maturing on January 1, 2040 and 2046 are subject to mandatory sinking fund redemptions through 2041 and 2046 with annual amounts of \$1,720 to \$2,930 and \$1,290 to \$3,485, respectively. Interest is payable each January 1 and July 1. The University's obligation under the loan agreement is an unsecured, unconditional obligation. There are no related covenants underlying the bonds and the University has complied with all continuing disclosure requirements.

Reynolda Campus issued \$97,900 of tax-exempt North Carolina Capital Facilities Finance Agency Educational Facilities Revenue and Revenue Refunding Bonds, Series 2018. The 2018 Series bonds were issued for the purpose of repaying a portion of the line of credit and financing the costs of acquisition, construction, renovation and installation of capital assets of the Reynolda Campus. The Series 2018 tax-exempt bonds are evidenced by a loan agreement dated July 1, 2018, by and between the University and Branch Banking and Trust Company, as trustee. The Series 2018 tax-exempt bonds have final maturities of January 1, 2039 for the series bonds and January 1, 2043 and 2048 for the term bonds. The 2018 bonds maturing on January 1, 2043 and 2048 are subject to mandatory sinking fund redemptions through 2043 and 2048 with annual amounts of \$875 to \$8,205 and \$4,870 to \$8,940, respectively. Interest is payable each January 1 and July 1. The University's obligation under the loan agreement is an unsecured, unconditional obligation.

The Series 2021 taxable bonds are evidenced by a loan agreement dated June 1, 2021, by and between the University and Truist Bank, as trustee. The Series 2021 taxable bonds have final maturities of January 1, 2044 for the term bonds and January 1, 2051 for the bullet bond. The 2021 bonds maturing on January 1, 2044 are subject to mandatory sinking fund redemptions from 2040 through 2044 with annual amounts of \$5,000. Interest is payable each January 1 and July 1. The University's obligation under the

Notes to Consolidated Financial Statements

June 30, 2021

loan agreement is an unsecured, unconditional obligation. There are no related covenants underlying the bonds and the University has complied with all continuing disclosure requirements.

WFUHS	Years to nominal maturity	Interest rate at June 30, 2021			2021	2020
Notes payable and finance leases:						
Line of credit	_	LIBOR plus 2.00%	Variable	\$	_	7,449
Loan agreement	<1 to 2	LIBOR plus 0.65%	Variable		3,669	5,671
Loan agreement	<1 to 5	1.88%	Fixed		4,227	4,896
Loan agreement	<1 to 4	LIBOR plus 1.05%	Variable		2,489	3,511
Finance lease	20	4.5%	Fixed		38,801	39,964
Finance lease	4	4.25% to 6.16%	Fixed	_	436	
Total notes payable				_	49,622	61,491
Bonds payable:						
Series 2019 A	<1 to 12	5.0 %	Fixed		38,485	39,540
Series 2012 B	<1 to 12	2.00% to 5.00%	Fixed		81,660	86,165
Unamortized bond premium					15,032	16,243
Unamortized bond issuance costs				_	(904)	(977)
Total bonds payable				_	134,273	140,971
Total notes payable, finance leases, and						
bonds payable				\$_	183,895	202,462

Effective March 26, 2011, NCBH, WFUHS, and WFUBMC formed a single obligated group (Obligated Group) under the existing NCBH Master Trust Indenture (MTI). New obligations were issued to WFUHS obligation holders under the NCBH MTI. In addition, substantially all of the subsidiaries of NCBH and WFUHS were included in the single credit group as Designated Members (Combined Group). Under the new credit structure, each member of the Obligated Group is jointly and severally liable for all debt and other obligations that are evidenced and secured under the MTI.

Bonds issued under the MTI are payable solely from the Obligated Group's revenues (as defined by the MTI). Additionally, the Combined Group must remain compliant with certain covenants and restrictions required by the MTI and loan agreements underlying the bonds. The Combined Group is subject to covenants under the MTI containing restrictions or limitations with respect to indebtedness, property encumbrance, consolidation or merger or transfer of assets. In addition, the Combined Group has agreed that it will not create any lien upon its property, accounts, or revenue now owned or hereafter acquired other than "permitted liens" as described in the MTI. WFUHS believes it is in compliance with such covenants and restrictions as of June 30, 2021. As of June 30, 2021, WFUHS is jointly and severally liable for \$728,722 of bonds payable borrowed by the other members of the Obligated Group and for \$19,199 and \$27,832, respectively, under WFUBMC's line of credit and notes payable. Because WFUHS does not expect to fund repayment of any of the amounts attributed to the other members of the Obligated Group under the MTI, no portion of these amounts meets the criteria for liability recognition in the accompanying consolidated financial statements.

Notes to Consolidated Financial Statements

June 30, 2021

Series 2019 Revenue Bonds represent bonds issued by Wake Forest Baptist Obligated Group, representing funds borrowed by the entities pursuant to loan agreements with the North Carolina Medical Care Commission (NCMCC). As a conduit issuer, the NCMCC loans the debt proceeds to the borrower and the bonds are issued by the NCMCC under a MTI structure. The MTI provides the flexibility for multiple parties to participate in debt issuances as part of an obligated group.

The Series 2019A bonds mature in full in fiscal year 2034. The fixed rate instruments bear interest at fixed coupon rates of 5.00%. Per the bond agreements, the principal and sinking fund payments on the bonds are due on December 1 of each year beginning in 2019 in annual amounts ranging from \$185 to \$4,505.

The Series 2012 Revenue Bonds represent bonds issued by Wake Forest Baptist Obligated Group, representing funds borrowed by the entities pursuant to loan agreements with the North Carolina Medical Care Commission (NCMCC). As a conduit issuer, the NCMCC loans the debt proceeds to the borrower and the bonds are issued by the NCMCC under a MTI structure. The MTI provides the flexibility for multiple parties to participate in the debt issuances as part of an obligated group.

The Series 2012B bonds mature in full in fiscal year 2034. The fixed rate instruments bear interest at fixed coupon rates ranging from 2.00% to 5.00%. Per the bond agreements, the principal and sinking fund payments on the bonds are due on December 1 of each year beginning in 2014 and in increasing annual amounts of \$3,385 to \$7,000. WFUHS entered into an unsecured, taxable line of credit agreement with a total borrowing capacity of \$200,000 to provide for the working capital needs of NCBH, WFUHS, and the Medical Center, all Borrowers under the credit facility. The line of credit terminated on April 2, 2021.

WFUHS entered into an unsecured loan agreement, with a variable interest rate based upon the one-month LIBOR plus a premium of 0.65% for \$20,014 to refinance two previously outstanding fixed rate notes. Fixed principal payments and accrued interest are due monthly with a final maturity date of April 1, 2023. This taxable loan is guaranteed by both NCBH and WFUBMC.

WFUBMC entered into a taxable, unsecured loan agreement, with WFUHS and NCBH as Borrowers, with a fixed interest rate of 1.88% to refinance a previously outstanding loan agreement held by WFUHS and NCBH and owned subsidiaries. Principal payments and accrued interest are due monthly with a final maturity date of April 15, 2027.

A WFUHS subsidiary entered into a notes payable obligation, with variable interest rates based on one-month LIBOR plus a premium of 1.05% and final maturities in 2021 and 2025.

WFUHS entered into a finance lease obligation of \$44,125 related to the Bowman Gray Center for Medical Education with an initial term of 15 years and additional renewal options. The obligation has a fixed interest rate of 4.5%.

Wake Forest Ambulatory Ventures, LLC entered into various finance lease obligations of \$538 related to equipment. The obligations have a fixed interest rates ranging from 4.25% to 6.16% and a final maturity dates through June 2025.

Notes to Consolidated Financial Statements

June 30, 2021

Aggregate annual maturities of notes, finance leases, and bonds payable for each of the five fiscal years subsequent to June 30, 2021 and thereafter are as follows:

	_	Reynolda Campus	WFUHS	Total
2022	\$	10,273	10,990	21,263
2023		16,433	10,122	26,555
2024		12,835	10,648	23,483
2025		13,482	11,264	24,746
2026		17,290	9,394	26,684
In total thereafter		507,018	131,477	638,495
	\$	577,331	183,895	761,226

Costs related to the registration and issuance of bonds, totaling \$21,673 and \$15,033, respectively, for Reynolda Campus and WFUHS, are carried at cost less accumulated amortization and are amortized over the life of the bonds on a method that approximates the effective-interest method and are included in bonds payable on the accompanying consolidated balance sheet. Total amortization expense for issue costs and premium is included in interest expense in the consolidated statements of activities for Reynolda Campus and WFUHS totaled \$865 and \$1,137, respectively, for 2021 and \$855 and \$1,137, respectively, for 2020.

## (14) Interest Rate Swap Agreements

To manage the fixed/variable allocation of its debt portfolio, including hedging exposure to increasing interest expense from variable rate debt, the University utilizes interest rate swap agreements. The University has only limited involvement with derivative instruments and does not use them for trading purposes.

Parties to interest rate swap agreements are subject to market risk for changes in interest rates as well as credit loss in the event of nonperformance by the counterparty. To minimize this exposure, the University verifies that the counterparties for these swap transactions are major financial institutions that meet the University's criteria for financial stability and creditworthiness. Additionally, the University is exposed to tax basis risk since a change in tax rate environments will change the level of correlation between the interest rate payments made on the variable rate bonds and the percentage of LIBOR payments being received from the counterparties.

Notes to Consolidated Financial Statements

June 30, 2021

The following table summarizes the general terms for each of the University's swap agreements:

	Reynol	Reynolda Campus				
	October 2008 interest rate swap	December 2016 interest rate swap	August 2002 interest rate swap			
Notional amount	\$ 50,000	7,625	19,289			
Effective date Maturity date Rate received	October 1, 2008 January 1, 2038 67% of one-month LIBOR	December 28, 2016 July 1, 2026 67% of one-month LIBOR	August 20, 2002 July 1, 2034 67% of one-month LIBOR			
Rate paid Collateral provisions	3.61 % 100% liability if > \$20,000	2.44 % None	3.67 % 100% asset/ liability – \$250 min			
Settlement frequency	Monthly	Monthly	Weekly			

The University records all interest rate swap agreements in other liabilities and deferrals on the consolidated balance sheet at their respective fair values. The estimated amount the University would pay to terminate the swap agreements at the reporting date, taking into account current forward interest rates and the current forward creditworthiness of the swap counterparties, approximates the fair value of the interest rate swap. All changes in fair value are reflected as a gain or loss in nonoperating activities in the consolidated statement of activities. Periodic net cash settlement amounts with counterparties are accounted for as adjustments to interest expense on the related debt and collateral to support the swaps is included in investments on the consolidated balance sheet. Collateral held by counterparties at June 30, 2021 and 2020, respectively, was \$0 and \$8,000 for Reynolda Campus, and \$3,890 and \$5,330 for WFUHS.

Notes to Consolidated Financial Statements
June 30, 2021

The related financial information on each of these instruments is as follows:

	_	202	21	2020			
		Fair value	Gain (Loss)	Fair value	Gain (Loss)		
Reynolda Campus: November 2006 interest							
rate swap	\$	_	_	_	85		
October 2008 interest rate swap December 2016 interest		(19,580)	6,814	(26,394)	(8,591)		
rate swap		(379)	263	(642)	(356)		
Total		(19,959)	7,077	(27,036)	(8,862)		
WFUHS: August 2002 interest rate							
swap		(3,952)	1,397	(5,349)	(1,319)		
Grand total	\$	(23,911)	8,474	(32,385)	(10,181)		

As of June 30, 2021, the University's adjusted debt portfolio, after taking into account the aforementioned swap agreements, was 100% fixed rate for Reynolda Campus, and 100% fixed rate for WFUHS.

## (15) Net Assets

The following is a summary of net assets at June 30:

		2021				
	_	Without donor restriction	With donor restriction	Total		
Reynolda Campus:						
Operating	\$	354,386	_	354,386		
Endowment		270,018	806,682	1,076,700		
Investment in plant, net		177,607	_	177,607		
Donor pledges and gifts		_	187,230	187,230		
Trust (annuity, perpetual, split-interest) and						
loan agreements	_		20,767	20,767		
Total net assets	\$_	802,011	1,014,679	1,816,690		

Notes to Consolidated Financial Statements
June 30, 2021

Without donor restriction         With donor restriction         Total           WFUHS:         Operating         \$ 205,139         — 205,139           Endowment         524,231         261,979         786,210           Investment in plant, net         193,992         — 193,992         — 7,981         7,981           Trust (annuity, perpetual, split-interest) and loan agreements         — 22,683         22,683         22,683           Total net assets         \$ 923,362         292,643         1,216,005           Without donor restriction         With donor restriction         Total           Reynolda Campus:           Operating         \$ 269,118         — 269,118           Endowment         221,229         627,804         849,033           Investment in plant, net         196,364         — 196,364           Donor pledges and gifts         — 157,585         157,585           Trust (annuity, perpetual, split-interest) and loan agreements         — 20,507         20,507           Total net assets         \$ 686,711         805,896         1,492,607           WFUHS:         — 291,776         209,378         501,154           Investment in plant, net         180,498         — 104,593           Endowment <t< th=""><th></th><th></th><th></th><th>2021</th><th></th></t<>				2021	
WFUHS:         Coperating         \$ 205,139         —         205,139           Endowment         524,231         261,979         786,210           Investment in plant, net         193,992         —         193,992           Donor pledges and gifts         —         7,981         7,981           Trust (annuity, perpetual, split-interest) and loan agreements         —         22,683         22,683           Total net assets         \$ 923,362         292,643         1,216,005           Reynolda Campus:         Without donor restriction         With donor restriction         Total           Operating         \$ 269,118         —         269,118           Endowment         221,229         627,804         849,033           Investment in plant, net         196,364         —         196,364           Donor pledges and gifts         —         157,585         157,585           Trust (annuity, perpetual, split-interest) and loan agreements         —         20,507         20,507           Total net assets         686,711         805,896         1,492,607           WFUHS:         —         20,3078         501,154           Investment in plant, net         180,498         —         104,593 </th <th></th> <th></th> <th></th> <th></th> <th></th>					
WFUHS:         Operating         \$ 205,139         —         205,139           Endowment         524,231         261,979         786,210           Investment in plant, net         193,992         —         193,992           Donor pledges and gifts         —         7,981         7,981           Trust (annuity, perpetual, split-interest) and loan agreements         —         22,683         22,683           Total net assets         \$ 923,362         292,643         1,216,005           Reynolda Campus:         Operating         Without donor restriction         With donor restriction           Operating         \$ 269,118         —         269,118           Endowment         221,229         627,804         849,033           Investment in plant, net         196,364         —         196,364           Donor pledges and gifts         —         157,585         157,585           Trust (annuity, perpetual, split-interest) and loan agreements         —         20,507         20,507           Total net assets         \$ 686,711         805,896         1,492,607           WFUHS:         Operating         \$ 104,593         —         104,593           Endowment         291,776         209,378 </th <th></th> <th></th> <th></th> <th></th> <th>Total</th>					Total
Operating Endowment         \$ 205,139         —         205,139           Endowment Indowment Indowment Investment in plant, net         193,992         —         193,992           Donor pledges and gifts         —         7,981         7,981           Trust (annuity, perpetual, split-interest) and loan agreements         —         22,683         22,683           Total net assets         \$ 923,362         292,643         1,216,005           Without donor restriction           Monor restriction         With donor restriction         Total           Reynolda Campus:         —         269,118         —         269,118           Endowment         221,229         627,804         849,033         Investment in plant, net         196,364         —         196,364         —         196,364         Donor pledges and gifts         —         157,585         157,585         157,585         Trust (annuity, perpetual, split-interest)         —         20,507	WELLIG.	-	10011011011	10011011011	
Endowment         524,231         261,979         786,210           Investment in plant, net         193,992         —         193,992           Donor pledges and gifts         —         7,981         7,981           Trust (annuity, perpetual, split-interest) and loan agreements         —         22,683         22,683           Total net assets         \$ 923,362         292,643         1,216,005           Without donor restriction           donor         without donor restriction         —           Doerating         \$ 269,118         —         269,118           Endowment         221,229         627,804         849,033           Investment in plant, net         196,364         —         196,364           Donor pledges and gifts         —         157,585         157,585           Trust (annuity, perpetual, split-interest) and loan agreements         —         20,507         20,507           Total net assets         \$ 686,711         805,896         1,492,607           WFUHS:         Operating         \$ 104,593         —         104,593           Endowment         291,776         209,378         501,154           Investment in plant, net         180,498         —         180,498      <		\$	205 139	_	205 139
Investment in plant, net   193,992   7,981	•	Ψ		261.979	
Trust (annuity, perpetual, split-interest) and loan agreements				_	
Total net assets   923,362   292,643   1,216,005	Donor pledges and gifts			7,981	7,981
Total net assets   \$923,362   292,643   1,216,005	, , , , , , , , , , , , , , , , , , , ,				
2020           Without donor restriction         With donor restriction         Total           Reynolda Campus:         269,118         —         269,118           Endowment         221,229         627,804         849,033           Investment in plant, net         196,364         —         196,364           Donor pledges and gifts         —         157,585         157,585           Trust (annuity, perpetual, split-interest) and loan agreements         —         20,507         20,507           Total net assets         \$ 686,711         805,896         1,492,607           WFUHS:         Operating         \$ 104,593         —         104,593           Endowment         291,776         209,378         501,154           Investment in plant, net         180,498         —         180,498           Donor pledges and gifts         —         13,323         13,323           Trust (annuity, perpetual, split-interest) and loan agreements         —         19,807         19,807	loan agreements	_		22,683	22,683
Without donor restriction         With donor restriction         Total           Reynolda Campus:         Sep. 118         —         269,118           Operating         \$ 269,118         —         269,118           Endowment         221,229         627,804         849,033           Investment in plant, net         196,364         —         196,364           Donor pledges and gifts         —         157,585         157,585           Trust (annuity, perpetual, split-interest)         —         20,507         20,507           Total net assets         \$ 686,711         805,896         1,492,607           WFUHS:         —         104,593         —         104,593           Endowment         291,776         209,378         501,154           Investment in plant, net         180,498         —         180,498           Donor pledges and gifts         —         13,323         13,323           Trust (annuity, perpetual, split-interest) and loan agreements         —         19,807         19,807	Total net assets	\$_	923,362	292,643	1,216,005
Without donor restriction         With donor restriction         Total           Reynolda Campus:         Sep. 118         —         269,118           Operating         \$ 269,118         —         269,118           Endowment         221,229         627,804         849,033           Investment in plant, net         196,364         —         196,364           Donor pledges and gifts         —         157,585         157,585           Trust (annuity, perpetual, split-interest)         —         20,507         20,507           Total net assets         \$ 686,711         805,896         1,492,607           WFUHS:         —         104,593         —         104,593           Endowment         291,776         209,378         501,154           Investment in plant, net         180,498         —         180,498           Donor pledges and gifts         —         13,323         13,323           Trust (annuity, perpetual, split-interest) and loan agreements         —         19,807         19,807					
Without donor restriction         With donor restriction         Total           Reynolda Campus:         Sep. 118         —         269,118           Operating         \$ 269,118         —         269,118           Endowment         221,229         627,804         849,033           Investment in plant, net         196,364         —         196,364           Donor pledges and gifts         —         157,585         157,585           Trust (annuity, perpetual, split-interest)         —         20,507         20,507           Total net assets         \$ 686,711         805,896         1,492,607           WFUHS:         —         104,593         —         104,593           Endowment         291,776         209,378         501,154           Investment in plant, net         180,498         —         180,498           Donor pledges and gifts         —         13,323         13,323           Trust (annuity, perpetual, split-interest) and loan agreements         —         19,807         19,807				2020	
Reynolda Campus:         restriction         restriction         Total           Operating         \$ 269,118         —         269,118           Endowment         221,229         627,804         849,033           Investment in plant, net         196,364         —         196,364           Donor pledges and gifts         —         157,585         157,585           Trust (annuity, perpetual, split-interest)         —         20,507         20,507           Total net assets         \$ 686,711         805,896         1,492,607           WFUHS:         Operating         \$ 104,593         —         104,593           Endowment         291,776         209,378         501,154           Investment in plant, net         180,498         —         180,498           Donor pledges and gifts         —         13,323         13,323           Trust (annuity, perpetual, split-interest)         —         19,807         19,807           and loan agreements         —         19,807         19,807		-	Without		
Reynolda Campus:       269,118       —       269,118         Endowment       221,229       627,804       849,033         Investment in plant, net       196,364       —       196,364         Donor pledges and gifts       —       157,585       157,585         Trust (annuity, perpetual, split-interest)       —       20,507       20,507         Total net assets       \$       686,711       805,896       1,492,607         WFUHS:       Operating       \$       104,593       —       104,593         Endowment       291,776       209,378       501,154         Investment in plant, net       180,498       —       180,498         Donor pledges and gifts       —       13,323       13,323         Trust (annuity, perpetual, split-interest)       —       19,807       19,807			donor	With donor	
Operating       \$ 269,118       —       269,118         Endowment       221,229       627,804       849,033         Investment in plant, net       196,364       —       196,364         Donor pledges and gifts       —       157,585       157,585         Trust (annuity, perpetual, split-interest)       —       20,507       20,507         Total net assets       \$ 686,711       805,896       1,492,607         WFUHS:       Operating       \$ 104,593       —       104,593         Endowment       291,776       209,378       501,154         Investment in plant, net       180,498       —       180,498         Donor pledges and gifts       —       13,323       13,323         Trust (annuity, perpetual, split-interest)       —       19,807       19,807		_	restriction	restriction	Total
Endowment       221,229       627,804       849,033         Investment in plant, net       196,364       —       196,364         Donor pledges and gifts       —       157,585       157,585         Trust (annuity, perpetual, split-interest)       —       20,507       20,507         Total net assets       \$       686,711       805,896       1,492,607         WFUHS:       Operating       \$       104,593       —       104,593         Endowment       291,776       209,378       501,154         Investment in plant, net       180,498       —       180,498         Donor pledges and gifts       —       13,323       13,323         Trust (annuity, perpetual, split-interest)       —       19,807       19,807         and loan agreements       —       19,807       19,807	Reynolda Campus:				
Investment in plant, net	Operating	\$	269,118	_	269,118
Donor pledges and gifts         —         157,585         157,585           Trust (annuity, perpetual, split-interest)         —         20,507         20,507           and loan agreements         —         20,507         20,507           Total net assets         \$         686,711         805,896         1,492,607           WFUHS:         Operating         \$         104,593         —         104,593           Endowment         291,776         209,378         501,154           Investment in plant, net         180,498         —         180,498           Donor pledges and gifts         —         13,323         13,323           Trust (annuity, perpetual, split-interest)         —         19,807         19,807				627,804	
Trust (annuity, perpetual, split-interest) and loan agreements         —         20,507         20,507           Total net assets         \$ 686,711         805,896         1,492,607           WFUHS:         Operating         \$ 104,593         —         104,593           Endowment         291,776         209,378         501,154           Investment in plant, net         180,498         —         180,498           Donor pledges and gifts         —         13,323         13,323           Trust (annuity, perpetual, split-interest) and loan agreements         —         19,807         19,807	·		196,364		
and loan agreements         —         20,507         20,507           Total net assets         \$ 686,711         805,896         1,492,607           WFUHS:         Operating         \$ 104,593         —         104,593           Endowment         291,776         209,378         501,154           Investment in plant, net         180,498         —         180,498           Donor pledges and gifts         —         13,323         13,323           Trust (annuity, perpetual, split-interest)         —         19,807         19,807			_	157,585	157,585
Total net assets \$ 686,711 805,896 1,492,607  WFUHS:  Operating \$ 104,593 — 104,593  Endowment 291,776 209,378 501,154  Investment in plant, net 180,498 — 180,498  Donor pledges and gifts — 13,323 13,323  Trust (annuity, perpetual, split-interest) and loan agreements — 19,807 19,807	, , , , , , , , , , , , , , , , , , , ,		_	20 507	20 507
WFUHS:       Operating       \$ 104,593       — 104,593         Endowment       291,776       209,378       501,154         Investment in plant, net       180,498       — 180,498         Donor pledges and gifts       — 13,323       13,323         Trust (annuity, perpetual, split-interest)       — 19,807       19,807	· ·	_	200 744	· · · · · · · · · · · · · · · · · · ·	
Operating       \$ 104,593       —       104,593         Endowment       291,776       209,378       501,154         Investment in plant, net       180,498       —       180,498         Donor pledges and gifts       —       13,323       13,323         Trust (annuity, perpetual, split-interest)       —       19,807       19,807	lotal net assets	\$ =	686,711	805,896	1,492,607
Endowment       291,776       209,378       501,154         Investment in plant, net       180,498       —       180,498         Donor pledges and gifts       —       13,323       13,323         Trust (annuity, perpetual, split-interest)       —       19,807       19,807	WFUHS:				
Investment in plant, net 180,498 — 180,498  Donor pledges and gifts — 13,323 13,323  Trust (annuity, perpetual, split-interest) and loan agreements — 19,807 19,807	. •	\$		_	
Donor pledges and gifts — 13,323 13,323  Trust (annuity, perpetual, split-interest)  and loan agreements — 19,807 19,807				209,378	
Trust (annuity, perpetual, split-interest) and loan agreements 19,807 19,807	• •		180,498	42.222	
and loan agreements 19,807 19,807			_	13,323	13,323
			_	19,807	19,807
	-	\$	576,867	242,508	819,375

## (16) Functional Expenses

Expenses are presented by functional classification in accordance with the overall mission of the University. The University's primary program services are academic, instruction and research, and health care and related services. Expenses for auxiliary enterprises, library, and student services are incurred in support of academic instruction and research, and as such are included therein. Plant operation and

Notes to Consolidated Financial Statements

June 30, 2021

maintenance expense is allocated to program and supporting activities based upon direct costing or allocated using a variety of allocation techniques such as square footage. The amounts allocated in 2021 and 2020 were \$142,256 and \$149,047, respectively.

Expenses are reported in the consolidated statements of activities in natural categories. Functional expenses for the years ended June 30, 2021 and 2020 are categorized as follows:

		2021								
		Academic, instruction, and research		Administration and Health care and other other institutional related services support		titutional	Total			
	_	Reynolda Campus	WFUHS	Reynolda Campus	WFUHS	Reynolda Campus	WFUHS	Reynolda Campus	WFUHS	
Salaries and wages Employee benefits	\$	196,604 52,827	174,085 34,493	_	562,573 111,108	28,290 8,833	_	224,894 61.660	736,658 145,601	
Student aid		3,331	8,667	_	_	_	_	3,331	8,667	
Services		50,775	54,850	_	88,537	8,235	22,895	59,010	166,282	
Clinical and laboratory supplies		_	20,716	_	75,720	_	_	_	96,436	
Other operating expenses Depreciation and		53,152	31,694	_	39,101	1,382	6,231	54,534	77,026	
amortization		45.053	10.209	_	17,724	5,693	8.464	50.746	36,397	
Interest on debt	_	15,066	2,949		3,322	685	1,513	15,751	7,784	
Total										
expenses	\$_	416,808	337,663		898,085	53,118	39,103	469,926	1,274,851	

	2020							
	Academic, instruction, and research		Administration and Health care and other other institutional related services support			Total		
	Reynolda Campus	WFUHS	Reynolda Campus	WFUHS	Reynolda Campus	WFUHS	Reynolda Campus	WFUHS
	Jumpus	**** 0110	Janipus	*** 5115	Jumpus		Jampus	-11.0110
Salaries and wages	\$ 194,306	166,734	_	506,542	24,374	2,879	218,680	676,155
Employee benefits	53,254	32,931	_	98,776	4,286	561	57,540	132,268
Student aid	3,505	8,335	_	_	_	_	3,505	8,335
Services	44,475	51,634	_	112,418	14,209	4,232	58,684	168,284
Clinical and laboratory								
supplies	_	14,612	_	72,062	_	_	_	86,674
Other operating expenses	57,503	29,660	_	44,519	482	9,159	57,985	83,338
Depreciation and								
amortization	45,404	10,826	_	17,539	5,907	8,789	51,311	37,154
Interest on debt	15,099	2,848		3,362	680	1,546	15,779	7,756
Total								
expenses \$	\$ <u>413,546</u>	317,580		855,218	49,938	27,166	463,484	1,199,964

## (17) Contingencies and Other Commitments

The estimated cost to complete construction in progress at June 30, 2021 and 2020, respectively, were \$39,608 and \$52,411 for Reynolda Campus, and \$30,889 and \$7,985 for WFUHS.

Expenditures related to federal and state grants and contracts are subject to adjustment based upon review by the granting agencies. Amounts of expenditures that granting agencies might disallow cannot be determined at this time. These amounts affect government grants and contracts revenue as well as

Notes to Consolidated Financial Statements

June 30, 2021

facilities and administrative cost recovery. The University would not expect these costs to influence the consolidated financial position significantly.

The University is self-insured for dental benefits, self-insured or fully insured for retiree medical benefits (depending on retiree benefit elections), and self-insured for active employees receiving medical benefits. The University provides an accrual for actual claims reported but not paid and a provision for incurred but not reported claims based on historical trends. Accrued employee health and dental costs, including estimated claims incurred but not reported, amounted to approximately \$1,144 and \$1,127 at June 30, 2021 and 2020, respectively, for Reynolda Campus and \$6,347 and \$5,714 at June 30, 2021 and 2020, respectively, for WFUHS and are included in other liabilities and deferrals in the accompanying consolidated balance sheet.

The estimated liability for self-insurance claims will be significantly affected if current and future claims differ from historical trends. While management monitors reported claims closely and considers potential outcomes as estimated by its actuaries when determining its self-insurance liability accruals, the complexity of the claims, the extended period of time to settle the claims and the wide range of potential outcomes complicate the estimation. In the opinion of management, adequate provision has been made for this related risk.

The University self-insures workers' compensation liability with excess commercial insurance providing per loss and aggregate annual coverage. The University provides an accrual for actual claims reported but not paid and a provision for incurred but not reported claims based on historical trends, which is included in other liabilities and deferrals on the accompanying consolidated balance sheet.

The estimated liability for workers' compensation claims will be significantly affected if current and future claims differ from historical trends. While management monitors reported claims closely and considers potential outcomes as estimated by its actuaries when determining its self-insurance liability accruals, the complexity of the claims, the extended period of time to settle the claims and the wide range of potential outcomes complicate the estimation. In the opinion of management, adequate provision has been made for this related risk.

Under the Health Insurance Portability and Accountability Act of 1996 (HIPPA), the federal government has authority to complete fraud and abuse investigations. HIPPA has established substantial fines and penalties for offenders. WFUHS maintains policies, procedures and requires regular training sessions to employers to monitor compliance with HIPPA, as well as other applicable local, state and federal statutes and regulations.

The University is involved in various legal matters arising in the normal course of activities. Management, after taking into consideration advice of legal counsel, believes that the matters will not have a materially adverse effect, individually or in the aggregate, upon the University's consolidated financial statements. The University accrued \$12,500 and \$5,000 during June 30, 2021 and 2020, respectively, for legal obligations, including legal expenses. These costs were included in the consolidated financial statements.

Notes to Consolidated Financial Statements

June 30, 2021

## (18) Sale-Leaseback Agreement

In 2006, WFUHS entered into a sale-leaseback agreement to sell and lease back certain assets. The initial lease term is 20 years with four 5-year renewal options. The lease is classified as an operating lease. Operating lease expected payments in each year from 2022 to 2026 are \$8,058, \$8,139, \$8,220, \$8,302, and \$8,385 respectively, and \$7,229 thereafter.

In 2010, WFUHS entered into another sale-leaseback agreement to sell and lease back certain assets. The initial lease term is 16 years with three 5-year renewal options. The lease is classified as an operating lease. Operating lease payments are due monthly and expected payments each year from 2022 to 2026 are \$6,223, \$6,379, \$6,539, \$6,702 and \$6,870, respectively, and \$7,041 thereafter.

WFUHS has a deferred gain related to the sale and leaseback of certain assets, which is amortized over the remaining lease term using the straight-line method. The deferred gain was \$11,395 and \$13,341 at June 30, 2021 and 2020, respectively, and is included in other liabilities and deferrals in the accompanying consolidated balance sheet.

#### (19) Retirement Plans

Substantially all employees of the University are eligible to participate in defined contribution benefit plans. The University contributes a specified percentage of each employee's salary to the plans. Contributions for the years ended June 30, 2021 and 2020, respectively, were \$15,125 and \$14,852 for Reynolda Campus and \$46,944 and \$36,244 for WFUHS.

Certain employees of the University are eligible to participate in other benefit plans including a defined supplemental executive retirement plan, deferred compensation arrangements, and supplemental retirement agreements. The Reynolda Campus and WFUHS have accrued \$1,885 and \$2,946 at June 30, 2021, respectively, and \$3,433 and \$5,067 at June 30, 2020, respectively, for liabilities associated with these plans. These liabilities are included in other liabilities and deferrals on the consolidated balance sheet.

### (20) Postretirement Benefits

The University sponsors defined benefit postretirement medical and dental plans that cover all of its full-time employees who elect coverage and satisfy the plans' eligibility requirements when they retire. In addition, Reynolda Campus sponsors a death benefit plan, which pays a \$2 benefit for each retiree. To be eligible, retired employees of Reynolda Campus must be at least 62 years of age with ten or more years of service or be at least 65 years of age with five or more years of service.

WFUHS sponsors a defined benefit postretirement medical and dental plan that covers all WFUHS full-time employees who elect coverage and satisfy the plan eligibility requirements when they retire. On June 2, 2011, the Board of WFUHS approved that effective as of January 1, 2012, the defined benefit postretirement plan would be discontinued for most future retirees and the minimum age required for postretirement benefits will increase from 60 to 62. However, the additional requirement of the Rule of 75 (age and years of service) remains unchanged. All current retirees and currently eligible employees previously grandfathered will continue to be eligible for benefits under this plan. Any WFUHS employee who is within 5 years of meeting the new retirement eligibility of age 62 with combined age and years of service equal to at least 75 as of January 1, 2012 will be grandfathered into this benefit.

Notes to Consolidated Financial Statements
June 30, 2021

The measurement date for the defined postretirement benefit plan is June 30.

The following table provides a reconciliation of the changes in each plan's benefit obligation, fair value of plan assets, and funded status for the years ended June 30, 2021 and 2020:

	_	Reynolda Campus	WFUHS	Total	2020 Total
Change in benefit obligation: Benefit obligation at					
beginning of year	\$	13,624	28,432	42,056	43,424
Service cost		591	7	598	714
Interest cost		390	691	1,081	1,460
Participants' contributions		534	183	717	658
Actuarial loss (gain)		(233)	(1,186)	(1,419)	(1,526)
Benefits paid		(954)	(1,840)	(2,794)	(2,674)
Special termination					
benefits	_	590	<u> </u>	590	
Benefit obligation at end					
of year	_	14,542	26,287	40,829	42,056
Change in plan assets: Fair value of plan assets at beginning of year		_	_	<u> </u>	_
Employer's contributions		420	1,657	2,077	2,016
Participants' contributions		534	183	717	658
Benefits paid		(954)	(1,840)	(2,794)	(2,674)
Fair value of plan assets at end of year	_	<u> </u>			_
Total liability	\$_	(14,542)	(26,287)	(40,829)	(42,056)
Amounts recognized in unrestricted net assets: Prior service (cost)					
credit	\$	(2,674)	56	(2,618)	3,122
Net actuarial (gain) loss	_	(4,105)	3,830	(275)	6,711
Total (decrease)					
increase	\$	(6,779)	3,886	(2,893)	9,833
	_				_

Notes to Consolidated Financial Statements

June 30, 2021

The following table provides the components of net periodic benefit cost for the years ended June 30, 2021 and 2020:

	_				
		Reynolda		_	2020
		Campus	WFUHS	Total	Total
Service cost	\$	591	7	598	714
Interest cost		390	691	1,081	1,460
Amortization of prior service					
credit		(374)	(19)	(393)	(403)
Amortization of net actuarial					
(gain) loss		(195)	_	(195)	(455)
Special termination benefits	_	590		590	
Net periodic					
benefit cost	\$_	1,002	679	1,681	1,316

The prior service costs are amortized on a straight-line basis over the average remaining service period of active participants. Gains in excess of 10% of the greater of the benefit obligation and the market-related value of assets are amortized over the average remaining service period of active participants.

The actuarial net gain and prior service credit for the defined postretirement benefits plans that will be amortized from accumulated nonoperating income into net periodic benefit cost over the next fiscal year for Reynolda Campus and WFUHS are \$558 and \$518, respectively.

The weighted average discount rate used to determine the accumulated postretirement benefit obligation at June 30, 2021 for Reynolda Campus and WFUHS, respectively, was 2.94% and 2.48%, and at June 30, 2020 was 2.92% and 2.53%, respectively. The discount rate reflects the current yield curve results as of June 30, 2021 and 2020. For management purposes, Reynolda Campus used 5.80% and 6.10%, and WFUHS used 7.80% and 6.88% for 2021 and 2020, respectively, for the annual rate of increase in the per capita cost of covered healthcare benefits for the first year, and a 4.5% rate was assumed in each year as the ultimate rate.

Notes to Consolidated Financial Statements
June 30, 2021

Assumed healthcare cost trend rates have a significant effect on the amounts reported for the postretirement benefit plan. A 1% change in assumed healthcare cost trend rates would have the following effects:

_	One percentage increase	One percentage decrease
\$	35 268	(30) (236)
\$	 10	<u> </u>
		percentage increase  \$ 35 268

Aggregate benefits expected to be paid by the University, net of participant contributions, for the postretirement benefits plans are as follows:

	R	Reynolda			
		Campus	WFUHS	Total	
2022	\$	788	2,179	2,967	
2023		796	2,045	2,841	
2024		841	2,011	2,852	
2025		822	1,960	2,782	
2026		792	1,905	2,697	
Five years thereafter		4,308	8,524	12,832	

The expected benefits to be paid are based on the same assumptions used to measure the University's benefit obligation at June 30, 2021 and include estimated future employee service.

### (21) Related-Party Transactions

WFUHS and NCBH each incur expenses in the course of managing WFB as an integrated academic medical center. These expenses are aggregated and allocated between WFUHS and NCBH such that each individual entity bears a share of the expenses that is proportionate to the benefit received by each entity. Additionally, WFUHS and NCBH share certain facilities, provide various services, and incur certain expenses on behalf of each other. These transactions are recorded at fair value and the costs associated with operating and maintaining jointly occupied facilities are ultimately paid by the party having beneficial occupancy.

Notes to Consolidated Financial Statements

June 30, 2021

These transactions are recorded as follows in the consolidated financial statements:

	 2021	2020
Revenue from MCIA	\$ 228,263	231,419
Corporate service allocation, net	91,915	99,544
Other professional fees, net	 91,904	56,328
Total net revenue from NCBH	\$ 412,082	387,291
Accounts receivable from NCBH	\$ 67,573	77,658

In 2015, WFUBMC entered into an unsecured, taxable line of credit with a total borrowing capacity of \$125,000 and a \$60,000 unsecured loan agreement that is guaranteed by both NCBH and WFUHS. In 2019, WFUBMC exercised an accordion feature on the line of credit, bringing its total borrowing capacity to \$150,000. In 2020, the line of credit was amended to increase the borrowing capacity to \$200,000. The outstanding balance on the line of credit was \$34,199 as of June 30, 2020, of which WFUHS recorded a liability of \$7,449 as of June 30, 2020. The outstanding balance of the unsecured loan was \$0 as of June 30, 2020, of which WFUHS recorded a liability of \$0, due to WFUBMC in other liabilities and deferrals that represented the portion of the unsecured loan utilized by WFUHS. This loan was terminated on April 2, 2021.

As part of the health system integration agreement, in fiscal year 2021, CMHA contributed \$150,000 to WFUHS to create an unrestricted academic endowment to be used for new, ongoing or enhanced academic or research initiatives of the WFB entities. WFUHS received the unrestricted contribution in March 2021, and its Board established a \$150,000 quasi-endowment fund.

## (22) Professional Liability Insurance

WFUHS maintains professional liability coverage, which included a \$6,000 per occurrence and a \$30,000 annual aggregate self-insurance retention for the year ended June 30, 2021. WFUHS estimates its professional liability on an actuarial basis. WFUHS' accrued professional liability costs, including estimated claims incurred but not reported, amounted to approximately \$48,229 and \$44,613 at June 30, 2021 and 2020, respectively, and are included in other liabilities and deferrals on the consolidated balance sheet. In the opinion of management, adequate provision has been made for the related risk.

Notes to Consolidated Financial Statements

June 30, 2021

The estimated liability for self-insurance claims will be significantly affected if current and future claims differ from historical trends. While management monitors reported claims closely and considers potential outcomes as estimated by its actuaries when determining its self-insurance liability accruals, the complexity of the claims, the extended period of time to settle the claims and the wide range of potential outcomes complicate the estimation. In the opinion of management, adequate provision has been made for this related risk.

## (23) Subsequent Events

Management has evaluated subsequent events from June 30, 2020 through October 25, 2021, the date the financial statements were available to be issued, and determined that there are no additional items to disclose.

## Schedule of Expenditures of Federal Awards Year ended June 30, 2021

	Federal CFDA no. or other grant	Pass-through entity	Passed through to	Federal
Federal grantor/pass-through grantor/program or cluster title	identifying no.	identifying number	subrecipients	expenditures
deral award expenditures: Research and Development Cluster:				
Wake Forest University Health Sciences:				
U.S. Department of Health and Human Services: National Institutes of Health Direct Programs:				
Family Smoking Prevention and Tobacco Control Act Regulatory Research	93.077		\$ 3,256,917	4,090,906
Environmental Health Research Related to Deafness and Communication Disorders	93.113 93.173		129,647	997,575 305,798
Telehealth Programs	93.211		40.245	160,503 759,485
Research and Training in Complementary and Integrative Health Mental Health Research Grants	93.213 93.242		10,315 41,570	1,245,189
Alcohol Research Programs Drug Abuse and Addiction Research Programs	93.273 93.279		43,756 426,205	4,826,991 5,834,885
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286		98,081	823,764
Minority Health and Health Disparities Research	93.307		150,614	454,847
Trans-NIH Research Support National Center for Advancing Translational Sciences	93.310 93.350		32,909 62,453	418,071 5,110,359
Research Infrastructure Programs	93.351		_	1,472,493
21st Century Cures Act – Beau Biden Cancer Moonshot Nursing Research	93.353 93.361		286,002 148,778	738,497 963,952
Cancer Cause and Prevention Research	93.393		1,121,654	4,319,461
Cancer Detection and Diagnosis Research Cancer Treatment Research	93.394 93.395		1,127,888	463,875 2,806,852
Cancer Biology Research	93.396		362,208	3,356,118
Cancer Centers Support Grants Cancer Research Manpower	93.397 93.398		68,461 5.400	3,303,951 644,386
Cancer Control	93.399		301,027	4,816,344
Cardiovascular Diseases Research Lung Diseases Research	93.837 93.838		2,512,354 671,275	9,386,021 1,591,242
Blood Diseases and Resources Research	93.839		_	556,364
Arthritis, Musculoskeletal and Skin Diseases Research Diabetes, Digestive, and Kidney Diseases Extramural Research	93.846 93.847		2,027,234	294,368 8,853,621
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853		689,070	2,632,236
Allergy and Infectious Diseases Research Biomedical Research and Research Training	93.855 93.859		484,227 474,565	4,505,900 3,801,569
Child Health and Human Development Extramural Research	93.865		39,598	695,233
Aging Research Vision Research	93.866 93.867		6,630,182 60,631	26,299,185 1,866,015
Multi-Ethnic Study of Atherosclerosis (MESA)	93.UNKNOWN		00,031	492,255
Systolic Blood Pressure Intervention Trial (SPRINT)	93.UNKNOWN 93.UNKNOWN		-	433,913
WHIMS-ECHO Hormone Therapy and Cognitive Aging in Older Postmenopausal Women Women Health Initiative – Regional Center	93.UNKNOWN 93.UNKNOWN		38,746 35,629	1,003,528 375,537
National Clinical Trials Network	93.UNKNOWN		_	13,767
Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT	93.UNKNOWN			6,415
Subtotal National Institutes of Health Direct Programs			21,337,396	110,721,471
Family Smoking Prevention and Tobacco Control Act Regulatory Research: Brown University	93.077	00001306		2,757
University of Minnesota	93.077	P006719502	_	11,317
University of North Carolina at Chapel Hill University of North Carolina at Chapel Hill	93.077 93.077	5118449 None Identified	=	13,206 2,782
University of Oklahoma Health Sciences	93.077	None Identified	_	48,215
University of Pennsylvania	93.077	575399	_	(6,749)
University of Pennsylvania University of Pennsylvania	93.077 93.077	577788 580522	=	20,843 19,949
University of Pittsburgh	93.077	CNVA00059872 (132560-1)	_	(2,769)
University of Vermont American Heart Association	93.077 93.077	1R01DA51001-01 FX-ATRAC-WF-05	_	19,142 (31)
Total Family Smoking Prevention and Tobacco Control Act Regulatory Research				128,662
Oral Diseases and Disorders Research:				120,002
New York University School of Medicine	93.121	F7834-01	_	25,700
University of Texas – Houston	93.121	0012976A		12,306
Total Oral Diseases and Disorders Research				38,006
Research and Training in Complementary and Alternative Medicine:	00.040	40.400.4		400 700
University of Arizona	93.213	494064		102,786
Total Research and Training in Complementary and Alternative Medicine				102,786
Mental Health Research Grants: Georgia Health Sciences University	93.242	26733-01		(797)
Research Foundation for Mental Hygiene	93.242	130157	32	32
University of Washington Virginia Tech	93.242 93.242	BPO8603 412600-19541	_	(1,222)
· ·	33.242		32	181,669
Total Mental Health Research Grants  Alcohol Research Programs:				179,682
Johns Hopkins University	93.273	PTEID 2003378008	_	2,205
Oregon Health & Sciences University	93.273	1006932_WF	_	15,311
Oregon Health & Sciences University University of Utah	93.273 93.273	None Identified 10050883-01/PO U000161503	_	5,349 60,972
Total Alcohol Research Programs				83,837
Drug Abuse and Addiction Research Programs:				55,557
University of Pittsburgh	93.279	None Identified	_	78,298
Duke University Medical Center	93.279	A032166 2036634	_	219,961
Duke University Medical Center Duke University Medical Center	93.279 93.279	A030186	_	1,015 (2,666)
Indiana University	93.279	None Identified	- - - - - -	225,771
Medical Univ. of South Carolina Medical Univ. of South Carolina	93.279 93.279	MUSC19-011-8D703 A00-3828-S001PO #410087	=	170,120 49,957
Medical Univ. of South Carolina	93.279	None Identified	_	90,699
Oregon Health & Sciences University Scripps Research Institute	93.279 93.279	1012971_WAKEFOREST 5-53580	=	22,056 80
University of California – San Diego	93.279	None Identified	_	341,837
University of California – San Diego University of Kentucky	93.279 93.279	7U01DA043799 PO# 7800004964	Ξ	20,436 71,978
University of N Carolina-Chapel Hill	93.279	5118065	_	50,246
McLean Hospital	93.279 93.279	3UG1DA015831-18S9 3 UG1DA015831-19S1	_	60,662
Yale University School of Medicine	93.278	3 OG IDAV13031-1951		115,200
Total Drug Abuse and Addiction Research Programs				1,515,650
Minority Health and Health Disparities Research:  Duke University	93.307	A033206	_	72,003
Kaiser Permanente Southern California	93.307	RNG210374-WF-01	=	16,801
New York University Winthrop Hospital Washington University – St. Louis	93.307 93.307	7R01MD009055-06 / R01MD009055 None Identified	=	15,484 3,517
Total Minority Health and Health Disparities Research	33.307			107,805
. oral millionty i realist and i realist Disparities (1656dicil				107,000

## Schedule of Expenditures of Federal Awards Year ended June 30, 2021

	Federal CFDA no.		Passed	
Federal grantor/pass-through grantor/program or cluster title	or other grant identifying no.	Pass-through entity identifying number	through to subrecipients	Federal expenditures
Trans-NIH Research Support:				
Albert Einstein College of Medicine Albert Einstein College of Medicine	93.310 93.310	311572 311818	\$ <u> </u>	18,769 90.852
University of Alabama – Birmingham	93.310	U01AR071133	_	19,228
University of Florida	93.310	None Identified	_	637,130
University of Florida University of Florida	93.310 93.310	SUB00002562 SUB00002564	_	928,569 40,970
University of Florida	93.310	SUB00002211	_	26,774
University of N Carolina-Chapel Hill	93.310	5114838	_	40,281
University of N Carolina-Chapel Hill University of Pittsburgh	93.310 93.310	5118547 CNVA00053409	_	213,694 71,919
Women & Infants Hospital	93.310	5001441	_	319,610
Total Trans-NIH Research Support			_	2,407,796
National Center for Advancing Translational Sciences:			<u></u>	
Duke University	93.350	None Identified	_	2,571
Emory University New York University School of Medicine	93.350 93.350	U54TR001456 None Identified	_	(879) 82,968
The Rockefeller University	93.350	SUB00000122	_	63,588
University of Pittsburgh	93.350	None Identified		35,999
Total National Center for Advancing Translational Sciences				184,247
Nursing Research:				
Boston Medical Center	93.361 93.361	7633 R01NR018979	_	30,188 26,405
SUNY Upstate Medical University University of California – Irvine	93.361	2017-3533	_	5,530
Total Nursing Research			_	62,123
Cancer Cause and Prevention Research:				
Alliance for Clinical Trials in Oncology	93.393	A011106	_	2,833
Brown University	93.393	00001077	_	5,006
Dana-Farber Cancer Institute Massachusetts General Hospital	93.393 93.393	1204002 232008	_	39,606 17,627
Mount Sinai School of Medicine	93.393	0255-0851-4609	_	24,250
Purdue University	93.393	11000720-011	_	33,990
Northewestern Univ Feinburg School The University of North Carolina at Chap	93.393 93.393	None Identified None Identified	_	72,952 18,295
University of Texas – Houston	93.393	164457/164399		4,183
Total Cancer Cause and Prevention Research				218,742
Cancer Detection and Diagnosis Research:				
Case Western Reserve University Case Western Reserve University	93.394 93.394	U24CA199374 / sub RES514677 RES512735	11,513	83,148 (125)
University of Iowa	93.394	7R21CA219899-03	_	5,890
Total Cancer Detection and Diagnosis Research			11,513	88,913
Cancer Treatment Research:				
Adult Brain Tumor Consortium	93.395	1601	_	9,287
Adult Brain Tumor Consortium Adult Brain Tumor Consortium	93.395	ABTC1501	_	15,390
Adult Brain Turnor Consortium  Alliance for Clinical Trials in Oncology	93.395 93.395	ABTC1603 A051301	=	48,184 4,939
Alliance for Clinical Trials in Oncology	93.395	A051701	_	373
Alliance for Clinical Trials in Oncology Alliance Foundation Trials, LLC	93.395 93.395	None Identified None Identified	=	70 49
Brigham & Women's Hospital	93.395	None Identified	_	7,832
Canadian Cancer Trials Group	93.395	CCTG CE.7	_	1,050
Children's Hospital Of Philadelphia Children's Hospital Of Philadelphia	93.395 93.395	9500080215-13C FP00013087_SUB206_01	=	21,122 67,016
Children's Hospital Of Philadelphia	93.395	None identified	_	17
ECOG-ACRIN Cancer Research Group	93.395	EA1151	Ξ	7,552
ECOG-ACRIN Cancer Research Group ECOG-ACRIN Cancer Research Group	93.395 93.395	EA2165 EA8143	=	185 3,772
ECOG-ACRIN Cancer Research Group	93.395	None identified	_	2,692
George Washington University	93.395	19-M113	_	2,486
Gynecologic Oncology Group Icahn School of Medicine at Mount Sinai	93.395 93.395	27469 041 0254-4022-4605	=	3 6,166
John Wayne Cancer Institute	93.395	JWCIMSLTII	_	9
Johns Hopkins University Johns Hopkins University	93.395 93.395	ABTC 1701 ABTC1202	_	211 274
Johns Hopkins University	93.395	PO#2002555394	_	1,427
Johns Hopkins University	93.395	None Identified	=	2,409
Johns Hopkins University Johns Hopkins University	93.395 93.395	None Identified None Identified		17,535 906
Johns Hopkins University	93.395	None Identified	_	(5,810)
Mount Sinai School of Medicine	93.395	0254-7376-4605	= =	1,643
NRG Oncology NRG Oncology	93.395 93.395	GU002 NRG-GI005	_	6,388 270
NRG Oncology	93.395	NRG-LU005	Ξ	24,537
NRG Oncology NRG Oncology	93.395 93.395	NRG-GI004 None Identified	_	432 360
Regents of the University of CA	93.395	None Identified	_	43,140
Regents of the University of CA	93.395	None Identified	_	1,359
Senex Biotechnology Southwest Oncology Group	93.395 93.395	None Identified S1929	=	11,646 47
Southwest Oncology Group	93.395	S1826	_	299
Southwest Oncology Group	93.395	SWOG S1801	_	680
Southwest Oncology Group University of Iowa	93.395 93.395	None identified S00583-01	=	10,960 34,119
University of Iowa	93.395	S01738-01	_	5,344
University of North Carolina Chapel Hill	93.395 93.395	5115842 None Identified	_	1,807 27,984
University of Texas at Arlington Total Cancer Treatment Research	93.395	None identified		386,161
				300,101
Cancer Biology Research: Georgia Tech	93.396	None Identified	_	55,696
Georgia Tech	93.396	U01CA215848 45155 SUP1	_	86,980
Georgia Tech Health Research, Inc.	93.396 93.396	None Identified 335-01	_	166,091
Health Research, Inc. Health Research, Inc.	93.396 93.396	335-01 333-01	=	(1,401) 9,612
Health Research, Inc.	93.396	None Identified	_	8,379
Ohio State University Pennsylvania State University	93.396 93.396	R21CA229027 6080-WF-DHHS-9700	_	35,960 27,816
Pennsylvania State University Pennsylvania State University	93.396	6072-WF-DHHS-7261	=	29,265
Total Cancer Biology Research				418,398

## Schedule of Expenditures of Federal Awards Year ended June 30, 2021

Federal grantoripass-through grantoriprogram or cluster title	Federal CFDA no. or other grant identifying no.	Pass-through entity identifying number	Passed through to subrecipients	Federal expenditures
Cancer Centers Support Grants:			_	
University of Texas M.D. Anderson Cancer Center University of Texas M.D. Anderson Cancer Center	93.397 93.397	None Identified 3001702762	5 _	14,781 58,125
Total Cancer Centers Support Grants				72,906
Cancer Research Manpower:	00.000	N 11 17 1		0.700
University of Alabama – Birmingham University of Alabama – Birmingham	93.398 93.398	None Identified 000519795-001	=	8,725 3,361
Total Cancer Research Manpower			_	12,086
Cancer Control:				
Alliance for Clinical Trials in Oncology Alliance for Clinical Trials in Oncology	93.399 93.399	None Identified A081801	_	11 73
Alliance for Clinical Trials in Oncology	93.399	None Identified	_	777
Alliance for Clinical Trials in Oncology Alliance for Clinical Trials in Oncology	93.399 93.399	A011401 None Identified	=	809 3,552
Oregon Health & Sciences University Oregon Health & Sciences University	93.399 93.399	None Identified None Identified	=	36,384 8,008
ECOG-ACRIN Cancer Research Group	93.399	1014562_WAKEFOREST	_	754
ECOG-ACRIN Cancer Research Group ECOG-ACRIN Cancer Research Group	93.399 93.399	None Identified None Identified	_	2,576 63,066
Southwest Oncology Group University of Massachusetts	93.399 93.399	None Identified S1616	_	360 25,864
Total Cancer Control	33.333	51010		142,234
Strengthening Public Health Systems and Services			-	1-12,20
National Association of County and City	93.421	2020-063001	_	13,709
The Task Force for Global Health	93.421	None Identified		62,149
Total Strengthening Public Health Systems and Services				75,858
ardiovascular Diseases Research: Arizona State University	93.837	ASUB00000742	_	405
Beth Israel Deaconess Medical Center Boston Medical Center	93.837 93.837	01062872 4500003578	_	54,035 23,743
Brigham & Women's Hospital	93.837	119532	_	13,424
Brigham & Women's Hospital Case Western Reserve University	93.837 93.837	117349 RES513068	_	50,726 95,737
Columbia University Johns Hopkins University	93.837 93.837	None Identified 2004538358	_	(297 924,783
Kent County Memorial Hospital	93.837	5001381-SHUMAKER	=	6,230
Oregon Health & Sciences University Partners Healthcare	93.837 93.837	1002459_WakeF 225712	_	537 32,966
New England Research Institute	93.837	None Identified	=	16,12
Tulane Üniversity Medical Center University of Minnesota	93.837 93.837	None Identified None Identified	=	9,340 (35,363
University of Minnesota	93.837 93.837	None Identified N004944404	_	(20 3.857
University of Minnesota University of Minnesota	93.837	None Identified		99,884
University of North Carolina Chapel Hill University of Pennsylvania	93.837 93.837	5116925 574075PO4476120PO 4601819	_	11,630 9,154
University of Texas SW Med Cen -Dallas	93.837	GMO 190911		66,733
University of Texas SW Med Cen -Dallas University of Washington	93.837 93.837	GMO 180101 UWSC9055	_	59,399 23,405
University of Washington University of Washington	93.837 93.837	None Identified UWSC10978	_	27,143 55,082
University of Washington	93.837	BPO16612	_	(15,564
University of Washington University of Washington	93.837 93.837	UWSC7564 UWSC9382	_	82 (1,425
University of Washington	93.837	UWSC9382	=	1,425
Vanderbilt University Medical Center Yale University School of Medicine	93.837 93.837	None Identified None Identified		20,528 852
Total Cardiovascular Diseases Research				1,554,552
ung Diseases Research:				
Brigham & Women's Hospital Brigham & Women's Hospital	93.838 93.838	122869 122287	_	3,190 6,852
Brigham & Women's Hospital	93.838	122869	_	150,283
Columbia University Columbia University	93.838 93.838	8(GG015835-01) 33(GG015997-01)	_	(3 81,715
Columbia University Columbia University	93.838 93.838	8(GG015835-02) 7(GG010919-03)	_	156,344 (417
Indiana University	93.838	8587	_	16,944
Intermountain Medical Center Massachusetts General Hospital	93.838 93.838	None Identified Insight Fund #236620	=	11,604 2.225
Massachusetts General Hospital	93.838 93.838	3U01HL123009 WFUHS Z17448	100,064	122,078
Massachusetts General Hospital Tufts University	93.838	102680-00001	33,104	67,982 126,742
University of Arizona University of California – San Francis	93.838 93.838	435611 10458sc	=	87,286 231,170
University of N Carolina-Chapel Hill	93.838	5114595	_	2,281
University of N Carolina-Chapel Hill University of N Carolina-Chapel Hill	93.838 93.838	5116381 5118116	_	30,145 32,661
University of North Carolina Chapel Hill	93.838 93.838	5117256-H3WFUNIVER (current) 5114474-H3WFUNIVER (prior) 31438-01-004-SUB0003	_	47,146 32,392
University of Vermont University of Vermont	93.838	32723SUB52545	_	228,579
University of Washington University of Washington	93.838 93.838	UWSC9506 PO# BPO32909 UWSC9506 PO# BPO32909	_	495 25,674
Weill Cornell Medical College	93.838	192243-12		6,758
Total Lung Diseases Research			133,168	1,470,126
lood Diseases and Resources Research:	00 000	0001043106		6 000
Fred Hutchinson Cancer Research Center UNC Chapel Hill	93.839 93.839	None Identified	_	6,263 853
University of Pennsylvania	93.839	570994		132,947
Total Blood Diseases and Resources Research:				140,063
		None Identified	_	13,177
arthritis, Musculoskeletal and Skin Diseases Research:	93.846	identified	_	24,746
vthritis, Musculoskeletal and Skin Diseases Research: Johns Hopkins University New York University School of Medicine	93.846 93.846	17-A1-00-005969-01Project 110088		
Arthritis, Musculoskeletal and Skin Diseases Research: Johns Hopkins University	93.846 93.846 93.846 93.846	17-A1-00-005969-01 Project 110088 U01AR073485 None Identified	=	
Arthritis, Musculoskeletal and Skin Diseases Research: Johns Hopkins University New York University School of Medicine University of Michigan	93.846 93.846	U01AR073485	_	3,472
Arthritis, Musculoskeletal and Skin Diseases Research: Johns Hopkins University New York University School of Medicine University of Michigan University of Pittsburgh Total Arthritis, Musculoskeletal and Skin Diseases Research Diabetes, Digestive, and Kidney Diseases Extramural Research:	93.846 93.846 93.846	U01AR073485 None Identified		3,472 54,622
Arthritis, Musculoskeletal and Skin Diseases Research: Johns Hopkins University New York University School of Medicine University of Michigan University of Mitchigan Total Arthritis, Musculoskeletal and Skin Diseases Research Diabetes, Digestive, and Kidney Diseases Extramural Research: Advent Health	93.846 93.846	U01AR073485 None Identified 120322		13,227 3,472 54,622 14,491 181,471
Arthritis, Musculoskeletal and Skin Diseases Research: Johns Hopkins University New York University School of Medicine University of Michigan University of Pittsburgh Total Arthritis, Musculoskeletal and Skin Diseases Research Diabetes, Digestive, and Kidney Diseases Extramural Research:	93.846 93.846 93.846	U01AR073485 None Identified	<u>=</u> 	3,472 54,622

## Schedule of Expenditures of Federal Awards Year ended June 30, 2021

Federal grantor/pass-through grantor/program or cluster title	Federal CFDA no. or other grant identifying no.	Pass-through entity identifying number	Passed through to subrecipients	Federal expenditures
George Washington University	93.847	19-B02	s –	875
George Washington University	93.847	S-DPP2122-JC01	_	20,917
George Washington University George Washington University	93.847 93.847	20-B02 None Identified	Ξ	47,098 57,740
George Washington University	93.847	S-GRD1920-LL43	_	120,727
Harvard Pilgrim Health Care Johns Hopkins University	93.847 93.847	AH000650 2002910217	_	114,871 (709)
Mt. Sinai Medical Center	93.847	5U54DK083909	_	175,246
Northern California Institute for Research	93.847	None Identified	_	83,855
Texas A &M University Tufts University	93.847 93.847	M1902585 None Identified	Ξ	27,065 320
Tufts University	93.847	None Identified	_	13,012
University of California – San Francis	93.847 93.847	1R01DK120886-01A1 REVISED 3004195234	_	25,187
University of Michigan University of Michigan	93.847	3004195235	_	15,267 32,122
University of Michigan	93.847	3003773938	_	1,281
University of Michigan	93.847 93.847	3003482457 3003773940	_	4,508
University of Michigan University of N Carolina-Chapel Hill	93.847	5115004	Ξ	3,498
University of N Carolina-Chapel Hill	93.847	None Identified	_	52,596
University of N Carolina-Chapel Hill University of N Carolina-Chapel Hill	93.847 93.847	1R01DK123206-01A1 None Identified	=	59,430 (11,613)
University of N Carolina-Chapel Hill	93.847	5105187	_	(2,260)
University of N Carolina-Chapel Hill	93.847	5104211	_	(1,054)
University of N Carolina-Chapel Hill University of N Carolina-Chapel Hill	93.847 93.847	5112044 5117125	_	10,213 73,542
University of Pennsylvania	93.847	5772264	_	(6,072)
University of Pennsylvania	93.847	572042	_	33
University of Pennsylvania University of South Carolina	93.847 93.847	574485 18-3668PO 2000039782	=	27 32,607
University of Southern California	93.847	78078941	_	73,830
University of Washington	93.847	UWSC8594	_	(1,590)
Vanderbilt University	93.847	VUMC71249		23,894
Total Diabetes, Digestive, and Kidney Diseases Extramural Research				1,310,855
Extramural Research Programs in the Neurosciences and Neurological Disorders:				
Duke University	93.853	1U24NS114416-01 REVISED	_	15,815
Emory University Emory University	93.853 93.853	T651854 (Yr4 T473217) T473217	Ξ	4,890 5,069
Georgia College & State University	93.853	36613-WFM-01	_	12,731
Johns Hopkins University	93.853	PO#2003044864PO#2001948320	_	18,795
Massachusetts General Hospital Massachusetts General Hospital	93.853 93.853	None Identified None Identified	_	300 12,417
Massachusetts General Hospital	93.853	U01NS114001	_	41,369
Massachusetts General Hospital	93.853	227810	_	50,089
Mayo Clinic Mayo Clinic	93.853 93.853	U01NS080168 WAK-224063-01 (effective 3/1/18) WAK187276 WAK-232483	=	58,918 28,367
Ohio State University	93.853	60065846	_	12,656
Virginia Tech Carilion School of Medic	93.853	431884-19541	_	(8,830)
Stanford University Stanford University	93.853 93.853	5U01NS038455-18 5U01NS038455-17	=	563 13,691
University of California – Davis	93.853	amendment doesn't report a change *A20-2531-S001	_	11,362
University of California – Davis	93.853	7R01NS058949	_	41,649
University of California – Davis University of Cincinnati	93.853 93.853	A20-2531-S001 U01NS102289	=	2,262 500
University of Cincinnati	93.853	012043-138224	_	8,473
University of Cincinnati University of Cincinnati	93.853 93.853	011266-138224 None Identified	_	12,655 13,178
University of Cincinnati	93.853	010785-138224	_	33.657
University of Cincinnati	93.853	011337-138224	_	14,913
University of Cincinnati	93.853 93.853	None Identified 013215-002	_	198,980 21.095
University of Cincinnati Medical Center University of Miami	93.853	U54NS092091	_	4,179
University of Miami	93.853	5U54NS092091	_	40
University of N Carolina-Chapel Hill University of Pittsburgh	93.853 93.853	5109025 1U24NS115708-01	_	25,916 2.638
University of Pittsburgh	93.853	None Identified	_	6,088
University of Washington	93.853	UWSC7779	_	19,588
Weill Cornell Medical College	93.853	170326-03		13,834
Total Extramural Research Programs in the Neurosciences and Neurological Disorders				697,847
Allergy and Infectious Diseases Research:				
Cincinnati Children's Hospital Columbia University	93.855 93.855	309362 (Admin) 2U19Al067773	_	4,625 981
Columbia University  Columbia University	93.855	2019Al067773 21(GG011896-34)	_	(2,249)
Duke University	93.855	A031945	_	87,527
Duke University Duke University	93.855 93.855	A031946 A030236	_	234,691 93
Duke University Medical Center	93.855	A0334212U19AI067798	_	295,625
Fred Hutchinson Cancer Research Center	93.855	0001062475	_	1,550
Fred Hutchinson Cancer Research Center Fred Hutchinson Cancer Research Center	93.855 93.855	0001060439 0001040874	_	6,976 97.954
Fred Hutchinson Cancer Research Center	93.855	0001040695	_	48,000
Institute for Clinical Research, Inc.	93.855	M52-WF-034-1101-3	_	16,497
New York University School of Medicine Partners Healthcare	93.855 93.855	17-A0-00-007347 Project# 108240 227111	_	99,544 390
Tufts University	93.855	None Identified	=	81,007
University of Hawaii	93.855	5R21AI140248		20,192
Total Allergy and Infectious Diseases Research				993,403
Child Health and Human Development Extramural Research:				
CiceroDx,Inc.	93.865	R44HD097750	_	40,938
Cincinnati Children's Hospital Michigan State University	93.865 93.865	None Identified R21HD103039	_	25,349 28,487
Michigan State University University of Michigan	93.865 93.865	R21HD103039 3004583867	=	28,487 69,980
Women & Infants Hospital	93.865	9373		812
Total Child Health and Human Development Extramural Research			_	165,566
Aging Research:				
AdventHealth	93.866	1534612-WFU	_	172,139
Beckman Research Institute	93.866	60254.2005087.669302	_	25,451
Boston Medical Center Brigham & Women's Hospital	93.866 93.866	7765 1R01AG067507-01 / R01AG067507	_	35,533 34,729
Brown University	93.866	None Identified	_	34,729 38,796
Columbia University	93.866	6(GG015822-01)	_	3,251
Duke University Duke University	93.866 93.866	A032814 A034526	_	7,117 35,106
Duke University Duke University Medical Center	93.866	A034526 A033319	_	1,086
Duke University Medical Center	93.866	A03-0907	_	3,480

## Schedule of Expenditures of Federal Awards Year ended June 30, 2021

Federal grantor/pass-through grantor/program or cluster title	Federal CFDA no. or other grant identifying no.	Pass-through entity identifying number	Passed through to subrecipients	Federal expenditures
Duke University Medical Center	93.866	A033976	\$ —	35,721
Indiana University	93.866 93.866	8677	_	75,432
Johns Hopkins University Johns Hopkins University	93.866	2004070511 None Identified	_	5,483 87,735
Johns Hopkins University	93.866	2003189929	_	141,416
Johns Hopkins University	93.866	2003589933	_	376,930
Johns Hopkins University Mayo Clinic	93.866 93.866	2003379640 WAK-250202-01/PO #67268411	=	(269) 32,609
Mayo Clinic	93.866	WAK-230202-017FO #07208411 WAK-275475/PO #67674988	_	77,532
Northwestern University	93.866	60057255	_	2,505
Ohio State University	93.866	60067302PO RF1531329	_	42,141
Pennington Biomedical Research Center California Pacific Medical Center	93.866 93.866	None Identified subaward # 280201015-S222	=	51,376 1,555,104
Duke Clinical Research Institute	93.866	A03-2816	_	41,107
Duke Clinical Research Institute	93.866	A03-3860	_	146,243
Duke Clinical Research Institute	93.866	A03-2818	_	197,632
Duke Clinical Research Institute Duke Clinical Research Institute	93.866 93.866	A03-3881 A03-3865	Ξ	442,620 1,007,770
Duke Clinical Research Institute	93.866	A03-2827	_	25,602
The Regents of the University of California	93.866	None Identified	_	270,882
The Regents of the University of California	93.866	00010176 TUL-HSC-558413-20/21	2,062,500	2,809,771
Tulane University Medical Center Univ. of California – San Diego	93.866 93.866	42024655	_	34,254 145,677
University of California – Davis	93.866	A21-0198-S002	_	38.371
University of California – Irvine	93.866	2020-1363	_	26,162
University of California – Irvine	93.866	2018-3598	_	9,660
University of California LA University of California LA	93.866 93.866	None Identified 1558 G WA345	40,906	192,444
University of California LA University of Maryland	93.866	65520-Z0159203	40,900	1,759 17,186
University of Miami	93.866	5U01AG052410	_	(8,027)
University of Miami	93.866	None Identified	_	60,395
University of Miami	93.866	OS00000065	_	62,573
University of N Carolina-Chapel Hill University of N Carolina-Chapel Hill	93.866 93.866	5107610 5106148	Ξ	36,862 19,437
University of N Carolina-Chapel Hill University of Pittsburgh	93.866 93.866	AWD00003000(135310-9)	=	19,437 30,172
University of Southern California	93.866	None Identified	_	1,784
University of Southern California	93.866	None Identified	_	20,351
University of Southern California	93.866	118035962	_	25,843
University of Southern California University of Southern California	93.866 93.866	93356607 133616791	_	280,597 8,722
University of Southern California	93.866	75696819	_	23,330
University of Southern California	93.866	130991038	_	1,901
University of Southern California	93.866	107786842	_	14,622
University of Southern California	93.866	None Identified 105791377	_	45,430
University of Southern California University of Southern California	93.866 93.866	105/913// Subaward No. 120188648	=	127,345 24.960
University of Southern California	93.866	131392798	=	18,453
University of Southern California	93.866	129211757	_	28,215
University of Texas Health Science Center	93.866	166855/165761	_	18,252
University of Utah	93.866	10055540-02PO U000265955 UWSC11053; BPO38317	_	27,780
University of Washington University of Wisconsin	93.866 93.866	UWSC11053; BPO38317 Subaward No. 0000001242R01AG070883	=	2,505 16,113
University of Wyoming	93.866	None Identified	_	433,975
University of Wyoming	93.866	1004121B-WF	_	(1,183)
Vanderbilt University	93.866	UNIV59652	_	443,529
Washington State University	93.866	132471 SPC002273		5,427
Total Aging Research			2,103,406	10,016,906
Vision Research:				
Cincinnati Children's Hospital	93.867	1R01EY030521-01	_	7,805
Cincinnati Children's Hospital	93.867	309380	_	26,837
City of Hope Comprehensive Cancer Center	93.868	23030.1914940.669305		636
Total Vision Research				35,278
Medical Library Assistance:				
Brigham & Women's Hospital	93.879	117673	_	79,704
Children's Hospital Medical Center Cincinnati	93.879	304838		(16,048)
Total Medical Library Assistance			_	63,656
Fogarty International Center:				
Fogarty International Center: University of Massachusetts	93.989	PTE: 5 R01TW010647-03WFU SUBAWARD#OSP24660-00	_	17,029
	33.303	5 // 100 /		
Total Fogarty International Center				17,029
ASPR Science Preparedness and Response Grants				
Asell, LLC Environmental Health	93.081	20180011	_	118
Environmental Health: University of Southern California	93.113	93343187	_	48,755
Research Related to Deafness and Communication Disorders:	93.119	555-10101	_	40,733
Ohio State University	93.173	60068546	_	107,927
The Healthy Brain Initiative				
Alzheimers Association	93.334	None Identified	_	47,991
21st Century Cures Act – Beau Biden Cancer Moonshot University of Alabama – Birmingham	93.353	000526841-SC005	_	32.234
Nurse Education, Practice Quality and Retention Grants	93.333	000320041*3C003	_	32,234
NRG Oncology	93.359	NRG-BR004	_	901
Biomedical Research and Research Training:				
Tufts University	93.859	None Identified	_	3,694
ung Organ Tissue Equivalent Platform For Modeling Chlorine Gas Toxicology:  Biomedical Advanced Research and Development Authority	93.UNKNOWN	None Identified		4,229,527
Impact of Nicotine Reduction on Adolescent Cigarette Use:	93.UNNNUWN	None identified	_	4,229,527
Southwest Oncology Group	93.UNKNOWN	SWOG S1803	_	2,037
Cancer Trials Support unit(CTSU) Phase II:				
Children's Hospital of Philadelphia	93.UNKNOWN	None Identified	_	509
BPCA Pediatric Trials Network: Duke Clinical Research Institute	93.UNKNOWN	202 7000		0.400
Duke Clinical Research Institute  Jackson Heart Study Coordinating Center	93.UNKNOWN	203-7988	_	2,489
University of Mississippi	93.UNKNOWN	SP13925-SB12	_	35.197
University of Mississippi	93.UNKNOWN	66111350819-13	_	4,099
Change in Relative Cerebral Blood Volume as a Biomarker:				
ECOG-ACRIN Cancer Research Group	93.UNKNOWN	None Identified	_	7,843
Randomized Phase III Study of Ibrutinib (PCI-32765)-based Therapy:	00 11611/01/01/01	None Id485-4		200
ECOG-ACRIN Cancer Research Group Treatment of Gardnerella Vaginalis Vaginal Colonization with Amoxicillin:	93.UNKNOWN	None Identified	_	203
Treatment of Gardnerella Vaginalis Vaginal Colonization with Amoxicillin: University of Alabama-Birmingham	93.UNKNOWN	000524050-T003-002	_	9.458
University of Alabama-Birmingham  University of Alabama-Birmingham	93.UNKNOWN 93.UNKNOWN	000524050-1003-002 000500918-T012-002	_	2,470
Sexually Transmitted Infections Clinical Trials Group Admin Core:				
University of Alabama-Birmingham	93.UNKNOWN	524050-T009-006	_	6,325
Jackson Heart Surveillance Study (JHS Surveillance):	OS LINICALOMA	66111350040 44		4.070
University of Mississippi	93.UNKNOWN	66111350819-14	_	4,079

## Schedule of Expenditures of Federal Awards Year ended June 30, 2021

Federal CFDA no. Passed				
Federal grantor/pass-through grantor/program or cluster title	or other grant identifying no.	Pass-through entity identifying number	through to subrecipients	Federal expenditures
University of Mississippi	93.UNKNOWN	SP13925-SB12	\$ —	55,781
Atherosclerosis Risk in Communities (ARIC) – Field Center: University of North Carolina at Chapel Hill	93.UNKNOWN	5109158	_	(287)
University of North Carolina at Chapel Hill University of North Carolina at Chapel Hill	93.UNKNOWN 93.UNKNOWN	5116067 5119475	_	206,563 349,983
University of North Carolina at Chapel Hill University of North Carolina at Chapel Hill	93.UNKNOWN	5109427		(537)
Total Atherosclerosis Risk in Communities (ARIC) – Field Center				555,722
Atherosclerosis Risk in Communities (ARIC) Study – Coordinating Center: University of North Carolina at Chapel Hill	93.UNKNOWN	5106342	_	154
University of North Carolina at Chapel Hill	93.UNKNOWN	5119570		86,403
Total Atherosclerosis Risk in Communities (ARIC) - Coordinating Center				86,557
Molecular Basis of Exercise-induced Changes in HDL Function:				
University of South Carolina Multi -Ethnic Study of Atherosclerosis (MESA):	93.UNKNOWN	19-3841	_	39,766
University of Washington	93.UNKNOWN	UWSC8541 / PO # 33396	_	71
Analysis of RSV Load and Immune Response in Adult Leidos Biomedical Research, Inc	93.UNKNOWN	17X203-1	_	8
Influenza Vaccine Effectiveness for Preventing Laboratory-Confirmed Severe Influenza Illness: Vanderbilt University	93.UNKNOWN	VUMC75295		45,957
Tobacco Product Transitions and Health across the Life Course			_	
American Heart Association Randomized Master Protocol for Immune Modulators	93.UNKNOWN	None Identified	_	(603)
Duke University PETAL Network International Coordinating Center for ACTIV-3 Trial Initiative	93.UNKNOWN	None Identified	_	29,304
Massachusetts General Hospital	93.UNKNOWN	237165	20,000	194,900
ADCC Passive Transfer and Dengue Virus Challenge Naval Medical Research Center	93.UNKNOWN	None Identified	_	15,073
Multicenter Platform Evaluating Putative Therapeutics for the Treatment of COVID-19 in Hospitalized Adults Social and Scientific Systems, Inc.	93.UNKNOWN	None Identified		28,767
Clinical-trial of COVID-19 Convalescent Plasma in Outpatients (C3PO)			_	
University of Michigan CHS Research for the Cardiovascular Health	93.UNKNOWN	None Identified	_	1,297
University of Washington	93.UNKNOWN	UWSC12414BPO 52782		35,215
Systems Modeling Guided Bone Regeneration University of Texas – Houston	93.UNKNOWN	None Identified	_	(180)
Medical Imaging and Data Consortium University of Chicago	93.UNKNOWN	AWD101462-U		43,169
Mycoplasma Genitalium Among Men			_	
University of Alabama – Birmingham COVID-19 Post-hospital Thrombosis Prevention Study	93.UNKNOWN	000500918-T011-001	_	6,038
University of Pittsburgh Versiti Wisconsin, Inc.	93.UNKNOWN 93.UNKNOWN	None Identified :T2HL156812	_	891 17,054
Enhanced Rapid Assay For Monitoring Immunosuppressant			_	
Intelligent Optical Systems, Inc.  Adaptive Platform Treatment Trial for Outpatients With COVID-19 (Adapt Out COVID)	93.UNKNOWN	W81XWH-20-C-0044	_	4,258
PPD Investigator Services	93.UNKNOWN	ACTIV-2/A5401		4,885
Subtotal National Institutes of Health Pass-Through Programs			2,268,119	28,455,581
Total National Institutes of Health			23,605,515	139,177,052
Food and Drug Administration Pass-Through Programs From: Food and Drug Administration_Research:				
Children's Hospital – Boston	93.103	GENFD0001539553	-	822
Medical Device Innovation Consortium Evaluating Fitness-for-Use of Electronic Health Records	93.103	None Identified	155,045	339,646
Duke University	93.UNKNOWN	250543		2,100
Total Food and Drug Administration			155,045	342,568
Substance Abuse and Mental Health Services Administration Direct Program: Substance Abuse and Mental Health Services_Projects of Regional and National Significance	93.243		137,713	470,070
Total Substance Abuse and Mental Health Services Administration			137,713	470,070
Health Services and Resources Administration Direct Programs:			<u> </u>	
Maternal and Child Health Federal Consolidated Programs  Nurse Anesthetist Traineeship	93.110 93.124		=	296,399 20,301
Coordinated Services and Access to Research for Women, Infants, Children, and Youth	93.153		_	474,261
Geriatric Academic Career Awards Grants for Primary Care Training and Enhancement	93.250 93.884		_	93,203 2,946
Special Projects of National Significance	93.928			20,796
Subtotal Health Services and Resources Administration Direct Programs				907,906
Health Services and Resources Administration Pass-Through Programs From: Area Health Education Centers:				
University of North Carolina at Chapel Hill	93.107	5112711	_	17,400
University of North Carolina at Chapel Hill Maternal and Child Health Federal Consolidated Programs: Hemophilia of Georgia, Inc.	93.107 93.110	5112711 None Identified	_	17,400 16,436
University of North Carolina at Chapel Hill Maternal and Child Health Federal Consolidated Programs: Hemophilia of Georgia, Inc. PPHF Gerlatric Education Centers:	93.110	None Identified	-	16,436
University of North Carolina at Chapel Hill Maternal and Child Health Federal Consolidated Programs: Hemophilia of Georgia, Inc. PPHF Geriatric Education Centers: University of North Carolina at Chapel Hill University of North Carolina at Chapel Hill	93.110 93.969 93.969	None Identified 5117311 5117316	- - -	16,436 1,079 2,644
University of North Carolina at Chapel Hill Maternal and Child Health Federal Consolidated Programs: Hemophilia of Georgia, Inc. PPHF Geriatric Education Centers: University of North Carolina at Chapel Hill University of North Carolina at Chapel Hill University of North Carolina at Chapel Hill	93.110 93.969	None Identified 5117311		16,436 1,079 2,644 3,001
University of North Carolina at Chapel Hill Maternal and Child Health Federal Consolidated Programs: Hemophilia of Georgia, Inc. PPHF Geriatric Education Centers: University of North Carolina at Chapel Hill University of North Carolina at Chapel Hill University of North Carolina at Chapel Hill Subtotal Health Services and Resources Administration Pass-Through Programs	93.110 93.969 93.969	None Identified 5117311 5117316		16,436 1,079 2,644 3,001 40,560
University of North Carolina at Chapel Hill Maternal and Child Health Federal Consolidated Programs: Hemophilia of Georgia, Inc. PPHF Geriatric Education Centers: University of North Carolina at Chapel Hill University of North Carolina at Chapel Hill University of North Carolina at Chapel Hill Subtotal Health Services and Resources Administration Pass-Through Programs Total Health Services and Resources Administration	93.110 93.969 93.969	None Identified 5117311 5117316		16,436 1,079 2,644 3,001
University of North Carolina at Chapel Hill Maternal and Child Health Federal Consolidated Programs: Hemophilia of Georgia, Inc. PPHF Geriatric Education Centers: University of North Carolina at Chapel Hill Subtotal Health Services and Resources Administration Pass-Through Programs Total Health Services and Resources Administration Centers for Disease Control and Prevention Direct Programs: HIV Demonstration, Research, Public and Professional Education Projects	93.110 93.969 93.969 93.969	None Identified 5117311 5117316		16,436 1,079 2,644 3,001 40,560 948,466
University of North Carolina at Chapel Hill Maternal and Child Health Federal Consolidated Programs: Hemophilia of Georgia, Inc. PPHF Geriatric Education Centers: University of North Carolina at Chapel Hill University of North Carolina at Chapel Hill University of North Carolina at Chapel Hill Subtotal Health Services and Resources Administration Pass-Through Programs Total Health Services and Resources Administration Centers for Disease Control and Prevention Direct Programs:	93.110 93.969 93.969 93.969	None Identified 5117311 5117316		16,436 1,079 2,644 3,001 40,560 948,466
University of North Carolina at Chapel Hill Maternal and Child Health Federal Consolidated Programs: Hemophilia of Georgia, Inc. PPHF Geriatric Education Centers: University of North Carolina at Chapel Hill University of North Carolina at Chapel Hill University of North Carolina at Chapel Hill Subtotal Health Services and Resources Administration Pass-Through Programs Total Health Services and Resources Administration Centers for Disease Control and Prevention Direct Programs: HIV Demonstration, Research, Public and Professional Education Projects Assistance Programs for Chronic Disease Prevention and Control	93.110 93.969 93.969 93.969	None Identified 5117311 5117316		16,436 1,079 2,644 3,001 40,560 948,466 294,629 449,504
University of North Carolina at Chapel Hill Matemal and Child Health Federal Consolidated Programs: Hemophilia of Georgia, Inc. PPHF Geriatric Education Centers: University of North Carolina at Chapel Hill Subtotal Health Services and Resources Administration Pass-Through Programs Total Health Services and Resources Administration Centers for Disease Control and Prevention Direct Programs: HIV Demonstration, Research, Public and Professional Education Projects Assistance Programs for Chronic Disease Prevention and Control Sexually Transmitted Diseases (STD) Provider Education Grants Subtotal Centers for Disease Control and Prevention Direct Programs Centers for Disease Control and Prevention Programs From:	93.110 93.969 93.969 93.969	None Identified 5117311 5117316	111,218 72,255 8,965	16,436 1,079 2,644 3,001 40,560 948,466 294,629 449,504 105,087
University of North Carolina at Chapel Hill Maternal and Child Health Federal Consolidated Programs: Hemophilia of Georgia, Inc. PPHF Geriatric Education Centers: University of North Carolina at Chapel Hill Subtotal Health Services and Resources Administration Pass-Through Programs Total Health Services and Resources Administration Centers for Disease Control and Prevention Direct Programs: HIV Demonstration, Research, Public and Professional Education Projects Assistance Programs for Chronic Disease Prevention and Control Sexually Transmitted Diseases (STD) Provider Education Grants Subtotal Centers for Disease Control and Prevention Direct Programs Centers for Disease Control and Prevention Pass-Through Programs From: Birth Defects and Developmental Disabilities — Prevention and Surveillance:	93.110 93.969 93.969 93.969 93.941 93.945 93.978	None Identified 5117311 5117316 5118288	111,218 72,255 8,965	16,436 1,079 2,644 3,001 40,560 948,466 294,629 449,504 105,087
University of North Carolina at Chapel Hill Maternal and Child Health Federal Consolidated Programs: Hemophilia of Georgia, Inc. PPHF Geriatric Education Centers: University of North Carolina at Chapel Hill Subtotal Health Services and Resources Administration Pass-Through Programs Total Health Services and Resources Administration Centers for Disease Control and Prevention Direct Programs: HIV Demonstration, Research, Public and Professional Education Projects Assistance Programs for Chronic Disease Prevention and Control Sexually Transmitted Diseases (STD) Provider Education Grants Subtotal Centers for Disease Control and Prevention Direct Programs Centers for Disease Control and Prevention Pass-Through Programs From: Birth Defects and Developmental Disabilities – Prevention and Surveillance: Duke University Biod Disorder Program: Prevention, Surveillance, and Research:	93.110 93.969 93.969 93.969 93.941 93.945 93.978	None Identified 5117311 5117316 5118288	111,218 72,255 8,965 192,438	16,436 1,079 2,644 3,001 40,560 948,466 294,629 449,504 105,087 849,220
University of North Carolina at Chapel Hill Maternal and Child Health Federal Consolidated Programs: Hemophilia of Georgia, Inc. PPHF Gerilaritic Education Centers: University of North Carolina at Chapel Hill Subtotal Health Services and Resources Administration Pass-Through Programs Total Health Services and Resources Administration Centers for Disease Control and Prevention Direct Programs: HIV Demonstration, Research, Public and Professional Education Projects Assistance Programs for Chronic Disease Prevention and Control Sexually Transmitted Diseases (STD) Provider Education Grants Subtotal Centers for Disease Control and Prevention Direct Programs Centers for Disease Control and Prevention Pass-Through Programs From: Birth Defects and Developmental Disabilities – Prevention and Surveillance: Duke University Biood Disorder Program: Prevention, Surveillance, and Research: University of North Carolina at Chapel Hill University of North Carolina at Chapel Hill	93.110 93.969 93.969 93.969 93.941 93.945 93.978	None Identified 5117311 5117316 5118288	111,218 72,255 8,965 192,438	16,436 1,079 2,644 3,001 40,560 948,466 294,629 449,504 105,087 849,220
University of North Carolina at Chapel Hill Maternal and Child Health Federal Consolidated Programs: Hemophilia of Georgia, Inc. PPHF Gerlaritic Education Centers: University of North Carolina at Chapel Hill Subtotal Health Services and Resources Administration Pass-Through Programs Total Health Services and Resources Administration Centers for Disease Control and Prevention Direct Programs: HIV Demonstration, Research, Public and Professional Education Projects Assistance Programs for Chronic Disease Prevention and Control Sexually Transmitted Diseases (STD) Provider Education Grants Subtotal Centers for Disease Control and Prevention Direct Programs Centers for Disease Control and Prevention Direct Programs Centers for Disease Control and Prevention Direct Programs From: Birth Defects and Developmental Disabilities — Prevention and Surveillance: Dube University Biood Disorder Program: Prevention, Surveillance, and Research: University of North Carolina at Chapel Hill	93.110 93.969 93.969 93.969 93.969 93.941 93.945 93.978	None Identified 5117311 5117316 5118288  A03-2439 5115925 5119711	111,218 72,255 8,965 192,438	16,436 1,079 2,644 3,001 40,560 948,466 294,629 449,504 105,087 849,220 233 6,345 16,125
University of North Carolina at Chapel Hill Maternal and Child Health Federal Consolidated Programs: Hemophilia of Georgia, Inc. PPHF Gerlaritic Education Centers: University of North Carolina at Chapel Hill Subtotal Health Services and Resources Administration Pass-Through Programs Total Health Services and Resources Administration Pass-Through Programs  Total Health Services and Resources Administration Centers for Disease Control and Prevention Direct Programs: HIV Demonstration, Research, Public and Professional Education Projects Assistance Programs for Chronic Disease Prevention and Control Sexually Transmitted Diseases (STD) Provider Education Grants Subtotal Centers for Disease Control and Prevention Direct Programs Centers for Disease Control and Prevention Direct Programs Centers for Disease Control and Prevention Direct Programs From: Birth Defects and Developmental Disabilities — Prevention and Surveillance: Dube University Biood Disorder Program: Prevention, Surveillance, and Research: University of North Carolina at Chapel Hill	93.110 93.969 93.969 93.969 93.969 93.978 93.978 93.073 93.080 93.080	None Identified 5117311 5117316 5118288  A03-2439 5115025 5119711 None Identified	111,218 72,255 8,965 192,438	16,436 1,079 2,644 3,001 40,560 948,466 294,629 49,504 105,087 849,220 233 6,345 16,125 73,420
University of North Carolina at Chapel Hill Matemal and Child Health Federal Consolidated Programs: Hemophilia of Georgia, Inc. PPHF Geriatric Education Centers: University of North Carolina at Chapel Hill Subtotal Health Services and Resources Administration Pass-Through Programs Total Health Services and Resources Administration Centers for Disease Control and Prevention Direct Programs: HIV Demonstration, Research, Public and Professional Education Projects Assistance Programs for Chronic Disease Prevention and Control Sexually Transmitted Diseases (STD) Provider Education Grants Subtotal Centers for Disease Control and Prevention Direct Programs Centers for Disease Control and Prevention Programs From: Birth Defects and Developmental Disabilities – Prevention and Surveillance: Duke University Blood Disorder Program: Prevention, Surveillance, and Research: University of North Carolina at Chapel Hill Assistance Programs For Chronic Diseasese: University of North Carolina at Chapel Hill Assistance Programs for Chronic Diseasese Prevention and Control:	93.110 93.969 93.969 93.969 93.969 93.978 93.978 93.073 93.080 93.283 93.323	None Identified 5117311 5117316 5118288  A03-2439 5115025 5119711 None Identified 5112088	111,218 72,255 8,965 192,438	16,436 1,079 2,644 3,001 40,560 948,466 294,629 449,504 105,087 849,220 233 6,345 16,125 73,420 38,609
University of North Carolina at Chapel Hill Maternal and Child Health Federal Consolidated Programs: Hemophilia of Georgia, Inc. PPHF Gerlatinic Education Centers: University of North Carolina at Chapel Hill Subtotal Health Services and Resources Administration Pass-Through Programs Total Health Services and Resources Administration Centers for Disease Control and Prevention Direct Programs: HIV Demonstration, Research, Public and Professional Education Projects Assistance Programs for Chronic Disease Prevention and Control Sexually Transmitted Diseases (STD) Provider Education Grants Subtotal Centers for Disease Control and Prevention Direct Programs Centers for Disease Control and Prevention Direct Programs From: Birth Defects and Developmental Disabilities – Prevention and Surveillance: Duke University Blood Disorder Program Prevention, Surveillance, and Research: University of North Carolina at Chapel Hill University of North Carolina at Chapel Hill CDC and Prevention Investigations and Technical Assistance: North Carolina Department of Health and Human Services Epidemiology and Laboratory Capacity for Infectious Disease: University of North Carolina at Chapel Hill Assistance Programs for Chronic Disease Prevention and Control: University of North Carolina at Chapel Hill Assistance Programs for Chronic Disease Prevention and Control: University of North Carolina at Chapel Hill Assistance Programs for Chronic Disease Prevention and Control: University of North Carolina at Chapel Hill Assistance Programs for Chronic Disease Prevention and Control: University of North Carolina at Chapel Hill Assistance Programs for Education and Chapel Hill Assistance Programs for Education Assistance	93.110 93.969 93.969 93.969 93.969 93.978 93.978 93.073 93.080 93.080	None Identified 5117311 5117316 5118288  A03-2439 5115025 5119711 None Identified	111,218 72,255 8,965 192,438	16,436 1,079 2,644 3,001 40,560 948,466 294,629 49,504 105,087 849,220 233 6,345 16,125 73,420
University of North Carolina at Chapel Hill Maternal and Child Health Federal Consolidated Programs: Hemophilia of Georgia, Inc. PPHF Gerlatinc Education Centers: University of North Carolina at Chapel Hill Subtotal Health Services and Resources Administration Pass-Through Programs Total Health Services and Resources Administration Centers for Disease Control and Prevention Direct Programs: HIV Demonstration, Research, Public and Professional Education Projects Assistance Programs for Chronic Disease Prevention and Control Sexually Transmitted Diseases (STD) Provider Education Grants Subtotal Centers for Disease Control and Prevention Direct Programs Centers for Disease Control and Prevention Direct Programs From: Bith Defects and Developmental Disabilities – Prevention and Surveillance: Duke University Biod Olisorder Program: Prevention, Surveillance, and Research: University of North Carolina at Chapel Hill Chiversity of North Carolina at Chapel Hill CDC and Prevention Investigations and Technical Assistance: North Carolina Department of Health and Human Services Epidemiology and Laboratory Capacity for Infectious Disease: University of North Carolina at Chapel Hill Assistance Programs for Chronic Disease Prevention and Control: University of North Carolina at Chapel Hill Assistance Programs for Chronic Disease Prevention and Control: University of North Carolina at Chapel Hill Assistance Programs for Chronic Disease Prevention and Control: University of North Carolina at Chapel Hill Assistance Programs for Chronic Disease Prevention and Control: University of North Carolina at Chapel Hill Assistance Programs for Chronic Disease Prevention and Control: University of Alabama Burmingham Sexually Transmitted Diseases (STD) Provider Education Grants University of Alabama Burmingham	93.110 93.969 93.969 93.969 93.969 93.978 93.978 93.073 93.080 93.283 93.323	None Identified 5117311 5117316 5118288  A03-2439 5115025 5119711 None Identified 5112088	111,218 72,255 8,965 192,438	16,436 1,079 2,644 3,001 40,560 948,466 294,629 449,504 105,087 849,220 233 6,345 16,125 73,420 38,609
University of North Carolina at Chapel Hill Maternal and Child Health Federal Consolidated Programs: Hemophilia of Georgia, Inc. PPHF Geriatric Education Centers: University of North Carolina at Chapel Hill Subtotal Health Services and Resources Administration Pass-Through Programs Total Health Services and Resources Administration Centers for Disease Control and Prevention Direct Programs: HIV Demonstration, Research, Public and Professional Education Projects Assistance Programs for Chronic Disease Prevention and Control Sexually Transmitted Diseases (STD) Provider Education Grants Subtotal Centers for Disease Control and Prevention Direct Programs Centers for Disease Control and Prevention Pass-Through Programs From: Birth Defects and Developmental Disabilities – Prevention and Surveillance: Duke University Biod Disorder Program: Prevention, Surveillance, and Research: University of North Carolina at Chapel Hill COC and Prevention Investigations and Technical Assistance: North Carolina Department of Health and Human Services Epidemiology and Laboratory Capaely for Infectious Disease: University of North Carolina at Chapel Hill Assistance Programs for Chronic Diseases Prevention and Control: University of North Carolina at Chapel Hill Assistance Programs for Chronic Diseases Prevention and Control: University of North Carolina at Chapel Hill Assistance Programs for Chronic Diseases Prevention and Control: University of North Carolina at Chapel Hill Assistance Programs for Chronic Diseases Prevention and Control: University of Nath Carolina at Chapel Hill Assistance Programs for Chronic Diseases Prevention and Control: University of Nath Carolina at Chapel Hill Assistance Programs for Chronic Diseases Prevention and Control: University of Nathama Birmingham	93.110 93.969 93.969 93.969 93.969 93.978 93.978 93.073 93.080 93.283 93.323 93.977	None Identified 5117311 5117316 5118288  A03-2439 5115025 5119711 None Identified 5112088 000526519-001	111,218 72,255 8,965 192,438	16,436 1,079 2,644 3,001 40,560 948,466 294,629 49,504 105,087 849,220 233 6,345 16,125 73,420 38,609 75,599

## Schedule of Expenditures of Federal Awards Year ended June 30, 2021

	Federal		December	
	CFDA no. or other grant	Pass-through entity	Passed through to	Federal
Federal grantor/pass-through grantor/program or cluster title	identifying no.	identifying number	subrecipients	expenditures
Applied Research to Address the COVID-19 Emerging Public Vysnova Partners, Inc.	93.UNKNOWN	SC-75D30120C08405	s –	317,035
IVY: COVID-19 Ancillary Studies			*	
Vanderbilt University	93.UNKNOWN	VUMC81591		20,701
Subtotal Centers for Disease Control and Prevention Pass-Through Programs				931,263
Total Centers for Disease Control and Prevention			192,438	2,728,949
Agency for Healthcare Research and Quality Direct Programs: Research on Healthcare Costs, Quality and Outcomes Agency for Healthcare Research and Quality Pass-Through Programs:	93.226		_	112,626
Research on Healthcare Costs, Quality, and Outcomes: Atrium/ Carolinas Healthcare System	93.226	A18-0236-S008	_	4,933
Children's Hospital Medical Center – Cincinnatti Children's Hospital Medical Center – Cincinnatti	93.226 93.226	305227 / PO 3100611304 Sub 305227 / PO 3100675660	_	(8,418) 16,799
Indiana University	93.226	IN4683532	_	20,357
University of North Carolina at Chapel Hill University of North Carolina at Chapel Hill	93.226 93.226	5115013 5R18HS027078	_	8,335 12,623
University of North Carolina at Chapel Hill	93.226	1R18HS027078	=	8,683
University of North Carolina at Chapel Hill	93.226	5111272		68,846
Total Research on Healthcare Costs, Quality, and Outcomes				132,158
Total Agency for Healthcare Research and Quality				244,784
Office of Minority Health Direct Program:  Community Programs to Improve Minority Health Grant Program	93.137		15,793	112,673
Total Office of Minority Health			15,793	112,673
Total U.S. Department of Health and Human Services			24,106,504	143,076,096
U.S. Department of Defense: U.S. Department of Defense Direct Programs:			24,180,004	140,070,000
Military Medical Research and Development: Department of Army	12.420		1,969,179	7,417,439
Basic Scientific Research :				
Department of Army Follow up REMIND Project for Development of a Human Memory Prosthetic:	12.431		43,840	327,213
Defense Advance Research Project Determining The Fundamental Differences Among Tissue Organoids From Different Species:	12.UNKNOWN		3,888	224,415
Defense Threat Reduction Agency	12.UNKNOWN		249,836	1,250,487
Subtotal U.S. Department of Defense Direct Programs			2,266,743	9,219,554
U.S. Department of Defense Pass-Through Programs From:				
Naval Medical Research Henry Jackson Foundation	12.340	None Identified		238,983
Military Medical Research and Development:			_	
American Burn Association Department of Defense	12.420 12.420	W81XWH-19-2-0043 None Identified	_	5,485 736
Duquesne University	12.420	W81XWH2010864 USAMRAA	_	20,719
Duquesne University Duquesne University	12.420 12.420	W81XWH2010854 W81XWH-20-1-0276	Ξ	5,389 18,863
Henry Jackson Foundation	12.420	FA8650-20-C-6215	_	21,282
Johns Hopkins University Johns Hopkins University	12.420 12.420	859167 None Identified	_ _ _	205,664 19,613
Johns Hopkins University	12.420	W81XWH-16-2-0060	_	75
Lynntech, Inc. Military& Health Research Foundation	12.420 12.420	None Identified ARM-057II	Ξ	74 12,554
Military& Health Research Foundation Military& Health Research Foundation	12.420 12.420	Subcontract Number: SC-18-05 P.O. Number: 0087 Subcontract Number: SC-18-05 P.O. Number: 0115	=	120,180 413,134
RegenMed Development Organization	12.420	SC-18-05/PO 0051	_	(255)
RegenMed Development Organization The Geneva Foundation	12.420 12.420	2017-601-002 (B) 2017-601-001 (M)	Ξ	566,426 719,304
The Geneva Foundation	12.420	S-1415-02	_	(19,260)
The Metis Foundation The Metis Foundation	12.420 12.420	S-1414-03 S-W81XWH-20-2-0024-02	Ξ	126,289 162,818
Univ. of California – San Diego	12.420	S-W81XWH-17-2-0002-003	_	139,350
Univ. of California – San Diego Univ. of California – San Diego	12.420 12.420	105647161 MP Invoice #S90032013 96446991 (MP Invoice #S9001830)	=	14,119 14,770
University of Michigan University of Michigan	12.420 12.420	96348471 (MP Invoice #S9001833) 3004015759	=	30,725
University of Michigan	12.420	3005984578	_	(358) 12,636
University of Michigan University of Michigan	12.420 12.420	PO 3005982713 None Identified	Ξ	14,918 17.000
University of Pittsburgh	12.420	SUBK00014082PO 3006186397	_	20,519
University of Pittsburgh University of Pittsburgh	12.420 12.420	CNVA0056666 (413614-20) 0046827(411515-1)	_	917 56,078
University of Pittsburgh	12.420	0046853 (411562-1)		75,972
Total Military Medical Research and Development				2,795,736
Basic Scientific Research: Ohio State University	12.431	60070860	_	83,406
Uniformed Services University Medical Research Projects: Johns Hopkins University	12.UNKNOWN	W0440V 47 D000		
Warrior Injury Assessment Manikin (WIAMan) Biomechanics Product Team:		W911QX-17-D006	_	63,730
Johns Hopkins University  Prospective Study of Early Mechanical Stabilization and Bleeding in Disruption of the Pelvic Ring:	12.UNKNOWN	APL Contract No. 151535	_	(5,770)
Johns Hopkins University Pre-Clinical Assessment of Bioprinted Human Skin for Wound Healing	12.UNKNOWN	None Identified	-	14,677
and Skin Regeneration:  Medical Technology Enterprise Consortium	12.UNKNOWN	None Identified	_	600,519
Development Of A Universal Bioreactor Platform For Regenerative Medicine Clinical Manufacturing: RegenMed Development Organization NEOCARE Platform to Prolong Tissue Preservation	12.UNKNOWN	2017-601-003 (BIOMFG)	28,932	445,031
Duquesne University	12.UNKNOWN	FA8650-20-2-6224		75,143
Subtotal U.S. Department of Defense Pass-Through Programs			28,932	4,311,455
Total U.S. Department of Defense			2,295,675	13,531,009
U.S. Department of Transportation:				
U.S. Department of Transportation Direct Programs: Crash Injury Research and Engineering Network Center				
National Highway Traffic Safety Administration U.S. Department of Transportation Pass-Through Programs From:	20.UNKNOWN	None Identified	55,183	447,871
National Highway Traffic Safety Administration Discretionary Grants				
Global Human Body Models Consortium LLC	20.614	GHBMC 17-0031 A2	119,444	489,021
Total U.S. Department of Transportation			174,627	936,892

## Schedule of Expenditures of Federal Awards Year ended June 30, 2021

	Federal CFDA no.		Passed	
Federal grantor/pass-through grantor/program or cluster title	or other grant identifying no.	Pass-through entity identifying number	through to subrecipients	Federal expenditures
National Aeronautics and Space Administration:				
National Aeronautics and Space Administration Direct Programs: Exploration	43.003		\$ 29,613	224,716
Space Operations	43.007			46,700
Subtotal National Aeronautics and Space Administration Direct Programs  National Aeronautics and Space Administration Pass-Through Programs From:			29,613	271,416
Improving Cardiovascular Risk Prediction:	43.003	PO# 7000000584, TRISH Project# EO0003		7,737
Baylor College of Medicine Baylor College of Medicine	43.003	NNX16A069A	=	42,618
Baylor College of Medicine Baylor College of Medicine	43.003 43.003	PO # 700000458 None Identified	_	230,535 145,325
Medical College of Wisconsin Wyle Laboratories	43.003 43.003	80NSSC19K0498 None Identified	=	84,001 15,488
Subtotal National Aeronautics and Space Administration Pass-Through Programs	40.000	(total identified		525,704
Total National Aeronautics and Space Administration			29,613	797,120
National Science Foundation:				
National Science Foundation Direct Programs: Engineering Grants	47.041		_	175,440
Education and Human Resources	47.076		43,726	484,996
Subtotal National Science Foundation Direct Programs  National Science Foundation Pass-Through Programs From:			43,726	660,436
Engineering Grants:	47.044	2000444		40.470
North Carolina Agricultural and Technical College	47.041	260311A	43,726	18,173 678,609
Total National Science Foundation U.S Department of Veterans Affairs:			43,720	678,609
U.S. Department of Veterans Affairs Direct Programs: Headache Centers of Excellence Collaboration	64.UNKNOWN			20,406
Magnetic Resonance Imaging (MRI) Scanner and Magnetoencephalography (MEG) Scanner	64.UNKNOWN			114,717
Total U.S. Department of Veterans Affairs Direct Programs				135,123
U.S. Department of Veterans Affairs Pass-Through Programs From: Structural & Functional Neurobiology of Veterans Exposed to Primary Blast Forces:				
W.G. Hefner VA Medical Center	64.UNKNOWN 64.UNKNOWN	None Identified	_	111,183
W.G. Hefner VA Medical Center The Retirement Research Foundation	64.UNKNOWN	None Identified None Identified	_	(12,400) 136
Charles George VA Medical Center	64.UNKNOWN	None Identified		11,855
Total U.S. Department of Veterans Affairs U.S. Environmental Protection Agency:				245,897
U.S. Environmental Protection Agency Pass-Through Programs From:				
Science to Achieve Results (STAR) Research Program University of Washington	66.509	UWSC10118		30,464
Total U.S. Environmental Protection Agency				30,464
U.S. Department of Education: U.S. Department of Education Pass-Through Programs:				
Special Education-Grants for Infants and Families				
North Carolina Department of Health and Human Services  Total U.S. Department of Education	84.181	None Identified		3,691,468
Subtotal – Wake Forest University Health Sciences			26,650,145	162,987,555
Reynolda Campus:				,,
U.S. Department of Health and Human Services:  National Institutes of Health Direct Programs:				
Aging Research Allergy and Infectious Disease Research	93.866 93.855		1.730	298,300 249,708
Arthritis Musculoskeletal and Skin Diseases Research	93.846		422,996	801,598
Biomedical Research and Research Training Blood Diseases and Resources	93.859 93.839		=	95,142 149,870
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286		404.700	350,438 1,945,056
Subtotal National Institutes of Health Direct Programs  National Institutes of Health Pass-Through Programs From:			424,726	1,943,030
Aging Research	93.866	60067306	_	44 200
Ohio State University DePaul University	93.866	501436SG167	=	41,299 4,074
Allergy and Infectious Disease Research Emory University	93.855	T405249	_	3,508
Arthritis Musculoskeletal and Skin Diseases Research Brigham & Women's Hospital	93.846	119689	_	44,504
Diabetes, Digestive, and Kidney Diseases Extramural Research Texas A&M University	93.847	M1902587		25.210
Biomedical Research and Research Training				
Ohio State University Blood Diseases and Resources Research	93.859	60067614	_	21,307
University of Pittsburgh East Carolina University	93.839 93.839	0060113 (131944-1) A20-0023-S001	=	117,937 42,822
Augusta University (Board of Regents of the University System of Georgia on behalf of Augusta University) Cardiovascular Diseases Research	93.839	33737-17	_	491
Northwestern University Harvard University (President and Fellows of Harvard College)	93.837 93.837	60057351 WF 111282-5116336	_	10,438 19,561
Drug Abuse and Addiction Research Programs			_	
Ohio State University Temporal Approach to Estimating County-Level Opiod Misuse Rates	93.279	60067559	_	27,224
University of Denver Minority Health and Health Disparities Research	93.242	SC37991-01	_	30,815
Washington University Trans-NIH Research Support	93.307	2940827H	-	30,814
University of Florida	93.310	UFDSP00011593	_	153,324
University of Pittsburgh Subtotal U.S. Department of Health and Human Services Pass-Through Programs	93.310	CNVA00053409(133873-2)		12,930 586,258
Total U.S. Department of Health and Human Services			424,726	2,531,314
U.S. Department of Defense Direct Programs:			,	,,,,,,,,,
Assembly of Topologic Streamline Automation, LLC	12.UNKNOWN	1153-SC-01-R0	_	51,007
Streamline Automation, LLC Room Temperature Quantum Memory	12.UNKNOWN	1147-SC-01-R0	_	10,000
Streamline Automation, LLC	12.UNKNOWN	1148-SC-01-R0		29,224
Subtotal U.S. Department of Defense Pass-Through Programs				90,231
Total U.S. Department of Defense				90,231

## Schedule of Expenditures of Federal Awards Year ended June 30, 2021

	Federal CFDA no. or other grant	Pass-through entity	Passed through to	Federal
Federal grantor/pass-through grantor/program or cluster title	identifying no.	identifying number	subrecipients	expenditures
National Sciences Foundation Direct Programs: Engineering Grants	47.041		s –	222,052
Mathematical and Physical Sciences	47.049		-	414,451
Geosciences Computer and Information Science Engineering	47.050 47.070		54,509 —	133,408 82,518
Science and Technology Centers	47.073			40,332
Biological Sciences Social, Behavioral, and Economic Sciences	47.074 47.075		141,478	637,173 52,378
Education and Human Resources	47.076			82,633
Subtotal National Science Foundation Direct Programs			195,987	1,664,945
National Sciences Foundation Pass-Through Programs:				
Geosciences: Duke University	47.050	14-NSF-1032		30,802
Biological Sciences	47.050		_	30,602
Brown University	47.074	00001545	_	169,960
Social, Behavioral, and Economic Sciences  Board of Trustees of the University of Illinois	47.075	17342-00	_	3,074
University of Oregon	47.075	2012S0A		43,672
Subtotal National Science Foundation Pass-Through Programs				247,508
Total National Sciences Foundation			195,987	1,912,453
Agency for International Development Direct Programs:				
USAID Foreign Assistance for Programs Overseas	98.001			940,716
Subtotal Agency for International Development Direct Programs				940,716
Total Agency for International Development				940,716
U.S. Department of Energy Direct Programs:	04.040		040.000	270 200
Office of Scientific Financial Assistance Program	81.049		218,900	370,326
Subtotal Agency for International Development Direct Programs			218,900	370,326
U.S. Department of Energy Pass-Through Programs:				
University of California	81.UNKNOWN	723011	_	122
Parallel Tensor Decompositions for Massive Data Sandia National Laboratories	81.UNKNOWN	1877799	_	(272)
Directed Electrode Nanostructure Engineering				
Oak Ridge Associated Universities	81.UNKNOWN	606121		45,381
Subtotal Agency for International Development Pass-Through Programs				45,231
Total U.S. Department of Energy			218,900	415,557
U.S. Department of Agriculture Direct Programs:	10.310		6,261	73,476
Agriculture and Food Research Initiative	10.310			
Subtotal U.S. Department of Agricultural Direct Programs			6,261	73,476
U.S. Department of Agriculture Pass-Through Programs: Summer Food Service Program for Children				
North Carolina Department of Public Instruction	10.559	9077	_	(881)
Agriculture and Food Research Initiative University of Georgia	10.310	SUB00002497	_	43,739
Subtotal U.S. Department of Agricultural Pass-Through Programs	10.010	0000002407		42,858
Total U.S. Department of Agriculture			6 261	
			6,261	116,334
U.S. Department of State Public Diplomacy Programs	19.040		15,306	15,306
Total U.S. Department of State			15,306	15,306
National Aeronautics and Space Administration Pass-Through Programs:				
Streamline Automation, LLC	43.UNKNOWN	3009-SC-01-RO	_	15,079
Trustees of Dartmouth College	43.UNKNOWN	R1491		45,671
Subtotal National Aeronautics and Space Administration Pass-Through Programs				60,750
Total National Aeronautics and Space Administration				60,750
Subtotal – Reynolda Campus			861,180	6,082,661
Total Research and Development Cluster			27,511,325	169,070,216
Student Financial Assistance Cluster:				
Wake Forest University Health Sciences: U.S. Department of Education Direct Programs:				
Federal Direct Student Loans	84.268			38,031,977
Subtotal U.S. Department of Education Direct Programs				38,031,977
Total U.S. Department of Education				38,031,977
Subtotal – Wake Forest University Health Sciences				38,031,977
Reynolda Campus:				
U.S. Department of Education Direct Programs:	84 007			697.018
Federal Supplemental Educational Opportunity Grant Federal Direct Student Loans	84.268		=	39,959,644
Federal Work Study Program	84.033		_	843,074 11 735 176
Federal Perkins Loan Program Federal Pell Grant Program	84.038 84.063		_	2,416,103
Subtotal U.S. Department of Education Direct Programs				55,651,015
Total U.S. Department of Education				55,651,015
Subtotal – Reynolda Campus				55,651,015
Total Student Financial Assistance Cluster				93,682,992
Training and Other Programs:				93,002,992
Wake Forest University Health Sciences:				
U.S. Department of Treasury Pass-Through Programs From:				
COVID-19 – Coronavirus Relief Fund Pass-Through Programs From: State of NC	21.019	None identified	2,381,018	10,492,632
UNC-Asheville	21.019	21-004		10,461
Subtotal – Wake Forest University Health Sciences			2,381,018	10,503,093
Reynolda Campus: COVID-19 – Coronavirus Relief Fund				
North Carolina State Education Assistance Authority	21.019	21-37	_	736,034
North Carolina Department of Commerce	21.019	51-00		250,000
Subtotal – Reynolda Campus				986,034
Subtotal 21.019			2,381,018	11,489,127

## Schedule of Expenditures of Federal Awards Year ended June 30, 2021

Federal grantor/pass-through grantor/program or cluster title	Federal CFDA no. or other grant identifying no.	Pass-through entity identifying number	Passed through to subrecipients	Federal expenditures
Wake Forest University Health Sciences:				
U.S. Department of Education Direct Programs: COVID-19 – Education Stabilization Fund				
HEERF Institutional Portion	84.425F		s –	293,388
HEERF Student Portion	84.425E			331,960
Subtotal Wake Forest University Health Sciences			_	625,348
Reynolda Campus: U.S. Department of Education Direct Programs: COVID:19 – Education Stabilization Fund				
HEERF Institutional Portion	84.425F		_	5,928,429
HEERF Student Portion	84.425E			3,072,748
Subtotal U.S. Department of Education Direct Programs				9,001,177
U.S. Department of Education Pass-Through Programs: COVID-19 – Governor's Emergency Education Relief Fund North Carolina State Education Assistance Authority	84.425C	30-03-37	_	54,281
Subtotal Reynolda Campus				9,055,458
Subtotal 84.425			_	9.680.806
Total U.S. Department of Education				9.680.806
Wake Forest University Health Sciences:				5,000,000
U.S. Department of Health and Human Services Direct Programs: COVID-19 – Provider Relief Funds	93.498		_	16,107,125
COVID-19 – HRSA COVID-19 Uninsured Program	93.461		_	170,229
U.S. Department of Health and Human Services Pass-Through Programs: HIV Care Formula Grants:				
Central Carolina Health Network	93.917	CFY2019-2020-WFMC-Part B	_	1,378
Central Carolina Health Network	93.917	CFY2018-2019-WFMC-Part D	_	75,898
North Carolina Department of Health & Human Services	93.917	None Identified		902,735
Total HIV Care Formula Grants				980,011
Grants to Provide Outpatient Early Intervention Services with Respect to HIV Disease: Health Resources and Services Administration	93.918	None Identified		608.886
Coordinated Services and Access to Research for Women, Infants, Children, and Youth:	33.310	None identified	_	000,000
Central Carolina Health Network	93.153	CFY2019-2020-WFMC-Part D		26,040
Total Coordinated Services and Access to Research for Women, Infants, Children and Youth				26,040
Ryan White HIV/AIDS Dental Reimbursement and Community Based Dental Partnership Grants: Health Resources and Services Administration	93.924	None Identified		26,822
Subtotal – Wake Forest University Health Sciences				17,919,113
Reynolda Campus:				
Corporation for National and Community Service (CNCS) AmeriCorps VISTA Recruitment Support	94.027		_	10,217
Total Corporation for National and Community Service				10,217
Federal Emergency Management Agency (FEMA) Pass-Through Programs:				
Disaster Grants – Public Assistance (Presidentially Declared Disasters) North Carolina Department of Public Safety	97.036	4393-DR-NR		140,246
Total Federal Emergency Management Agency (FEMA) Pass-Through Programs				140,246
Subtotal – Reynolda Campus				150,463
Total Training and Other Programs			2,381,018	39,239,509
Total Federal Award Expenditures			\$ 29,892,343	301,992,717
·			· — — — —	

See accompanying notes to schedule of expenditures of federal awards and schedule of expenditures of state awards.

## Schedule of Expenditures of State Awards

Year ended June 30, 2021

State grantors/pass-through grantors/agencies	State expenditures
Wake Forest University Health Sciences:	
NC Department of Health and Human Services	\$ 1,027,667
State Of North Carolina	(440)
North Carolina State Education Assistance Authority:	
Forgivable Education Loans for Services (FELS)	758,000
State of NC pass-through funds from:	
North Carolina Biotechnology Center	222,552
North Carolina Association of Free and C haritable Clinics	108,565
Cardinal Innovations Healthcare	739,750
Curamericas Global, Inc.	164,212
Mountain Area Health Education Center	51,581
Duke University	87,264
University of North Carolina at Chapel Hill Governor's Institute on Alcohol and Substance Abuse	14,909,060
North Carolina Hospital Foundation	32,636 15,944
Notifi Carolina Hospital Foundation	15,944
Subtotal – Wake Forest University Health Sciences	18,116,791
Reynolda Campus:	
Golden LEAF Scholarship Program (GOLD)	9,000
NC National Guard Tuition Assistance Program (NCTAP)	5,400
NC Veterans Scholarships (NCVET)	43,400
NC Need-Based Scholarships (NBS)	1,366,492
Subtotal – Reynolda Campus	1,424,292
Total State Award Expenditures	\$ 19,541,083

See accompanying notes to schedule of expenditures of federal awards and schedule of expenditures of state awards.

Notes to Schedule of Expenditures of Federal Awards and Schedule of Expenditures of State Awards Year ended June 30, 2021

## (1) Basis of Presentation

The accompanying schedule of expenditures of federal awards (the schedule) includes all grants, contracts, and similar agreements entered into directly between Wake Forest University (the University) and agencies and departments of the federal government and all subawards to the University by nonfederal organizations pursuant to federal grants, contracts, and similar agreements and is presented on the accrual basis of accounting. The information in the schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Therefore, some amounts presented in the schedule may differ from amounts presented in, or used in the preparation of, the consolidated financial statements.

The accompanying schedule of expenditures of state awards includes all grants, contracts, and similar agreements entered into directly between the University and agencies and departments of the state government and all subawards to the University by nonfederal organizations pursuant to state grants, contracts, and similar agreements and is presented on the accrual basis of accounting.

## (2) Summary of Significant Accounting Policies

Expenditures for certain federal student financial aid programs are recognized as incurred and include the federal share of students' Federal Supplemental Educational Opportunity Grant (FSEOG) program grants and Federal Work Study (FWS) program earnings, Pell grants, loan disbursements, and administrative cost allowances, where applicable.

Expenditures for other federal awards of the University's academic and other divisions are recognized following, as applicable, either the cost principles in OMB Circular A-21, Cost Principles for Educational Institutions, or the cost principles contained in Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards, wherein certain types of expenditures are not allowable or are limited as to reimbursement.

Expenditures for non–financial aid awards include indirect costs, related primarily to facilities operation and maintenance and general, divisional, and departmental administrative services, which are allocated to direct cost objectives (including federal awards) based on negotiated formulas commonly referred to as facilities and administrative cost rates. Facilities and administrative costs allocated to such awards for the year ended June 30, 2021 were based on predetermined rates negotiated with the University's cognizant federal agency, the U.S. Department of Health and Human Services. The University has elected not to use the 10-percent de minimis indirect cost rate as allowed under the Uniform Guidance.

Negative balances presented in the schedule represent programs with unfunded expenditures prior to normal close-out procedures, which were subsequently transferred to nonfederal cost centers.

Notes to Schedule of Expenditures of Federal Awards and Schedule of Expenditures of State Awards

Year ended June 30, 2021

## (3) Summary of Facilities and Administrative Costs and Administrative Cost Allowances – Governmental Sources

Facilities and administrative cost recoveries and administrative cost allowances for the University's academic and other divisions for the year ended June 30, 2021 are summarized as follows:

#### Federal:

Research and development	\$ 45,597,690
Student financial aid	 84,386
Total	\$ 45,682,076

## (4) Federal Student Financial Aid Loan Programs

The Federal Perkins Loan, Health Professions Student Loan (HPSL), and the Primary Care Loan (PCL) programs are administered directly by the University and balances and transactions relating to these programs are included in the University's consolidated financial statements. There were no current year loaned amounts under the Federal Perkins Loan program, the HSPL or PCL programs. The balance of loans outstanding under the Federal Perkins Loan program was \$9,270,692 as of June 30, 2021. There were no loans outstanding for the HPSL and PCL programs as of June 30, 2021.

The University disbursed the following amounts of new loans under the Federal Direct Student Loan Program to students of the University during the year ended June 30, 2021:

Federal subsidized stafford loans	\$ 2,658,709
Federal unsubsidized stafford loans	43,509,864
Federal PLUS loans	31,823,048
Total	\$ 77,991,621

The University is responsible only for the performance of certain administrative duties with respect to the Federal Direct Student Loan Program and, accordingly, these loans are not included in its basic financial statements. It is not practicable to determine the balance of loans outstanding to students and former students of the University under these programs as of June 30, 2021.

## (5) Matching

Under the FWS program, the University did not match any compensation to students for the year ended June 30, 2021.

Under the FSEOG program, the University matched \$232,339 in funds awarded to students for the year ended June 30, 2021 in addition to the federal share of expenditures in the accompanying schedule.

Notes to Schedule of Expenditures of Federal Awards and Schedule of Expenditures of State Awards Year ended June 30, 2021

## (6) Provider Relief Fund (CFDA # 93.498)

As required by the granting agency, the Provider Relief Fund (PRF) amount presented in the Schedule represents eligible expenses and lost revenues as reported to the U.S. Department of Health and Human Services for the PRF Portal Reporting time periods of July 1, 2021 to September 30, 2021.



KPMG LLP Suite 800 500 W 5th St Winston-Salem, NC 27101

Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With Government Auditing Standards

The Board of Trustees Wake Forest University:

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States, the consolidated balance sheet of Wake Forest University (the University), which comprise the consolidated financial statements as of June 30, 2021, and the related consolidated statements of activities, and cash flows for the year then ended, and the related notes to the consolidated financial statements, and have issued our report thereon dated October 25, 2021.

## **Internal Control Over Financial Reporting**

In planning and performing our audit of the consolidated financial statements, we considered the University's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control. Accordingly, we do not express an opinion on the effectiveness of the University's internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A material weakness is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's consolidated financial statements will not be prevented, or detected and corrected on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

### **Compliance and Other Matters**

As part of obtaining reasonable assurance about whether the University's consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the consolidated financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.



## **Purpose of this Report**

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the University's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the University's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

KPMG LLP

Greensboro, North Carolina October 25, 2021



KPMG LLP Suite 800 500 W 5th St Winston-Salem, NC 27101

Independent Auditors' Report on Compliance for Each Major Federal Program; Report on Internal Control over Compliance; and Report on the Schedule of Expenditures of Federal Awards Required by the Uniform Guidance and the Schedule of Expenditures of State Awards

The Board of Trustees Wake Forest University:

## Report on Compliance for Each Major Federal Program

We have audited Wake Forest University's (the University) compliance with the types of compliance requirements described in the *OMB Compliance Supplement* that could have a direct and material effect on each of the University's major federal programs for the year ended June 30, 2021. The University's major federal programs are identified in the summary of auditors' results section of the accompanying schedule of findings and questioned costs.

The University's financial statements include the operations of RegenMed Development Organization, an affiliate, which expended \$2,022,170 in federal awards which are not included in the University's schedule of expenditures of federal awards for the year ended June 30, 2021. Our audit, described below, did not include the operations of RegenMed Development Organization because the affiliate engaged other auditors to perform an audit of compliance.

## Management's Responsibility

Management is responsible for compliance with federal statutes, regulations, and the terms and conditions of its federal awards applicable to its federal programs.

## Auditors' Responsibility

Our responsibility is to express an opinion on compliance for each of the University's major federal programs based on our audit of the types of compliance requirements referred to above. We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Those standards and the Uniform Guidance require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about the University's compliance with those requirements and performing such other procedures as we considered necessary in the circumstances.

We believe that our audit provides a reasonable basis for our opinion on compliance for each major federal program. However, our audit does not provide a legal determination of the University's compliance.

## Opinion on Each Major Federal Program

In our opinion, the University complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended June 30, 2021.



## **Report on Internal Control Over Compliance**

Management of the University is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered the University's internal control over compliance with the types of requirements that could have a direct and material effect on each major federal program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for each major federal program and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of the University's internal control over compliance.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

## Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance and the Schedule of Expenditures of State Awards

We have audited the consolidated financial statements of the University as of and for the year ended June 30, 2021, and have issued our report thereon dated October 25, 2021, which contained an unmodified opinion on those consolidated financial statements. Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedule of expenditures of federal awards is presented for purposes of additional analysis as required by the Uniform Guidance and is not a required part of the consolidated financial statements. The accompanying schedule of expenditures of state awards is also presented for purposes of additional analysis and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards



generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards and the schedule of expenditures of state awards are fairly stated in all material respects in relation to the consolidated financial statements as a whole.

KPMG LLP

Winston-Salem, North Carolina September 30, 2022

# Schedule of Findings and Questioned Costs Year ended June 30, 2021

## (1) Summary of Auditors' Results

- (a) Type of report issued on whether the financial statements were prepared in accordance with generally accepted accounting principles: **Unmodified**
- (b) Internal control deficiencies over financial reporting disclosed by the audit of the financial statements:
  - Material weaknesses: No
  - Significant deficiencies: None Reported
- (c) Noncompliance material to the financial statements: No
- (d) Internal control deficiencies over major programs disclosed by the audit:
  - Material weaknesses: No
  - Significant deficiencies: None reported
- (e) Type of report issued on compliance for major programs: Unmodified
- (f) Audit findings that are required to be reported in accordance with 2 CFR 200.516(a): No
- (g) Major program:

Research and Development Cluster – various CFDA numbers

COVID-19 - Coronavirus Relief Fund (21.019)

**COVID-19 – Education Stabilization Fund (84.425)** 

COVID-19 - Provider Relief Fund (93.498)

- (h) Dollar threshold used to distinguish between Type A and Type B programs: \$3,000,000
- (i) Auditee qualified as a low-risk auditee: Yes
- (2) Findings Relating to the Financial Statements Reported in Accordance with Government Auditing Standards

None

(3) Findings and Questioned Costs Relating to Federal Awards

None